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Itch is defined as “a stimulation of free nerve endings, usually 
at the junction of the dermis and epidermis of the skin, that 
evokes a desire to scratch.” (Encyclopedia Britannica) Although 
most assume itch to be harmless, chronic itch can cause much 
discomfort and affect quality of life. Pain and itch are obviously 
different to the one experiencing either feeling, but whether 
these sensations are processed differently is not so obvious. 
Since the late nineteenth century when pain was discovered 
to be a real sensation, itch was thought of as just a weaker 
form of pain (Von Frey cited in Handwereker, 2014). Later, sci-
entists found certain unmyelinated C-fibres of the dorsal root 
ganglion that were sensitive specifically to histamine (Schmelz, 
et. al. 1997). Similar histamine sensitive neurons were found in 
lamina I of the spinal cord (Andrew, Craig, 2001). This led to the 
specificity theory for itch, also called the labelled line theory, 
which proposes that different sets of neurons exclusively medi-
ate itch or pain. However, many of the receptors that respond 
to itchy stimuli are also involved in mediating pain and later 
studies show that most of the neurons that respond to itch also 
react to pain producing substances (Shmelz, et.al.2003, Simons, 
2004, Davidson, et. al., 2007, Akiyama, et. al.2009, Akiyama, et.al. 
2010).  So although itch and pain have separate pathways, a lot 
of overlap seems to exist between them.
Methods
This review was written through the critical analysis of clinical 
research papers and peer reviewed journal articles. The papers 
were found in searches on Google Scholar and access was ob-
tained through the Touro College Library.
Discussion
Researchers first thought of itch as a milder form of pain, a 
theory known as the intensity theory. According to this theory, 
pain and itch sensations are mediated by the same neurons; if 
the stimulus is strong, there is a pain sensation, and if the stimu-
lus is weak, an itch sensation (quoted in Patel, Dong, 2010). The 
basis for this theory was that cordotomy, surgical disconnection 
of the spinothalamic tract, leads to loss of both itch and pain 
on the contralateral side of the cut, whereas the perception of 
touch is impaired on the ipsilateral side (Nathan, 1990). This led 
to the theory that itch and pain are conducted along the same 
ascending pathway whereas mechanosensation travels along a 
separate path  (quoted in Handwerker, 2014). However, many 
well-known characteristics of itch and pain don’t seem to fit 
with this theory.  For one, itch can be quite intense and never 
turn into pain, (Tuckett, 1982) and similarly, a painful stimulus 
does not feel like itch when administered at a lower intensi-
ty (Ochoa, Torebjork, 1989). More, the reflexes in response to 
pain and itch are quite different. The pain reflex is withdrawal, 
whereas the itch reflex is scratching. These observations seem 
to suggest that pain and itch have separate neural pathways. 
One of the first steps in the advancement of itch research was 
the discovery of histamine. Histamine is released from mast 
cells and white blood cells, as a response to allergens or inflam-
matory mediators. A “triple response” to histamine was found. 
There is a local reaction, swelling, and also erythema, a flare, 
skin reddening around the affected skin (quoted in Handwerker, 
2014). Histamine could be applied to specific regions and 
therefore allowed for the identification of the neurons which 
responded to it.  
The breakthrough came in 1997, when using the new comput-
er-assisted marking technique in microneurography, one group 
was able to identify histamine-sensitive C-fibers. Previous re-
search had shown that itch had sometimes been induced during 
microstimulation in skin nerves where C-fibers were recorded. 
But most C-fibers identified were insensitive or only weakly 
responsive to histamine. The new technique was able to identify 
even small units that could not be identified with the old meth-
ods.  Researchers identified 56 fibers in the superficial peroneal 
nerve of 52 healthy patients. Units were classified as mechan-
ically and heat-responsive (CMH), heat-responsive (CH), or 
unresponsive to mechanical and heat stimulation (CMiHi). All 
of the fibers were tested by iontophoresis of histamine and the 
subjects rated the itch feeling. After the application of histamine, 
itch was usually felt 30-60 seconds after, reached a maximum 
after 2-3 minutes, and lasted for about 10 minutes. Twenty- 
three of the fifty-six units studied were not at all excited by the 
histamine. Twenty were weakly activated but their discharges 
did not match up with the time response of the subjects. Eight 
of the units (5 CH and 3 CMiHi) showed lasting responses to 
the histamine that coordinated with the time response of the 
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subjects.  These neurons were found to have a much slower 
conduction velocity than the non- histamine responsive neu-
rons, suggesting that these neurons are a class onto themselves. 
The units with histamine responses had a mean velocity of 
.52m/sec., compared to the .9m/sec. of the other units.  The 
slow velocity reflects small axon diameters. Additionally, the 
units were found to have unusually large innervation territories. 
This finding explains the flare that is found after application of 
histamine (Schmelz, et. al. 1997). 
The next study that supported the idea of an itch-specific path-
way was done on cats and found a population of histamine-selec-
tive lamina I spinothalamic tract (STT) neurons. The researchers 
obtained recordings from 190 lamina I STT neurons that had 
distal hind limb fields in the lumbosacral spinal cords of 33 cats. 
After categorizing these neurons into three main classes- noci-
ceptive-specific, thermoreceptive- specific, and polymodal noci-
ceptive- based on response to natural mechanical and thermal 
stimuli, there were 17 neurons left that were mechanically and 
thermally insensitive.  Unlike the mechanically and thermally sen-
sitive neurons, these neurons did not show spontaneous activ-
ity. These neurons were found to have a similar response time 
after histamine application to their innervation area of skin to 
the histamine selective neurons found in the previous study.  The 
conduction velocities of these neurons were slower than the rest 
of the lamina I STT neurons, which is also consistent with the 
findings of the previously mentioned study. In addition, they all 
had large receptive fields, similar to the histamine selective fibers 
in the previous study. These characteristics that differed from the 
rest of the neurons seem to put these neurons into a class of 
their own. Some of the histamine-responsive neurons were test-
ed with mustard oil, which causes a burning sensation, and some 
responded to it. Of those that responded to the mustard oil, 
most had responses that were much weaker than the response 
to histamine. The neuron that had a strong response to the mus-
tard oil had been found to have a weaker response to histamine 
than the rest of the histamine-responsive neurons. Some of the 
histamine- responsive neurons did not respond at all to mustard 
oil, indicating that they are histamine-selective. (One should note, 
however, that the neurons were never tested with capsaicin, an 
algogen) (Andrew, Craig, 2001). This study and the one mentioned 
above both support the “specificity theory,” as it seems like units 
were found that responded specifically to histamine. 
Knowing that histamine is not the only pruritogen, a later study 
tested different pruritogens to see if the histamine-selective 
units would respond to them in accordance with pruritic po-
tency of the pruritogen. They found that many histamine-selec-
tive units responded to the other pruritogens more than the 
non-histamine-selective units. However, they also found that the 
mechano- insensitive, histamine responsive units could also be 
excited by capsaicin and bradykinin, both algogens, albeit with 
a different response pattern than the CMH units. The mecha-
no-responsive units had intense, short-lasting responses to cap-
saicin, whereas the mechano-insensitive units had longer lasting 
responses.  This challenges the specificity theory as the itch 
units were activated by algogens (Shmelz,et.al.2003). Another 
study tested the responsiveness of STT neurons from the ven-
tral posterior lateral nucleus of the thalamus in monkeys to 
different algogens and pruritogens. Neurons were found that 
responded to both histamine and capsaicin, another challenge 
to specificity, this time in the STT. (Simone, 2003) 
As the pathway for itch becomes clearer and more defined, the 
question of how the brain processes the signals from the path-
way as itch rather than pain remains uncertain. 
The Histamine Dependent Pathway
Histamine binds with histamine receptors on free nerve end-
ings. These receptors are classified into four subtypes, 1-4.  In 
order to determine which of the four histamine receptors are 
responsible for the Ca2+ influx into the cell after the applica-
tion of histamine, agonists of the different subtypes were applied 
with the histamine. The only agonist that stopped the calcium 
response was the histamine type-1 receptor (H1R) agonist, me-
pyramine (Nicolson, et.al. 2002). In pharmaceutical attempts to 
alleviate itch the H1R became the major target (Simons, 2004). 
In the mediation of itch, H1R was found to activate phospholi-
pase Cβ 3 (PLCβ3). PLCβ3 is expressed in neurons with histo-
logical markers for unmyelinated, C-fiber nociceptors. PLCβ3 is 
coexpressed with H1R in 90% of H1R neurons, suggesting that 
PLCβ3 may also be involved in the transduction of itch. Indeed, 
PLCβ3-deficient mice showed low Ca2+ release in response to 
histamine application, compared to the regular Ca2+ response 
to application of ATP, capsaicin, UTP, and bradykinin. In vivo 
testing showed that PLCβ3 deficient mice started scratching 
later and scratched less in response to histamine injection than 
wild-type mice. The PLCβ3 deficiency was most noticed when 
the H1R agonist, HTMT, was applied to the PLCβ3-deficient 
mice, and was compared to application of agonists of the other 
histamine receptors. The scratching response to HTMT was al-
most as low as the response to the control, saline injection. This 
indicates that PLCβ3 responds mainly to activity in the H1R 
receptor. Reduced scratching was also found in the response to 
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48/80, a substance that causes degranulation of mast cells and 
therefore the release of histamine  (Han, et.al. 2006).
Activation of PLCβ3 causes increase in intracellular Ca2+ in the 
DRG neurons through the ion channel TRPV1. TRPV1, transient 
receptor potential vanilloid receptor-1, an ion channel, is a re-
ceptor that is found on free nerve endings and allows the action 
potential to occur by allowing Ca2+ into the neuron.  Although 
TRPV1 was previously only known for its role in mediating pain, 
there were clues that it may also be involved in processing itch. 
For one, capsaicin, a major algogen that activates TRPV1, can 
cause itch when applied to the skin surface (Green, Shaffer, 
1993).  In addition, TRPV1 and histamine receptors are found on 
the same subset of neurons )Nicolson, et. al. 2002).  Lastly, when 
high levels of capsaicin are applied to the skin, TPRV1 is desensi-
tized and, interestingly, pruritus is also stopped (quoted in Shim, 
et. al. 2007). Indeed, studies show that TRPV1 has a role in medi-
ating itch. When H1R or TRPV1 alone was transfected to HEK 
293T cells, these cells did not respond to histamine. However, 
H1R and TRPV1 transfected together caused a large current in 
response to histamine application. Further, when capsazapine, 
a TRPV1 antagonist, was applied to the skin before histamine 
application, it caused smaller Ca2+ responses to histamine. In 
addition, TRPV1-deficient mice did not have a large increase 
in intracellular Ca2+ when histamine was applied, in contrast 
to wild-type mice who did. In vivo studies also proved TPRV1’s 
involvement in the mediation of itch. Capsazapine given before 
histamine injection in mice resulted in reduced scratching to 
the histamine. Compared to wild-type mice, TRPV1-deficient 
mice also showed reduced scratching in response to histamine 
injection (Shim, et.al. 2007).  These experiments demonstrate 
that TRPV1 plays a role in the transduction of itch.  
The Histamine Independent Pathway
Although histamine plays a role in allergic itch, histamine is not 
the main pruritic mediator in most diseases of chronic itch 
(Klein, Clark, 1999). The use of H1R antagonists, antihistamines, 
are ineffective in stopping chronic itch (Twycross, et.al. 2003). 
Chronic itch can be caused by the release of pruritogens from 
lymphocytes, mast cells, and eosinophils (Ikoma, et,al, 2006). In 
patients with atopic dermatitis, antihistamines did not suppress 
itch upon degranulation of mast cells. This suggests that there 
are mast cell itch mediators other than histamine (Rukweid, 
et.al. 2000). In addition, one of the regular characteristics of 
histamine induced itch, the flare, is missing in many types of itch 
(Ikoma, et. al. 2005). These findings point to another pathway for 
itch other than the mechano-insensitive C-fibres that mediate 
histamine induced itch. 
Cowhage, the common name for the spicules that cover the 
tropical plant Mucuna pruriens, causes severe itch without a 
flare response (Johanek, et. al. 2007).  It has been found in bio-
chemical studies that mucunain, a proteinase in the cowhage, 
is what makes cowhage itchy (Reddy, et.al. 2008) In a study 
designed to test if histamine and cowhage activate the same 
C-fibres, all CMH units responded to cowhage, and none of the 
CMi, histamine responsive, units did, proving that cowhage and 
histamine do not activate the same fibres (Namer, et.al. 2008). 
Thus, cowhage has been used in many studies to understand 
histamine- independent itch. 
Proteinases, such as mucunain, activate proteinase-activated 
receptors (PARs).  A specific proteinase-activated receptor, 
PAR-2, has been identified on afferent nerve fibers (Steinhoff, 
et. al. 2000). PAR-2 is also activated by trypsin and tryptase. 
Tryptase is released by mast calls and trypsin is expressed in 
the skin (quoted in Shimada, et. al. 2006). The first study that 
found a connection between PAR-2 and itch was done on mice 
and found that PAR-2 played a major role in allergic dermatitis. 
PAR-2 deficiency led to reduced ear swelling.  (Kawagoe, et.al. 
2002) Patients with atopic dermatitis (AD) were found to have 
an increase in PAR-2 signaling, which was seen through higher 
levels of codeine-induced tryptase, PAR-2 expression on kera-
tinocytes, and a greater response to PAR-2 agonist (Steinhoff, 
et.al. 2003). Another study found that itch was induced by PAR-2 
agonist, a peptide, SLIGRL-NH2. When mice were injected with 
SLIGRL-NH2 they started vigorously scratching in levels much 
higher than when injected with saline vehicle. The application 
of an antihistamine, pyrilamine, did not reduce the scratching, 
confirming that PAR-2 is a receptor in non-histaminergic itch 
(Shimada, et.al. 2006).
One of the drugs used to treat malaria is chloroquine. Many 
patients complain about intense itch while taking chloroquine. 
The itch can be so intense that they stop taking the medicine. 
Antihistamines were ineffective in relieving the itch (quot-
ed in Liu, et.al. 2009). Parts of the Mrgpr family (Mas related 
G-protein coupled receptors), a family of G protein-coupled 
receptors (GPCR), have been detected only on small-diameter 
sensory neurons in the DRG and TG. This would make them 
likely to be involved in the sensation of pain or itch. Itch induced 
by chloroquine was reduced in Mrpgr deficient mice, although 
the response to histamine induced itch was not significantly 
reduced in these mice. Further study found that the specific 
Mrgpr receptor for chloroquine was MrgprA3.  BAM-822 was 
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found to excite MrgprC11 (Liu, et.al. 2009).
TRPA1, an ion channel, plays the same role in histamine- inde-
pendent and chronic itch as TRPV1 plays in histamine dependent 
itch. That is, it allows the action potential to occur by allowing 
Ca2+ into the neurons. Researchers found that TRPA1 is greatly 
expressed in subset of TRPV1 positive neurons. Chloroquine 
and BAM-822 were found to activate the subset of TRPV1 
neurons that also expressed TRPA1. Yet, neurons from TRPV1-
deficient mice and neurons treated with capsazapine, a TRPV1 
antagonist, both showed regular Ca2+ signaling in response to 
BAM and chloroquine. There was also no difference in action 
potential firing in response to chloroquine and BAM between 
TRPV1-deficient neurons and wild-type neurons. Thus, it is 
shown that the TRPV1 ion channel is not required for the me-
diation of BAM and chloroquine itch. However, TRPA1-deficient 
neurons had significantly decreased responses to both BAM and 
chloroquine. (As would be expected, they did have normal re-
sponses to histamine.) Further testing showed that the primary 
target for the MrgprA3 and MrgprC11 receptors was TRPA1. 
Interestingly, BAM and chloroquine have different mechanisms 
leading to activation of TRPA1. Thus, TRPA1 is downstream of 
different histamine- independent itch pathways (Wilson, et.al. 
2011). Another study found TRPA1to be a vital mediator in 
chronic itch. Application of AEW (acetone/ether mixture with 
water) to the mouse cheek causes chronic itch-like symp-
toms in mice. It causes dry skin and increases scratching. It 
also causes epidermal thickening, a major symptom of chronic 
itch due to psoriasis in humans. Compared to wild-type mice, 
TRPA1-deficient mice showed significant reduction in scratch-
ing induced by AEW treatment. This is in contrast to TRPV1-
deficient mice who after AEW treatment showed no decrease 
in scratching. Further, injection of TRPA1 inhibitor, HC-030031, 
into cheeck also caused reduction in scratching in AEW treated 
mice. These results show that TRPA1 is required in chronic itch. 
(Wilson, et.al. 2013).
One study used a novel approach to test if there are distinct 
histaminergic and non-histaminergic pathways. Instead of de-
leting certain receptors or neurons, this group used QX-314, 
a sodium channel blocker, to selectively “silence” specific re-
ceptors. When QX-314 was inserted into the mouse along 
with histamine, sodium currents in TRPV1 alone were blocked, 
thus temporarily “silencing” TRPV1. QX-314 inserted along 
with chloroquine had the same effect on TRPA1, silencing it. 
When TRPV1 was silenced, histamine induced scratching was 
stopped, but chloroquine induced scratching was regular, and 
when TRPA1 was silenced, chloroquine induced scratching 
was stopped. This confirmed the separate pathways for itch. 
(Roberson, et.al. 2013)
The above information has shown at least two DRG pathways 
for itch- histaminergic and non-histaminergic. A few other itch 
pathways were found, such as the pathway for β-alanine which 
is unique (Liu, et.al. 2012 b). Some other receptors have been 
found as well, such as toll-like receptor 7 (TLR7) and toll-like 
receptor 3 (TLR3). Although TLR7 knockout mice showed 
normal sensitivity to thermal and mechanical pain and showed 
normal scratching response to histamine-dependent prurito-
gens, scratching response to non-histaminergic pruritogens 
was significantly reduced  (Liu, et.al. 2010). TLR3 knockout mice 
showed reduced scratching response to both histaminergic and 
non-histaminergic stimuli and TLR3 was found to be necessary 
in the development of chronic itch (Liu, et.al. 2012a). Another 
itch mediator found was the cytokine, interleukin-31 (IL-31). 
IL-31 is produced by T-cells and mice generated to overexpress 
it developed intense pruritus. IL-31 protein was fed to adult 
mice and within 3-4 days the mice developed severe pruritus 
(Dillon, et.al. 2004).
The separate histaminergic and non-histaminergic pathways 
continue into the spinal cord. In a study done on monkeys, 57 
dorsal horn, STT neurons were tested for responsiveness to his-
tamine and cowhage. Nineteen responded either to histamine 
or cowhage; none responded to both. This shows a continuation 
of the separate pathways. Interestingly, all pruritogen-responsive 
neurons also responded to capsaicin, further evidence against 
the specificity theory. As pointed out above, the study done on 
STT neurons that suggested the existence of histamine-specif-
ic neurons did not test for response to capsaicin, thus lacking 
evidence that those neurons did not respond to pain stimuli 
(Davidson, et. al., 2007). 
Just like overlap was found in the neurons mediating pain and 
itch in the dorsal root ganglia, overlap was also found in the 
trigeminal ganglia (TG) and the trigeminal subnucleus caudalis 
of mice. Mice TG neurons were tested with different prurito-
gens, i.e. histamine, PAR-2 agonist, and 5-HT, and algogens, i.e. 
capsaicin and AITC. Using calcium imaging it was found that of 
856 TG neurons, 15.4% responded to histamine and 5.8% to 
PAR-2 agonist. Although a small percentage of the pruritogen-
ic neurons only responded to one pruritogen, the majority of 
those pruritogenic neurons responded to AITC or capsaicin as 
well, another finding that is inconsistent with the specificity the-
ory. Consistent with the findings of different histaminergic and 
non-histaminergic pathways, most pruritogenic neurons were 
responsive to only one of the pruritogens. The majority of TG 
neurons that responded to pruritic stimuli were also respon-
sive to algogens  (Akiyama, et. al. 2010). Another study found 
neurons in the superficial dorsal horn that were responsive to 
PAR-2 agonist and 5-HT, yet most were also responsive to algo-
gens (Akiyama, et.al. 2009).
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As can be seen from the information presented above, many 
of the receptors in the itch pathways are also involved in the 
transduction of pain. TRPV1, PAR-2, TRPA1, and the TLRs all 
play roles in mediating pain. It has also been shown that algo-
gens can activate pruritogenic neurons. It seems that there is 
no itch-specificity. However, two neurons have been found that 
seem to be itch-specific GRPR+ neurons and, more recently, 
MrgprA3+ neurons. 
At the spinal level, gastrin-releasing peptide receptor, GRPR, has 
been found to be essential for mediating itch exclusively and 
not pain. GRP is expressed in a subgroup of dorsal root ganglion 
neurons. It is also colocalized with markers for unmyelinated 
fibers. In addition, approximately 80% of GRP+ neurons express 
TRPV1. GRP+ neurons are found only in the lamina I and II 
outer layer in the spinal cord. This data points to a possible in-
volvement of the GRP signaling pathway in itch and pain. GRPR 
mutant mice were tested along with wild-type mice. GRPR 
mutant mice did not show a significantly different response 
from the wild-type mice to heat, pain, or mechanical stimuli. 
The mice were then tested with three different pruritogenic 
agents: 48/80, a PAR-2 agonist (SLIGRL-NH2), and chloroquine. 
After the separate injection of each pruritogen, a scratch count 
was taken from the mice. Although the GRPR mutant mice did 
scratch as a response to the injection, the number of scratches 
was significantly reduced, showing that GRPR mediates itch. To 
test whether activating GRPR at the spinal level would induce 
itch, GRPR agonist, GRP18-27, was intrathecally administered to 
the wild-type mice.  It induced scratching behavior. As expected, 
the scratching response to GRP18-27 was significantly lower 
in GRPR mutant mice. In addition, when GRPR antagonist was 
inserted 10 minutes before the pruritogen in wild-type mice, 
scratching behavior was significantly reduced. Interestingly, the 
antagonist caused a lesser reduction in the effect of compound 
48/80 than it had on PAR-2 agonist and chloroquine. This may be 
because PAR-2 and chloroquine act through a histamine-inde-
pendent pathway, unlike compound 48/80. Since GRPR mutant 
mice showed regular pain responses to mechanical, thermal, 
and pain stimuli, but significantly reduced itch responses to pru-
ritogens, GRPR+ neurons seem to be itch-specific (Sun, Chen, 
2007). However, this does not rule out the possibility that GRPR 
neurons can also respond to pain and in GRPR mutant mice the 
loss of these neurons is compensated for by the other nocicep-
tive neurons and therefore pain is still felt.  
In order for something to be considered completely itch spe-
cific it needs to fulfill three criteria. First and most obvious, the 
neurons must respond to pruritic stimuli. Second, the loss of 
these neurons should only cause a loss of itch, not pain. Last, and 
most vital, only an itch response should be elicited when these 
neurons are specifically activated, not pain. The study done on 
the GRPR mutant mice fulfilled the first two criteria, but did not 
test for the third. 
One group of neurons that was found to fit all the criteria is 
the MrgprA3+ neurons. These neurons only innervate the skin 
and were found to be absent from all other tissues, one clue 
that these neurons may be specific to itch, which is only felt on 
the epidermis.  These neurons were coexpressed with TRPV1. 
They were also found to synapse with GRPR neurons in the 
spinal cord.  These neurons responded to all types of itch other 
than β-alanine. When these MrgprA3+ neurons where ablated 
from a mouse line, the mice still showed regular responses to 
pain stimuli, though response to itch stimuli was greatly re-
duced. Mice have clearly distinct responses to itch and pain and 
therefore it is easy to know what sensation is being felt. Facial 
wiping with the forelimb is the response to pain, and scratching 
with the hindpaw is the response to itch (Shimada, LaMotte, 
2008). (One interesting find was that the itch response to β-al-
anine was regular in MrgprA3+ -ablated mice, confirming that 
the neural pathway for β-alanine is unique.) In order to rule 
out the possibility that MrgprA3+ neurons are not necessary 
in pain response but can still be involved, MrgprA3+ neurons 
were specifically activated to see what response the neuron 
would elicit- pain or itch. The researchers used TRPV1-deficient 
mice and transfected TRPV1 only on the MrgprA3+ neurons. 
When capsaicin, an algogen, was injected into the cheek of these 
mice, the mice responded with scratching. This is in contrast to 
both wild-type mice that responded with wiping and TRPV1-
deficient mice that did not respond at all. Thus it was shown 
that MrgprA3+ neurons coexpressed with TRPV1 elicit an itch 
response, regardless of the stimuli (Han, et. al. 2013). This is the 
first study to prove the existence of itch-specific neurons. No 
matter what the stimulus was, the sensation transmitted by 
those neurons was itch. 
Conclusion
After the two initial studies that seemed to find itch-specific 
neurons, the support for the labelled line theory weakened. As 
seen above, many of the receptors for itch are also involved in 
the transduction of pain. Even more, itch responsive neurons 
in the DRG, TG, and the spinal cord also respond to algogens, 
such as capsaicin. However, with the finding of the MrgprA3+ 
itch-specific neurons, it is possible that the labelled line the-
ory is correct for at least some of itch transduction.  GRPR+ 
may also be part of this itch-specific group that mediates itch 
although further research would be necessary to confirm that. 
The study done on TG neurons also found a small population 
of pruriceptive neurons that only responded to pruritogens. 




Even if itch is mediated through the few pruriceptive-specific 
neurons, it is still possible that the units that respond to both 
pruritogens and algogens also signal itch. Pruriceptive neurons 
are a subset of nociceptive neurons. Some hypotheses are that 
if the brain only receives input from the pruriceptive neurons, 
it processes the sensation as itch. However, if the brain is also 
receiving input from the nociceptive neurons, the brain only 
processes the pain and not the itch. So although those pruricep-
tive neurons are responsive to both pruritogens and algogens if 
there is no activity in the nociceptive-specific neurons when an 
itch stimulus is activating the pruriceptive neurons, itch will be 
felt (quoted in Patel, Dong, 2010). Along the same lines, another 
possibility is that the pain pathway activates mechanisms that in-
hibit itch transduction.  Pain inhibiting itch is a familiar phenom-
enon, as it is well known that scratching relieves itch (Shmelz, 
et.al. 2003). A similar inhibition mechanism was suggested in the 
findings of a recent study. TRPV1 and TRPA1 both respond to 
algogenic stimuli. However, the study found that silencing one of 
them can cause algogens to elicit an itch response, i.e. scratch-
ing. This suggests that there can be inhibitors from the other ion 
channel that do not allow the brain to process the feeling as an 
itch (Roberson, 2013).
A final point for consideration is that most of these studies 
were done on animal models. But pain and itch may be mediat-
ed differently in different animals. Therefore, although research 
done on mice and other animals can give us an idea about the 
pathways in humans, further studies must be done to see how 
these mechanisms work in humans. 
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In Western societies, heart disease is the leading cause of death 
followed by cancer. In 2010, cardiovascular disease (CVD) 
caused a total of 788,000 deaths, which makes up nearly 32 per-
cent of all deaths. Heart disease is the leading cause of death in 
blacks, but second to cancer in Hispanics, Asians, and American 
Indians. In the United States alone, a national survey from 2007 
to 2010 showed that an estimated 83.6 million people either 
suffered from cardiovascular disease or were at risk for it. Of 
this number, 77.9 million people had hypertension and 15.4 mil-
lion people had coronary heart disease (NHLBI, 2012). As for 
cancer, more than thirteen million people in the US had cancer 
in a survey taken in 2012 (Seer, 2012).
Although important advances have been made in the treatment 
and control of cardiovascular, lung, and blood diseases, these 
diseases continue to be a major burden on the nation. It has 
been estimated that in 2009, for example, we spent $313 billion 
on treating CVD--$192 billion of which took the form of direct 
health expenditures and the other $121 billion was in the form 
of the indirect costs of mortality (NHLBI, 2012). 
Might there be a way to allay these financial and human costs? 
By way of an affirmative, this paper will explore the hypothesis 
that dietary measures can prevent and/or ameliorate cardiovas-
cular disease and cancer. 
Methods
Articles were located on the Touro library, University of Austin 
webpage, google scholar, and some journals found in the Touro 
library. The articles were critically read, reviewed, compared, 
and contrasted. 
Discussion: Genes or Diet?
Genes, surely, have role to play in explaining susceptibility to 
various diseases. For example, one of the risk factors for heart 
disease, elevated cholesterol, sometimes has a genetic cause. 
And with the rise of medical inventions, such as penicillin, people 
who might once have died young from infectious diseases now 
live long enough to develop other diseases, such as cardiovas-
cular ones and cancers. So it is possible that we are now seeing 
genetic dispositions come into play. 
However, it is unlikely that genes are the whole story. When 
people of the same genetic stock change their diet, their risk 
of getting serious diseases changes. For example, when Asian 
men move to the United States, they develop prostate cancer 
at a higher rate than their peers at home. (Cook, et. al. 1999). 
Since the men who moved to the United States did not alter 
their genes, the increased incidence of prostate cancer is likely 
a product of a change of lifestyle, of diet, or of both. Further, in 
the United States the annual number of deaths from cardio-
vascular disease increased substantially from 1900 to 1970 and 
remains high(NHLBI, 2012) ( Figure 2). While during this period, 
antibiotic use was on the rise, other changes were afoot. In par-
ticular, the way food was produced and consumed underwent 
enormous transformations. At the turn of the twentieth centu-
ry, refrigerators designed for home use had not been invented 
and meals had to be made from scratch. By 1970, housewives 
were able to buy packaged foods and fast-food restaurants were 
becoming more and more popular. 
It is plausible, then, that dietary and lifestyle factors might have 
greatly contributed to the development of serious diseases. Not 
only that, diet and lifestyle may also contribute to the disease’s 
amelioration. If so, it is only logical that cardiovascular (and can-
cer) therapy should involve changes in diet and lifestyle. 
The question then becomes: what type of diet and lifestyle is 
most protective against, and most able to ameliorate, cardiovas-
cular disease and cancer?
Non-Western Groups, Western Diseases
One place to look for answers is among groups of people who 
have low rates of serious disease. One such place is among 
hunters and gatherers, who have astonishingly low incidences 
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of both cardiovascular disease and cancer. Weston A. Price’s 
Nutrition and Physical Degeneration documents how agricul-
tural and hunter-gather groups eating their traditional diets 
tend to have very low rates of degenerative diseases. This hy-
pothesis has been supported by studies of particular groups. 
Only a few of them are listed here to give an idea of their low-
ered risk of disease. One study that surveyed blood pressure 
among Tsimani forager-farmers found that they had low blood 
pressure, and it remained low even as they aged—a finding that 
opposes the “normal” trend whereby blood pressure tends 
to increase with age.(Gurven, et al., 2012) Similarly, a study of 
traditional hunter-gatherer Cameroon Pygmies found that they 
had  less  aortic stiffness, lower LDL, and higher HDL than did 
semi-urbanized Pygmies and African Bantous.(Lemogoum, et 
al., 2012). The South Pacific commission of 1985 reported that 
the rate of cancer incidence among Fijiian Melanesians is quite 
low (Robertson, 1991). This finding is particularly striking since 
even the rates of lung cancer is one-fourth less than that of 
Polynesians and Micronesians, even though all groups smoke 
regularly. It is possible that the Melanesians’ consumption of 
leafy green vegetables, such as bele and taro leaves, is protective 
(Robertson, 1991). And in the first half of the twentieth century, 
Canadian and Alaskan Inuits eating their traditional diet had very 
low cancer rates compared to Westerners or to Inuits eating a 
non-traditional diet (Steffanson, 1960). However, in the second 
half of the twentieth century, “Inuit have undergone noticeable 
dietary changes from a diet mainly based on fish and sea mam-
mals towards a diet more dependent on imported food” and 
adapted, as well, to a Western way of life, at the same time, the 
incidence of cancer of the lung, breast, and colon, has increased 
(Friborg; Melbye, 2008). 
What characteristics do groups such as these share that might 
be protective against heart disease and cancer? The answer is not 
a particular diet per se since diets among different non-Western 
groups tend to vary quite radically. A traditional Melanesian diet, 
for example, was mostly plant-based, which included both leafy 
greens and starchy foods such as taro, but also included some 
seafood and coconut. At the other end of the spectrum, the 
Inuits traditionally subsisted on a high fat, high-meat diet that in-
cluded very little plants and other carbohydrates. Nevertheless, 
what they have in common is avoidance of a Western diet and 
lifestyle. According to this view, a Western diet and/or lifestyle 
is uniquely inflammatory and likely to increase risk factors for 
heart disease and cancer.
Untangling the Lifestyle and Diet Hypotheses
What might account for the tendency of Western diets and 
lifestyle to increase the incidence of cancer? There are many 
hypotheses ranging from an intake of excess calories to mi-
cronutrient deficiencies produced by processed foods One 
hypothesis, even, is that it is not a Western diet per se that 
increases cancer rates, but a Western lifestyle. In contrast to 
the high-stress Western lifestyle, non-Western groups tended 
to provide people with a cohesive community, a clear sense of 
purpose and/or identity, trust in a spiritual power, a more laid 
back life that is closer to the rhythm of the changing seasons 
and days. In support of this hypothesis, is the following evidence: 
Amish adults in Holmes County, Ohio had a cancer rate that 
was only 60 percent of the rate of cancer among non-Amish 
white adults in Ohio. (Westman, et al., 2010). However, since 
the Amish tend to prepare their own food, it is hard to know 
whether their lowered cancer rate was due to their lifestyle 
or to the benefits of a particular type of diet. Further com-
plicating this scenario is a study of the Old Order Amish in 
Pennsylvania, whose mean total serum cholesterol was 212 (and 
a standard deviation of 45.2), a little above the recommended 
cholesterol number (200). (Pollin, et al. 1991, Table 1). However, 
the Old Order Amish are known for being exceptionally long-
lived. (Sorkin, et al., 2005). This may be due to genetic mutation 
that protects them from the negative effects of high cholesterol. 
(Pollin, et al., 1991). 
 Given these complicating factors, one way to test the hypoth-
esis that lifestyle alone and not diet is what determines cancer 
risk would be to study groups of people that have a cohesive 
community, sense of purpose, and belief in God but eat a typical 
Western diet. If we were to find out that people on such a diet 
experienced rates of cancer similar to the general population, 
then this would contradict the lifestyle hypothesis. But such 
communities are very difficult to find, especially since people 
who adopt a Western lifestyle—even religious groups of peo-
ple—adopts, as well, the non-dietary accouterments of such a 
lifestyle, such as 9 to 5 jobs, smoking, and sedentary habits. For 
example, Seventh Day Adventists—who tend to be vegetari-
ans—tend to have lower mortality rates from serious diseases 
compared to the rest of the population. (Heuch, et al., 2005). 
But it is hard to untangle the factors that might explain this, 
since in the Seventh Day Adventist, this may be due to non-di-
etary factors, e.g. they are discouraged from smoking.
In the absence of such a stringent test, the next-best test 
would be to compare differing religious groups that each have a 
strong sense of community, purpose, and belief in God but that 
have different diets. Such a study has, in fact, been attempted 
in Denmark. A study of 11,580 Baptists, who have no dietary 
restrictions, and Danish Adventists, who are lacto-ovo veg-
etarians, found, first, that both groups, especially, the Seventh 
Day Adventists had cancer rates that were lower compared to 
the general Danish population (66.95 percent for men and 85 
percent for women), and that, second, overall “Adventists had 
lower hazard rates than Baptists” (Thygesen, et al., 2012). These 
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results suggest that both lifestyle and diet are protective or car-
cinogenic, since it turns out, first, that being part of a religious 
group might, in fact, be somewhat preventive against cancer and 
that, second, nonetheless certain kinds of diets may be more 
protective than other kinds of diet (and perhaps even more 
protective than the type of lifestyle one adopts). 
Seventh Day Adventists generally tend to consume a mostly 
vegetarian diet, suggesting that it might be a beneficial diet even 
among people who follow a Western lifestyle. 
Heart Disease: Causes and Characteristics
While some heart attacks are due to arrhythmias or faulty 
valves, endothelial injury, inflammatory oxidative stress, foam 
cell formation, and development of plaque can all be an intro-
duction for cardiovascular disease. In obstructive heart disease, 
high cholesterol sometimes oxidizes, attaches to fatty acids, 
and begins to clog the arteries (atherosclerosis). These plaques 
sometimes calcify in the body’s attempt to stabilize them, but 
this has the effect of further occluding the arteries. Occluded 
arteries make it harder to pump blood through them, and so 
blood pressure increases, in an attempt to ensure that adequate 
blood reaches vital organs. When the arteries are obstructed, 
or when the plaque is too unstable such that a clot forms and 
breaks off, then that blocks the flow of blood. This prevents 
enough oxygen from reaching the heart (as in ischemic heart 
disease), the brain (as in strokes), the lungs (pulmonary heart 
disease), or other vital organs. 
In this scenario, high cholesterol starts an inflammatory cascade. 
Dietary cholesterol is often the source of high blood choles-
terol, as well as of the fatty acids that the cholesterol trans-
ports, but the liver, too, can produce cholesterol and fatty acids. 
Further, when we take in too much sugar and starch than we 
need or than can be delivered to our cells, the liver converts 
them to fat. And insulin resistance, which prevents adequate dis-
posal of glucose, is a predictor of heart disease (Yip, et al., 1998). 
Insulin resistance shifts our metabolism from burning glucose to 
burning fat, which means that the blood will have elevated levels 
of circulating free fatty acids, which have also been implicated 
in heart disease. 
This picture is perhaps an overly simplified one. While it begins 
with the premise that the problem is elevated cholesterol, in 
a healthy body, ingested cholesterol generally should be con-
verted to pregnenolone, estrogen, testosterone, progester-
one, and cortisol. This raises the question: what is stopping or 
slowing down such a conversion? We may not be able to fully 
understand the genesis of heart disease without answering this 
question, but perhaps the answer is simply that we were not 
designed to ingest as much fat, sugar, and cholesterol that we 
currently do. So our bodies cannot convert all of it to various 
hormones.
Given these dynamics, we would expect that diets that have 
an abundance—not only of fat and cholesterol—but of sugar, 
fat, and cholesterol, to be ones that are effective at increasing 
the incidence of heart disease—which is the case in Western 
countries. Conversely, we would expect that diets that reduce 
our intake of fat and sugar would be beneficial at preventing and 
reversing heart disease.
Heart Disease and a Mediterranean Diet
There have been many attempts to find therapeutic diets that 
might prevent and reverse heart disease. One commonly stud-
ied diet is the Mediterranean diet, which comprises of mostly 
grains, fruits, vegetables, olive oil, nuts, some fish, dairy, and some 
occasional red meat. Fat makes up roughly 30 to 40 percent of 
the caloric intake and the fat itself was mostly monounsaturated 
(McKeown, et al., 2010). The Lyon Diet Heart Study was the 
first attempt to use this diet on 275 patients who had sur-
vived a first myocardial infarction. A test group was to follow 
the Mediterranean diet, while a control group was to follow the 
diet prescribed by their doctor. In patients who followed the 
test diet, the rate of cardiac death was 1.32/100 patients after 
27 months and 1.24 after 46 months. This was an impressive 
reduction in mortality compared to the control group, which 
had a mortality rate of 5.55 and 4.07 after 27 and 46 months, 
respectively (de Lorgeril, et al., 1999). Many further studies 
have attempted to replicate the success of the Lyon Diet Heart 
Study, with varying success. One review of observational studies 
estimated that a Mediterranean diet reduced the risk of heart 
disease by 8 to 45 percent (Panagiotakos, et al., 2004).
It might seem that favoring the intake of monounsaturated to 
saturated fats might account for these somewhat favorable re-
sults, but regardless of whether patients ate either type of fat, 
the disease spread just at the same rate (Castelli, 1996). Further, 
while compared to a control group, the results of adhering to a 
Mediterranean diet seem impressive, we must keep in mind that 
while it reduced the rate at which people died from coronary 
heart disease, it did not actually stop or reverse the progression 
of the disease. The disease continued to progress, albeit at a 
slower rate compared to the control group (de Lorgeril, et al, 
1999). 
Heart Disease and a Plant-Based Diet
It is possible that the Mediterranean diet is not restrictive 
enough or permits too much animal-based foods. In support of 
this hypothesis, we can point to how during World War II, when 
the Germans confiscated Norwegians’ livestock, the Norwegian 
diet was effectively limited to plants. During this time, the death 
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rates from strokes and heart attacks dropped considerably and 
then returned to pre-war levels when livestock was abundant 
again. This is an epidemiological study, but there is other evi-
dence that supports the use of a plant-based diet to control 
heart disease. First, on a jocular note, African green monkeys 
apparently find a plant-based diet to be heart protective, espe-
cially when used in conjunction with cholesterol-reducing med-
ication. Over a five-year period, these monkeys saw a halt to the 
progression of coronary artery disease (Rudel LL et al. 1995).
But clinical studies have yielded positive results for human be-
ings, too, who adopt a plant-based diet. In one study, patients 
put on a plant-based diet that had less than 10 percent fat saw a 
drop in their cholesterol: an average of fifty points, from 227 mg/
dL to 172 mg/dL. And there was a regression of heart disease 
in 82 percent of the 28 patients (Ornish et al., 1990). In this 
study, in addition to making dietary changes, the test patients 
had to exercise for three hours each week, as well as spend an 
hour a day on some type of stress-reducing exercise, such as 
meditation.
 It would have been useful to compare the effects of a regimen 
of stress-reduction alone to a dietary regimen only; this would 
allow us to better tease out the degree to which diet accounts 
for the results. But we have a semi-answer in the form of clin-
ical studies undertaken by Caldwell Esselstyn at the Cleveland 
Clinic. Twenty two patients with cardiovascular disease were 
put on a plant-based diet consisting of legumes, whole grains, 
fruits, and vegetables; the total fat intake was around 8 percent 
of total caloric intake. The 17 patients who adhered to this diet 
all witnessed a complete halt to the disease, and in 4 of them 
there were signs that the disease was reversed. One patient, 
who was limping from obstruction of the arteries in the leg, 
known as claudication, and who also had a low pulse volume 
experienced total pain relief after ten months of being on a 
plant based diet. Figure 3, below, presents the PET results of 
the myocardium of another patient before the diet and three 
weeks after: the restricted myocardial blood flow showed signs 
of restored blood flow (Esselstyn, 2014). 
While this study was a small one, a study consisting of a larger 
sample size, a cohort of 198 patients was performed. The pa-
tients had medical issues ranging from hyperlipidemia, hyperten-
sion, and diabetes. These patients were then counseled on the 
guidelines of the core of a plant-based diet. They were instructed 
to eat only whole grains, legumes, and fruits and vegetables. They 
were encouraged to take a multivitamin and a B12 supplement 
and then assured that these food and vitamins would provide 
all of their amino acid needs. Omega-6 and omega-3 essential 
fatty acids were provided in the form of flax seeds so were 
therefore also recommended as part of the diet.  Foods that 
contained oil, fish, meat, fowl, dairy, avocado, nuts, caffeine and 
sugar were foods that were prohibited. Out of these patients, 
twenty one patients were not adherent to the diet. Out of these 
twenty one patients, 13 (62 percent) experienced at least one 
cardiovascular disease event including sudden cardiac death, 
heart transplants, and ischemic stroke. This is in glaring contrast 
to the patients who did follow the diet. Out of the 198 patients, 
177 (89 percent) followed these guidelines and ninety-three 
percent of these adherent patients experienced improvement 
or even resolution of symptoms. There was only one major 
cardiovascular event that was related to disease progressions 
within the patients who adhered to the diet (Esselstyn, 2007). 
This is a 0.6 percent recurrent event rate. This contrasts sharply 
to the 62 percent recurrence rate recorded from the nonad-
herent patients. 
Because adherence is generally the hardest factor to maintain in 
a diet, this study provided the patients with a five hour counsel-
ing seminar before the start of the diet to inform the patients of 
the risks involved when ingesting animal products. The patients 
were then called and given psychological support during a 3.7 
year follow up to ensure they were adhering to the diet. This 
may have contributed to the success of the study. But there are 
some limitations to this study. First, it did not include a control 
group. Second, the patients who made up the cohort were very 
specific. They fell into a certain age range and all had history 
of cardiovascular disease. Further study would be needed to 
determine if complete prevention of cardiovascular disease can 
be accomplished in patients who do not have a history of car-
diovascular disease. Third, the sample size, even though larger 
than the sample included in the Cleveland Clinic study, is still 
rather small. 
Despite these limitations, in both of Esselstyn’s studies, the 
percentages of patients in which cardiovascular disease did not 
progress are consistent. The percentage of patients in the study 
who adhered to the diet and had a recurrence of cardiovascular 
disease events is less than one percent. This is strong enough 
data to be used in order to inform people of this cheap and 
effective option of preventing and reversing cardiovascular 





disease. And it supports the hypothesis that a plant-based diet 
can significantly affect the progression of the cardiovascular ep-
idemic that is rampant in Western countries.  
What might explain the impressive results of a plant-based 
diet? One possibility is that plant polyphenols themselves are 
heart-protective. Another is that a plant-based diet avoids the 
negative effects that might result from eating red meat, such 
as the production trimethylamine-N-oxide, a metabolite of 
L-carnitine, which has been linked to coronary artery disease 
(Tuso, et al.,  2015). Another possibility is that by restricting a 
macronutrient (fat), subjects ended up cutting out a huge source 
of calories, and so perhaps a plant-based diet better cuts calo-
ries than does a Mediterranean diet. Another possibility is that 
fat itself is harmful to the heart and so lowering dietary lipids 
to under 15 or even 10 percent might be advantageous. Perhaps 
even a zero-fat diet might not be ill-advised for some. One 
man cured himself of his migraines, reduced his blood pressure, 
and reduced his cholesterol from 252 to 206 by switching to a 
completely fat-free diet. (Brown et al. 1938). This diet, however, 
was not a plant-based one, but used sugar and defatted milk. If 
the results of this diet were shown to be useful to more than 
just one individual, then we might have found the mechanism by 
which a plant-based diet reverses heart disease: it’s the absence 
of high fat, not the plants themselves that are helpful. This would 
be a surprising finding but its validity, of course, is a question for 
further research to determine.
Cancer: Causes and Characteristics
Unlike the causes of heart disease, the causes of cancer are not 
well understood. They tend to share several basic characteris-
tics: angiogenesis (Baenke, et. al. 2013); altered fat metabolism 
(McAnderew; Baenke, et.al.2013); a preference for anaeorobic 
over aerobic metabolism (Warburg, 2009); and perhaps even 
the capacity for immortality. What might lead an organism to 
develop these characteristics? One hypothesis, forwarded by 
Otto Warburg, is that cancers are caused by derangements in 
respiratory function. Other hypotheses include the theory that 
cancer is a type of viral infection, that cancer cells are stem cells 
that (for some reason) have been unable to mature, and that 
cancer is a product of localized and/or systemic inflammation. 
But whichever hypothesis we choose, we would have to explain, 
e.g., the cause of respiratory dysfunction, the inability of stem 
cell maturation, or the causes of inflammation.
Cancer and a Plant-Based Diet
Seventh Day Adventists generally—not just, as we saw earlier, 
Danish Adventists—have lower cancer rates compared to the 
general population (Lemon, et al., 1964). Further, even among 
Adventists, the type of vegetarian diet adopted affected their 
cancer rates. Among 69,120 participants of the Adventist Health 
Study-2, there were 2,939 cases of cancer. While a vegetarian diet 
is sometimes associated with cancers of the gastrointestinal tract, 
here, vegetarians were less like to get such cancers, particularly if 
they were lacto-ovo vegetarians. Likewise, vegetarians—particu-
larly vegan vegetarians—had a lower risk of cancer compared to 
non-vegetarians (Tantamango-Bartley, et al., 2012).
 When we turn to studies assessing the relationship between 
a plant-based diet and lowered cancer risk, we find that a veg-
etarian diet, in general, even among the non-religious, appears 
to have protective effects. A 1990s prospective study of 63,550 
people in the United Kingdom found that, compared to people 
who ate meat, vegetarians were less likely to get cancer (except 
for colorectal cancer). For vegetarians, “the incidence rate ratio 
for all malignant neoplasms was 0.89” (Key, et al., 2009). 
Further, increasing people’s consumption of vegetables and whole 
grains may be beneficial even among people who have cancer. 
Case histories of cancer patients have revealed, for example, 
that pancreatic cancer patients who ate a low fat diet that in-
cluded moderately high fiber and reduced calorie had a higher 
1-year survival rate than patients who did not change their diets. 
Likewise, patients with stage D2 metastatic prostate cancer who 
followed such a diet survived longer and with improved quality of 
life compared to patients who did not change their diets (Carter, 
et al. 1993). Another study encouraged men with recurrent pros-
tate cancer to eat more vegetables and whole grains. “Median 
intake of whole grains increased from 1.7 servings/d at baseline 
to 6.9 and 5.0 servings/d at 3 and 6 months, respectively. Median 
intake of vegetables increased from 2.8 servings/d at baseline to 
5.0 and 4.8 servings/d at 3 and 6 months, respectively. The rate of 
PSA rise decreased when comparing the prestudy period (0.059) 
to the period from 0 to 3 months (-0.002, P < .01) and increased 
slightly, though not significantly, when comparing the period from 
0 to 3 months to the period from 3 to 6 months (0.029, P = 
.4316). These results provide preliminary evidence that adoption 
of a plant-based diet is possible to achieve as well as to maintain 
for several months in patients with recurrent prostate cancer” 
(Nguyen, et al., 2006). 
Additionally, a plant-based low-fat (10-15% kcal), high-fiber (30-
40 g per 1,000 kcal/day) diet, combined with daily exercise, in 
just two weeks reduced overweight women’s risk factors for 
breast cancer. This regimen reduced their serum estradiol, in-
sulin, and IGF-I. Further, serum taken from these women after 
two weeks proved able to induce apoptosis of several variants 
of breast cancer cells in vitro (Barnard, et al., 2006).
These are just a few studies, but the evidence is quite suggestive. 
Plants have a number of protective properties (such as poly-
phenols) so simply increasing plant foods may be protective. 
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But part of the protection may be also the result of reducing 
the consumption of other foods, particularly processed foods, 
meat, and added fats. It is striking that people such as McDougall, 
Ornish, and Pritikin emphasize the importance of keeping di-
etary fat low, not just of increasing the amount of plant matter. 
This makes sense to some extent since some fats themselves 
might contribute to the development of cancer. For example, 
prostate cancer is detected among men in the United States 
at a rate that is fifteen times higher than the rate of detection 
among men in Asian countries, who eat a lower-fat diet than 
American men (Parkin, et al., 1990). And, as mentioned earlier, 
when Asian men move to the United States and presumably 
increase their intake of fat, they develop prostate cancer at 
a higher rate than their peers at home (Cook, et. al., 1999). 
Further, compared to subjects who ingested less fat compared 
to the controls, lowering fat intake led to the development of 
smaller tumors as well as to tumors that grew more slowly—at 
least in immunodeficient mice who were able to eat ad libitum 
(Tung, 2014). It is worth noting that different types of fat may 
have different effects. In the study just cited, the mice on both 
the high-fat and low-fat diets ingested omega-6 fatty acids in the 
form of corn oil. In contrast, among mice whose main source of 
fat was saturated, there was little difference in the development 
of tumors in mice fed a diet high in fat (40 percent) versus those 
fed a diet low in fat (12 percent). This would suggest, as the 
authors of this study do, that lowering saturated fats does not 
slow the growth of prostate tumors, but reducing omega-6 fats 
might be beneficial (Lloyd, et al. 2010).
Cancer and Ketogenic Diets
Before we too hastily conclude that fat is carcinogenic, we should 
recognize that there is some evidence that ketogenic diets, which 
have been shown to be protective against epilepsy, might be pro-
tective against cancer too. Some scholars hypothesize that since 
cancer cells thrive on glucose, depriving them of it might, in princi-
ple, lead to their eventual death. On the other hand, since normal 
cells are able to run on ketones, a very high fat, low carb and low 
protein diet should be harmful only selectively (to cancer cells, not 
to normal cells) (Allen, 2014). There are very few human studies 
that demonstrate the purported benefits of a ketogenic diet. One 
of these studies included two young girls who had advanced-stage 
brain tumors that remained even after they were subjected to 
radiation and chemotherapy. Although the chemotherapy and 
radiation were not successful, the tumors were able to be man-
aged long-term by using a ketogenic diet. (Nebeling,1995). Thomas 
Seyfried has replicated these results among mice with brain 
tumors (Seyfried 2008; Seyfried 2003). Further studies on mice 
suggest that a ketogenic diet reduces blood glucose and slows 
the growth of tumors, a result that is compounded when used in 
conjunction with hyperbaric oxygen therapy (Poff, 2013). 
There is not enough evidence to determine which one is more 
effective, but it seems that a very high fat diet, just as a low 
fat plant-based diet, might be effective, to some extent, against 
cancer. 
High Fat or Low Fat?
On first glance, this seems to be a surprising result: two diets 
that could not be more different from each other both seem to 
exert some protective effects against cancer. Perhaps the same 
conclusions can be drawn as was earlier when confronted with 
the fact that non-Western people who consumed radically dif-
ferent diets nevertheless had similar low rates of cancer: the 
protective effects of different diets may be due less to their 
component parts than to their shared avoidance of certain 
foods, such as processed meats or artificial ingredients. Or it 
might be that a ketogenic diet is protective against certain type 
of cancers, but not others, while a low-fat, plant-based diet is 
more protective against other types of cancers. It should be 
noted that all of this is based on Warburg’s considering that all 
types of cancer have the same type of causes. But it is possible 
that each cancer has a different cause and that therefore resolv-
ing it would require a diet targeted for that particular cancer. It 
might even be that cancers themselves might evolve in slightly 
different ways so that someone who has stage-1 breast cancer 
might respond well to one kind of diet while the same person 
with a stage-4 breast cancer might respond badly to the same 
diet. 
However, bracketing that possibility for now, another hypothesis 
might be that certain foods—or food groups—are protective 
but only when taken alone such that combining them with an-
other type of food might weaken their protective effects, or 
even cause negative ones. According to this hypothesis, perhaps 
a very high fat alone may be protective, as is high-carb plant food 
diet. Combining both fat and plant-based carbs, on the other 
hand, might have a different effect. This is a topic for future 
research.
Conclusion
Western countries have the highest incidence of atherosclero-
sis. Not coincidentally, these countries have easy access to an 
abundance of foods that are high in fat, sugar, starch, and cho-
lesterol. If North America and Europe claim to have the most 
advanced medical care, what are these health care systems 
doing to prevent atherosclerosis, in particular, and heart disease, 
in general? In 1989, the National Research Council created a 
report called “Diet and Health,” which recommended keeping 
cholesterol levels under 200 mg/dL and dietary fat to 30 per-
cent of one’s caloric intake. However, these guidelines are con-
testable, since it is possible that “a greater reduction [of choles-
terol and dietary fat] would confer additional health benefits.” 
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(Ornish, 1998).  The suggestion that cholesterol levels between 
150 and 200 might be too high is supported by a study show-
ing that 35 percent of patients with ischemic heart disease had 
a cholesterol level between 150 and 200 (Castelli, 1996). The 
National Research Council, the American Heart Association, 
and the National Cholesterol Education Program recommend 
a diet that includes oil, low-fat milk, butter, and cheese. But if 
atherosclerosis and heart disease in general are closely linked to 
high cholesterol, their recommended diet by may be too lax to 
lower cholesterol levels. In light of the evidence, it would appear 
that in order to prevent and reverse heart disease, we would be 
well advised to adopt a very low fat, plant-based diet.
Adopting a low-fat, plant-based diet might also help reduce our 
chances of getting cancer, but there is also evidence suggesting 
that a high-fat ketogenic diet might be advantageous. Which diet 
should we prefer? Given differences in our genetics and physiol-
ogy, some people might be better off on a ketogenic diet while 
others might fare better on a low-fat plant-based diet. Current 
knowledge does not tell us who would do better on which diet, 
but it is reasonable to suppose that people whose ancestors ate 
a certain type of diet might be more adapted to that diet than 
other people. The Inuit, for example, over the generations might 
have evolved the capacity to be able to process huge amounts 
of fat safely. But other than a few groups whose ancestral diet 
is known, what should the average Indo-European person do?
Given our lack of knowledge about the long-term effects of 
ketogenic diets, it might be best to adopt a low-fat diet instead. 
We have no evidence comparable to that of long-term vege-
tarian diets, that a long-term ketogenic diet is safe or prevents 
the development cancer (as opposed to attenuating its growth). 
We cannot point to the Inuits in support of the safety of a 
ketogenic diet since, although they ate a high-fat diet, it was 
nevertheless not on a ketogenic one: they ate some carbohy-
drates and enough protein that could then be converted, via 
gluconeogenesis, to glucose. Therefore, it is wise for many of us 
to adopt a low-fat plant-based diet, especially since it appears to 
be beneficial in reducing heart disease.
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Introduction
The development of human beings, like any other organisms, is 
affected by the method and means of feeding. Breastfeeding has 
many undisputed benefits recognized across the board by the 
medical community. However, modern life makes it that physical 
breastfeeding effects are not an issue of life or death, or even 
keeping serious illnesses away (Christakis, 2013). Consequently, 
women need an alternative motive for choosing to breastfeed, 
and continuing to breastfeed. This paper examines some of the 
cognitive developmental findings related to prolonged breast-
feeding. Indeed, intelligence testing and imaging studies show an 
encouraging correlation between elevated IQ and babies who 
were breastfed. 
With all research indicating that breastfeeding is the superior 
option when it comes to feeding babies, continued exploration 
of the benefits may seem superfluous. Discovered benefits of 
breastfeeding, however, are mostly limited to physical health 
advantages, which is not enough to motivate women to breast-
feed. Reason being, the physical benefits are usually limited to 
early childhood, and do not have effects beyond that. Some 
examples of benefits that do not extend past early childhood 
include reduction of gastroenteritis, otitis media, and atopic ec-
zema (Christakis, 2013,). On the other hand, cognitive effects 
from breastfeeding have lifelong implications, starting at infancy, 
and extending way beyond early childhood. This compilation 
brings together research studies on IQ and brain structure of 
different age groups to present a significant correlation between 
breastfeeding and cognitive development. 
Methods
The perusal of journal articles and research papers through the 
Touro College online library system. 
Breastfeeding and Infant Intelligence
Intelligence in infants is a difficult factor to determine, as much 
of the cognitive functions of babies are shrouded in mystery. 
Yet, we know that a baby’s visual acuity gradually increases until 
it reaches a standstill at around twelve months. Consequently, 
researchers used visual acuity as a determining factor in intel-
ligence to look for a correlation between breastfeeding and 
early infant intelligence. Two groups of infants, one consisting of 
breastfed  infants and the other consisting of formula fed infants, 
were assessed for intellectual ability using visual acuity as an 
indicator. Behavioral testing analyzed infants’ tendencies to look 
at patterned cards versus blank cards at ages one, two, three, 
and four months. From the two groups that were assessed, both 
improved significantly from the first to fourth month. However, 
the group of breastfed babies significantly surpassed the formula 
fed babies in visual acuity scoring. These results were parallel to 
findings of “a decrease in docosahexaenoic acid (DHA) of red 
blood cells in formula  fed infants” (Michaelsen et al, 2003).  
DHA is an omega-3 fatty acid found in breast milk.  DHA  seems 
to play a role in cognitive development. This is evidenced by 
the combination of results of the former study and a random-
ized intervention study that supplemented infant formula with 
DHA  and tested the visual acuity of these infants. When infants 
took formula supplemented with DHA, their scores on the 
visual acuity test were better than infants who were drinking 
non-supplemented formula, but not as well as infants who were 
breastfeeding (Michaelsen, 2003). 
Yet, DHA cannot be the only ingredient in breast milk influenc-
ing cognitive development. If it were, the supplement of DHA 
in infant-formula would be enough to produce the same visual 
acuity results as breastfed infants. However, DHA along with 
other nutrients can be responsible for the cognitive benefits of 
breast milk over formula. These nutrients, which are not found 
in cow milk or formula, have positive effects on cognitive de-
velopment, and cannot be duplicated because they are not all 
known elements. “Nobody has been able to reproduce human 
breast milk because there are lots of elements in it that we 
probably don’t even know about” (Lisser, 2002). At least until 
we figure out how to duplicate all the nutrients found in breast 
milk, breastfeeding will remain the single, most-effective way to 
ensure the highest level of cognitive development in infants. 
Abstract
This paper explores the cognitive effects of breastfeeding through Intelligence Testing and Imaging Testing that compares 
IQ, success, and brain structure of individuals that were breastfed, formula fed, and both breastfed and formula fed. 
Intelligence studies available are widespread for all age groups and signify a causal relationship between breastfeeding and 
intelligence. However, imaging testing is not as extensive, but shows a strong correlation between cognitive development 
and breastfeeding. The mechanism of breast milk’s impact on cognitive development is at an exploratory phase, with a 
possibility that docosahexaenoic and arachidonic acids, along with other nutrients found in breast milk, contribute to 
preferential neural development. Altogether, the biological principle that structure equals function, is supported by evi-
dence from Intelligence and Imaging tests that structural differences in the brains of those who were breastfed, caused by 
the components of breast milk, results in superior intelligence (than non-breastfed individuals) throughout life.
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Breastfeeding and Toddler Intelligence
Toddlers  too, display higher levels of cognitive functioning when 
they are breastfed for prolonged periods, compared to babies 
who are breastfed for less than four months, or formula  fed. 
This was determined by assessing the cognitive development of 
two-year olds via mental and psychomotor development, using 
the Bayley Infant Developmental Tests. Psychologists adminis-
tering the tests found that “at 24 months, infants breastfed for 
longer than 4 months scored higher than those breastfed for 4 
months or less and higher than formula  fed infants” (Gomez-
Sanchiz et al., 2004). In another instance, toddlers who were 
breastfed up to three months scored 4-5 points higher than 
those who were formula fed on psychometric tests, determining 
IQ (Jedrychowski, 2011). 
Exclusive breastfeeding, as opposed to complementary breast-
feeding also plays a positive role in the IQ of toddlers. The 
younger the child, the more significant the difference in IQ is 
between exclusively breastfed toddlers, and complementary fed 
toddlers. In one year-olds, exclusive breastfeeding resulted in 
a .0547 disparity between intelligence scores of toddlers that 
were exclusively breastfed, and toddlers that were complemen-
tary breastfed. At two years, a notable disparity between the 
intelligence scores of the two groups still remained, but shrunk 
to .0386. Exclusive breastfeeding affects IQ in toddlers positive-
ly, even if the time period of exclusive breastfeeding is short 
(Jedrychowski et al., 2011).
Breastfeeding and Intelligence in  
School-Aged Children
During the first year of school, children who are breastfed 
have an academic advantage over children who are formula fed. 
According to teacher-assessed education assessments of five year 
old children in England, using FSP (Foundation Staged Profile), du-
ration of breastfeeding influenced the children’ academic success. 
In areas of personal, social, and emotional development, as well 
as communication, literacy, and language, longer breastfeeding 
caused higher scores to be more likely (Heikkilä, 2014). Duration 
of breastfeeding was divided into four categories; never, less than 
two months, two to four months, and longer than four months. 
Children breastfed for up to two months were 9% more likely 
than children never breastfed to receive good overall achieve-
ment scores. Additionally, the longer a child was breastfed, the 
more likely he/she was to receive good overall achievement 
scores. Putting the three categories of breastfeeding together, 
and comparing it to children who were never breastfed, shows 
a 10-16% greater chance of good overall achievement scores for 
children who were breastfed (Heikkilä, 2014). 
Notably, the relationship between breastfeeding and cognitive 
development is not   exclusive to academic success. Rather, 
breastfeeding affects cognitive development in areas that include 
emotional and social intelligence, as well. Emotional and social 
intelligence first begin to influence success in earlier grades of 
school, but continue  through high school and adulthood to 
have a more significant impact on success. Consequently, the 
influences of breastfeeding on emotional and social cognitive 
development are more prevalent throughout adulthood, com-
pared to early childhood. This directly supports the notion that 
positive cognitive effects of breastfeeding are long-term, and a 
better reason than the well-known, short-term physical health 
effects of breastfeeding, for which women choose to breastfeed 
(Heikkilä, 2014).
Breastfeeding and Intelligence in Adolescents
The effects of breast-feeding on cognitive development also ex-
tend into the realm of adolescent intelligence, which is a long 
way off from the actual act of breastfeeding. “In New Zealand, 
breastfeeding duration was positively associated with perfor-
mance in secondary school tests in students aged 18 years” 
(Victora et al., 2015). Students who are breastfed are also more 
likely to finish a higher grade of school. A study of 2,000 male 
Brazilian adolescents ages 18, found an increasing trend in fin-
ishing higher grades 
with students who were breastfed. “Those breastfed for 9 
months or more were ahead by 0.5-0.8 school grades, relative 
to those breastfed for less than 1 month” (Victora et al., 2005). 
Breastfeeding and Intelligence in Adults
Various studies on the effects of breastfeeding positively influ-
encing adult intelligence found a correlation between the two. 
In Brazil, intelligence, educational attainment, and income were 
all higher in 30 year-olds who were breastfed as infants. The 
table on the left shows that IQ mediated 72% of all incomes, 
with external factors only mediating 28% of income (Victora 
et al., 2015).
. This was after base cofounders, including family income at birth, 
parental education, household score index, genomic ancestry, 
maternal smoking during pregnancy, and birth weight, were 
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taken into account. The post-cofounder (educational attain-
ment) was also taken into account. The results of this study 
strongly supports the notion that breastfeeding influences IQ, 
which in turn influences income and educational attainment 
(Victora et al., 2015).
Other studies found a positive correlation between breastfeed-
ing and IQ in adults. For example, an IQ test administered to 
27 year old Danish citizens in Copenhagen found a six-point 
difference in the IQ scores of people breastfed for a while ver-
sus people who were not breastfed for a long period of time. 
“Babies breastfed less than a month had a mean IQ of 99, com-
pared with an average of 106 among infants breastfed seven 
to nine months” (Lisser, 2002). Similarly, in Belarus, IQ scores 
were on average 7.5 points higher in 65 year-old adults who 
were breastfed. Another study also shows that 53 year olds in 
Britain who were breastfed scored better on the National Adult 
Reading Test than their non-breastfed counterparts (Victora 
et al., 2015). Altogether, the studies on adult intelligence and 
breastfeeding support the thesis that breastfeeding affects in-
telligence at all ages.
Breastfeeding and Brain Structure
Now that a comprehensive analysis of breastfeeding effects 
on overall intelligence, from infant through adulthood, is un-
derstood, it is important to examine the physical effects of 
breastfeeding on the brain structure. Since we know structure 
parallels function, the development of an organ should correlate 
with the function it carries out. Consequently, if the brains of 
children who are breastfed have higher IQs, then something in 
their brains’ structure ought to represent the higher functioning 
intelligence emitted from the brain. Moreover, finding a specif-
ic occurrence in the brains of people who are breastfed that 
cannot be found in the brains of those who are not breastfed 
would solidify the conclusion that breastfeeding has long lasting 
cognitive effects.
Breastfeeding and Brain Structure in Toddlers
The brain structure of breastfed toddlers compared to the 
brain structure of non-breastfed toddlers show increased my-
elin water fraction (VFM) in the brain structure of the breastfed 
infants. Myelinated white matter makes up the backbone of the 
brain’s neural systems, and facilitates “rapid and synchronized 
brain messaging” needed for higher levels of cognitive functions 
(Deoni, 2013). “Aberrations in myelination, or deficiencies in 
myelin content or integrity, can have profound deleterious ef-
fects on brain function” (Fields, 2008). 
A study investigated brain white matter maturation in 133 tod-
dlers, ages 10 months to 4 years. Imaging times lasted 19 min-
utes in the younger toddlers, and 24 minutes in the 4 year olds. 
“Each infant was scanned using the mcDESPOT (multicompo-
nent Driven Equilibrium Single Pulse Observation of T1 and T2) 
white matter imaging technique which provides a quantitative 
measure of the myelin water fraction (VFM) at each imaging 
point throughout the brain” (Deoni et al., 2013). 
Results found that breastfed toddlers, in comparison to both 
formula fed, and to those that were breast and formula fed, had 
more VFM  in many regions of the brain associated with visual 
reception skills, and receptive language scores.  “In contrast with 
children who 
received both breast milk and formula, exclusively breastfed 
children had significantly greater VFM (p < 0.05, FER corrected) 
in brain regions including: left optic radiation adjacent to the an-
gular gyrus; right inferior parietal lobe, near the somatosensory 
cortex; bilateral premotor cortex; and right prefrontal cortex” 
(Deoni, 2013). Additional brain regions expected to mature 
later on had more VFM including the corpus callous, internal 
capsule,  corticospinal tract, cerebellum, and left optic radia-
tion. The results of this study support the researchers’ initial 
hypothesis that docosahexaenoic and arachidonic acids found in 
breast milk, and not present in formula, causes preferential brain 
development in breastfed toddlers (Deoni, 2013).
Breastfeeding and Brain Structure in Adolescents
The brain structure of breastfed adolescents compared to the 
brain structure of non- breastfed adolescents shows a notable 
difference in cortical thickness. From an MRI analysis of cortical 
regions associated with cognitive abilities relating to general 
intelligence, cortical thickness was assessed. Findings suggest 
that exclusive breastfeeding predicts cortical thickness in the 
superior and inferior parietal lobules of the parietal cortex 
(Kafouri et al., 2013). Even after adjustments were made for age 
and sex, findings show that the longer the duration of breast-
feeding, the thicker the cortex (Kafouri et al., 2013).  Although 
the mechanism for a correlation between cortical thickness and 
breastfeeding is unclear, one possibility was recently suggest-
ed: “long-chain polyunsaturated fatty acids (LC-PUFAs), mainly 
docosahexaenoic acid (DHA), underlie neurodevelopmental 
benefits of breast milk” (Kafouri et al., 2013). This possibility 
is supported by Deoni’s hypothesis that docosahexaenoic and 
arachidonic acids found in breast milk causes preferential brain 
development. Michaelson’s  finding of “a decrease in DHA of red 
blood cells in formula  fed infants” also supports this possibility 
(Michaelson, 2003).  
Conclusion
Relative to breastfeeding, intelligence testing on all age groups 
establishes a causal relationship between breastfeeding and IQ. 
Once imaging testing gets involved, however, the relationship 
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between cognitive development and breastfeeding is solidified. 
According to the basic biological principle that structure equals 
function, the function of greater intelligence, paired with differ-
ent brain structure in people who are breastfed, confirms, be-
yond a reasonable doubt, that breastfeeding has widespread and 
long-term positive effects on cognitive development. Indeed, 
studies conducted thus far are enough to conclude breast-
feeding’s effects on cognition. However, more studies on the 
structure of the brain might help us conclusively determine the 
mechanism of how breast milk positively influences cognitive 
development.
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We live in an age of incredible technology, discovery and med-
icine. Smartphones, spaceships, and bionic eyes are no longer 
reserved for science fiction. Vaccinations are among the ground-
breaking medical discoveries which “allow us to engage our 
adaptive immune systems to produce highly specific antibodies 
and immunological memory against a potential future infection” 
(Federman, 2014). Through exposure to an inactivated pathogen 
in a safe way, the body’s innate immunity learns how to properly 
adapt to the previously deadly pathogen. Still though, over two 
hundred years following Edward Jenner’s successful use of cow-
pox material to create immunity to smallpox, in 1796, there are 
still those hesitant to make use of vaccinations for themselves 
and their children (Riedel, 2005). Consequently, it is quite con-
cerning that an anti-vaccination movement persists. Particularly, 
people are concerned over a potential correlation between 
vaccinations and autism (Federman, 2014). Is vaccination so 
harmful that it is worth not getting vaccinated? Abstaining can 
put others at a higher risk of developing the given disease be-
cause there will be more disease carriers in the population. Or 
is vaccination harmless, or at minimum,  do the benefits greatly 
outweigh the potential harmful side effects? Further, is it a mat-
ter of science or simply emotion discomforting those against 
vaccinations?
Methods
The research obtained regarding the potential side effects and 
benefits of various vaccinations was collected from a variety 
of sources. Most notably was the use of Touro’s online library 
which provides access to databases such as Pubmed, Proquest, 
and more. Further, additional articles were found through 
Google  Scholar searches of relevant original and peer reviewed 
articles on the topic. After reviewing an adequate number of 
articles on the good and bad of vaccinations, evidence was com-
piled which attempts to answer the research question. 
Potential Benefits of Vaccinations
An important example of an efficacious vaccine is the Smallpox 
vaccination. In fact, the only way to be protected from Smallpox 
is through vaccination. Though Smallpox was once a virulent 
disease taking the lives of over one third of those infected, it has 
since been eradicated by means of vaccinations (Fenner et al., 
1988). The protection from Smallpox, influenza, polio and many 
other diseases and viruses are already well-known vaccination 
benefits. Consequently each specific type of vaccination will not 
be directly expressed in this paper; rather, on the CDC website 
(2015) the entire list of dozens of possible vaccinations can be 
located. Instead, further benefits associated with vaccination 
uptake will be presented. 
Are vaccinations effective at eradicating diseases? Regarding 
the effectiveness to eradicate an epidemic, there is a concept 
known as “herd immunity.” Fine (1993) explains that “If an in-
fection is to persist, each infected individual must, on average, 
transmit that infection to at least one other individual. If this 
does not occur, the infection will disappear progressively from 
the population.” Note, there are those who are too young or 
too sick to become vaccinated, without herd immunity, many 
people will be at risk. Therefore, the higher percentage of those 
vaccinated, the higher the efficacy of any given vaccination in 
Abstract
Research has proven that vaccines prevent disease. Important medical organizations conclusively support and advise 
the administration of vaccinations to prevent diseases that once caused devastating effects both in the individual who 
contracted, and in communities where these diseases spread. While some groups protest against the constitutionality 
of vaccinating, others counter that failure to do so subjects the unvaccinated to illness and death by contracting and 
spreading of the sickness. Despite statistics on reduced incidence of diseases with few consequences as a result of 
vaccine-induced passive immunity, fears of harm secondary to vaccination loom. In the 21st Century, many people are 
unaware of diseases that still occur in undeveloped countries due to herd immunity through a majority vaccinated pop-
ulation. The diseases, however, are only a plane ride away. Due to globalization, vaccine preventable diseases can land in 
anyone’s kindergarten. Although the link between vaccination and autism was pinned to research that was subsequently 
retracted, the rate of not vaccinating children continues to rise and these unvaccinated children pose risk to others 
who are unable to receive vaccines and compromise the core herd immunity. As modern science strives to demonstrate 
vaccine safety and efficacy, despite the rare but undisputed adverse effects, individual decisions to vaccinate remain a 
complex process with differences in perception, beliefs, and values to consider. These tenets will manage to produce 
research and evidence to support both pro-vaccination and against-vaccination in an attempt to determine if the poten-
tial benefits of getting vaccinated outweigh the detrimental side effects that may result. Further, a better understanding 
of the ramifications secondary to original research that noted negative correlations among vaccinated individuals and 
the vaccines they received will be understood. These controversies are the ripples experienced as a result of retracted 
and unethical research. 
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protecting not only those vaccinated, but also the population 
as a whole. 
Are vaccinations worth the expense? Vaccinations are cost ef-
fective and also save considerable amounts of money in health-
care costs. Zhou et al. (2014) determined that for children born 
in the United States in 2009, the nine vaccinations included in 
their study will prevent 20 million cases of disease and save 
42,000 children from early deaths. Further, the same vaccina-
tions will yield a savings of $13.5 billion in direct medical and 
non medical costs, including factors such as treatments for a 
primary infection, travel costs, special education and equipment 
costs for children disabled by disease, as well as further costs 
in extended hospital stays caused by medical complications. 
Furthermore, an additional $68.8 billion will be defrayed in total 
societal costs, most notably lost wages. The net savings would 
total a staggering $82.3 billion.
Though $82.3 billion is no small price, still this study did not 
include the Influenza vaccination, in their estimate. Therefore, 
the determined financial benefits of vaccinations may be un-
derstated. For example, during the eleven influenza epidemics 
in the United States from 1969 until 1994, there were between 
130,000 and170,000 influenza-associated hospitalizations per 
epidemic with more than 20,000 influenza-associated deaths in 
5 of epidemics; and over 40,000 influenza-associated deaths oc-
curred during the other 6 epidemics. (Pleis & Gentleman, 1998). 
Furthermore, this study is limited to the United States, globally 
there exists a more vast market for saving. The additional money 
that is saved in healthcare costs, the further resources  that can 
be allocated for vaccine research. For example, it is believed 
that diseases like cancer, epilepsy, and many more potentially 
can be prevented with vaccines but more research is needed. 
Regardless if these cures are a future possibility, there are plen-
ty other worthy uses for the extra money that can be saved 
through becoming vaccinated. 
Today healthcare workers are able to be protected from their 
sick patients with vaccine preventable viruses. Healthcare work-
ers can be immunized and safely care for sick patients. They need 
protection not only from airborne viruses but also blood borne 
viruses contractible via shared needles. In the United States, it is 
estimated that there are 385 thousand cases of reported needle 
stick injuries per year. Incidentally, this number is an underesti-
mation because it is expected that a  significant number is unre-
ported (Elmiyeh et al., 2004). People need to continue working 
and do not report needle stick injuries because they fear getting 
reprimanded for using equipment improperly.
Another potential benefit of vaccinations is to protect unborn 
children. Mothers who have received vaccinations can protect 
their unborn children from birth defects caused by certain vi-
ruses and further, vaccinated communities can help eradicate 
diseases to benefit future generations. Between 1963 and 1965, 
prior to the licensing of the rubella vaccine in 1969, a global 
rubella outbreak caused the deaths of 11,000 babies, and also 
birth defects in 20,000 babies in the United States. Therefore 
when women are vaccinated as children against rubella, they 
have significantly decreased the chance of passing the virus to 
their unborn or newborn children. This potentially eliminates 
the numerous birth defects associated with rubella, such as 
hearing and or vision loss, heart problems, congenital cataracts, 
liver and spleen damage, and mental disabilities (CDC, 2011). 
These birth defects can decrease quality of life and often require 
resources to help improve outcomes.
The last benefit is that research indicates that some viruses 
cause cancer. For example, the human papilloma virus (HPV) 
has been associated with cervical cancer (Marur et al., 2010). 
Therefore, it is important to realize that vaccinations are im-
portant to immunize against diseases to prevent the onset of 
side effects that can result; some of these may ultimately be 
lifesaving.
Potential Side Effects of Vaccinations
Regarding the possible negatives of vaccinations, it is important 
to consider the evidence for a correlation between vaccinations 
and developing autism. During the late nineties the link dissuad-
ed people from taking vaccinations and now almost twenty 
years later the fear lingers. A clinical study found that “behav-
ioral problems had been linked, either by the parents or by the 
child’s physician, with measles, mumps, and rubella vaccination” 
(Wakefield et al., 1998). This early report became widespread 
and propelled the anti-vaccination movements taking place even 
today. The study was preformed using twelve children ranging 
in ages three to ten, with eleven of them male. Prior tests de-
termined that all twelve children showed satisfactory achieve-
ment of early milestones. These children all lived normal lives, 
but then lost certain skills, notably the ability to communicate. 
Further, they all had gastrointestinal symptoms. e.g. diarrhea and 
abdominal pain. The children underwent assessment and review 
of their gastroenterological, neurological, and developmental 
records. Results indicated all twelve children had intestinal 
abnormalities, ranging from aphthoid ulceration to lymphoid 
nodular hyperplasia. Additionally, “onset of behavioral symptoms 
was associated, by the parents, with measles, mumps, and ru-
bella vaccination in eight of the twelve children with measles 
infection in one child, and otitis media in another” (Wakefield 
et al., 1998). They each developed autistic behavioral disorders, 
nine of which developed autism. Disintegrative psychosis and 
possible post-viral or vaccinial encephalitis were less prevalent, 
representing one and two cases respectively. 
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It is suggested that autistic-spectrum disorders have a direct 
connection to intestinal dysfunction (Wakefield et al., 1998). 
In addition to this study, there are previous studies that link 
the connection between a dysfunctional or inflamed intestine 
and autism. For example, the “opioid excess” theory of autism, 
proposed originally by Panksepp (1979) explains that autistic 
disorders result from “incomplete breakdown and excessive 
absorption of gut-derived peptides from foods, including bar-
ley, rye, oats, and caesin from milk and dairy produce.” These 
remaining peptides can stimulate the formation of harmful 
peptidase enzymes which break down endogenous central-ner-
vous-system opioids, leading to disruption of neuroregulation 
and brain development (Shattock, et al., 1991). Interestingly, 
it has been observed that following removal of a provocative 
enteric antigen, the children achieved symptomatic behavioral 
improvement (Lucarelli, et al., 1995).
Still, the debate around the cause of autism remains controver-
sial, and some, like Wakefield, postulate the incidence is cor-
related with childhood vaccination. To examine this hypothesis 
a retrospective study of 537,303 randomly selected children’s 
cases were examined to determine association of the Measles, 
Mumps, Rubella (MMR) vaccine and autistic disorder. Of the 
group, a total of 440,655 children had received the MMR vac-
cine, with only 758 children diagnosed with some degree on 
the autistic spectrum, of which 316 were diagnosed with the 
most severe on the spectrum, autistic disorder. The incidence 
rate was 0.17% which is insignificant compared to the 7.7% to 
11% range among various unvaccinated groups. Madsen et al, 
(2002) therefore concluded that there is no scientific causation 
between vaccination and autistic disorder or other autistic 
spectrum disorders. 
Regarding the two conflicting studies, the size of their corre-
sponding test groups is incomparable. Wakefield (1998) per-
formed the study on just 12 children in one time frame, while 
Madsen conducted a retrospective study on almost half a mil-
lion vaccinated children over the course of a few years. Though 
Wakefield seemingly proves a correlation between developing 
gastrointestinal problems following an MMR vaccination, more 
research is required to be conclusive that vaccinations can 
cause autism. However, in Madsen’s (2002) study utilized about 
half a million children studied over multiple years. Therefore, 
Madsen’s conclusion can be trusted that autism is not a side 
effect of vaccinations.
In an addendum to reinforce his conclusion, Wakefield added 
another 40 patients to his study, with 39 having the autistic syn-
drome. Still, his total of 52 patients is not as significant as the 
broader study done by Madsen. Another potential issue with 
Wakefield’s study is that he quotes Lucarelli who explains that 
autism is reversible; this is a powerful claim that has yet to be 
confirmed. Furthermore, the Lancet released an official state-
ment retracting Wakefield’s study. Here is their full statement:
Following the judgment of the UK General Medical 
Council’s Fitness to Practice Panel on Jan 28, 2010, it has 
become clear that several elements of the 1998 paper 
by Wakefield et al are incorrect, contrary to the find-
ings of an earlier investigation. In particular, the claims 
in the original paper that children were “consecutively 
referred” and that investigations were “approved” by 
the local ethics committee have been proven to be false. 
Therefore we fully retract this paper from the published 
record (the Editors of the Lancet, 2010).
In spite of this retraction, people clung to this concept that 
there is a relationship between vaccinations and a development 
of autistic spectrum disorders. It is astounding that the very 
Wakefield paper which led people to believe the MMR vaccina-
tion causes autism was retracted due to ethical misconduct.  In 
addition the Lancet retracted the Wakefield paper for nondis-
closure of financial interests. They reported that their sampling 
was randomized, however, in fact, it was selective. For example, 
in order to attract subjects, the researches offered a fee for 
parents of children who received the MMR vaccine and also had 
a previous diagnosis within the autism spectrum.(Sathyanaraya 
Rao & Andrade, 2011).
Not only does Madsen (2002) amply prove there is no correla-
tion between vaccinations and autistic disorders, Wakefield’s 
study has since been completely retracted. Perhaps the most 
appalling long-term affect is that the myth is so deeply ingrained 
that parents are refusing to vaccinate their kids out of fear of 
harm, and, unfortunately, some of these kids will or have already 
succumbed to the greater danger of contracting a vaccine-pre-
ventable illness. Because the official retraction was a mere para-
graph in length and lacks detailed explanations, it slipped under 
the radar of the common folk and now people still believe 
Wakefield has legitimacy. 
There is a potentially serious complication from vaccine admin-
istration known as Guillain–Barré Syndrome (GBS), which is a 
paralysis that begins on the lower extremities and migrates up 
the body. The legs become numb and as it ascends the body it 
leaves paralysis of muscles in its wake. An immune response is 
triggered that directly destroys either the myelin sheath sur-
rounding the peripheral nerves or even the axon itself, leaving 
scar tissue in its midst. Unfortunately, if not promptly treated 
it will paralyze the breathing center, which is located at C3 of 
the cervical spinal column and breathing will require mechani-
cal assistance (Koski, 1994). Dr. Tamar Lasky and her colleagues 
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studied the 1992-1993 Influenza Seasons and did in fact discover 
a direct increase in cases of Guillain–Barré Syndrome within the 
first six weeks following vaccination. At first glance, this discov-
ery should shy people away from getting vaccinated. However, 
Lasky determined the increased risk to be only an additional 
0.61 cases per million vaccinations. Further, even after an ad-
justment to include four factors that would make the original 
estimate conservative, their most accurate estimate of the at-
tributable risk would be 1.1 case per every million vaccinations. 
Therefore Lasky argues that, “Even if Guillain–Barré syndrome 
were a true side effect in subsequent years, the estimated risk 
for Guillain–Barré syndrome of 1 to 2 cases per million persons 
vaccinated is substantially less than that for severe influenza, 
which could be prevented by vaccination in all age groups, espe-
cially persons aged ≥65 years and those who have medical indi-
cations for influenza vaccination” (Lasky et al., 1998). Therefore, 
despite the reality of the GBS complication caused by vaccina-
tions, many still opt to prevent serious diseases by vaccination. 
Although avoiding vaccinations still remains controversial to 
many, the relative risk of experiencing a complication is low, and 
it could be considered neglect by parents to abstain from vac-
cination of children in an era where vaccines can protect these 
children from many serious diseases. As was aforementioned in 
this paper,  the disproportionate number of 20,000 lives that 
would be saved from influenza epidemics alone far outweighs 
the minimal risk of contracting GBS (Pleis & Gentleman, 1988). 
Each year there are 30,000 Vaccine Associated Events (VAE)s 
reported, with 13% comprising disability, hospitalization, serious 
illness, or death. While most of the reactions were classified as 
mild involving fever, irritability, or local reactions such as mild 
redness at the site of the injection that is sometimes caused by 
the preservative thimerosal or other innocuous inflammatory 
response (Vaers.hhs.gov, 2015). Even with the reporting system, 
many events are thought to occur by coincidence, as other syn-
dromes such as Sudden Infant Death Syndrome (SIDS) occurs 
without any etiological basis (Vaers.hhs.gov, 2015). As Hardt et. 
al. (2013) point out, vaccine associated disease incidence is re-
duced in populations to the point of inability to remember what 
these diseases are and how they can harm. This phenomenon 
may cause vaccine adverse reactions to loom as predominant 
errs in how we provide healthcare and disproportionately 
place fear of harm above disease prevention in the minds of 
well-meaning caregivers.  
An additional potential side effect from vaccinations can stem 
from the actual vaccinations. As was explained, a vaccination is 
effective through exposure to inactivated harmless pathogens. 
In some cases, though, the pathogen can potentially become 
harmful in the future. An example is varicella, commonly known 
as chickenpox, a vaccine-preventable illness which is a very 
common and usually benign childhood disease. Chickenpox 
however can cause serious painful complications in those who 
contract the illness in adulthood, in the form of Zoster, com-
monly known as shingles. The vaccine immunity wanes as one 
ages, and the dormant virus introduced with the vaccination can 
strike. As the body’s ability to mount an immune response de-
clines, the people will be more dependent on re-administering 
of the given vaccine (Shuette & Hethcote, 1999). This side effect 
may scare off potential patients, though in light of this potential 
side effect, maybe it is in fact more beneficial to withhold from 
the chicken pox vaccination. Though, a simple solution would 
be to receive a new vaccination every number of years. Further, 
Shuette and Hethcote (1999) discovered that even when those 
vaccinated for Chickenpox develop Shingles as adults, the symp-
toms are milder, since they still have some immunity,  compared 
to those never vaccinated. Even if chicken pox vaccinations have 
a reason to be withheld, this side effect is not a reason to refrain 
from other types of vaccinations, such as Polio, Smallpox or the 
MMR vaccinations. 
Discussion
In conclusion, research has not been able to produce a correla-
tion between autism spectrum disorder and vaccination. Still, 
it is important to acknowledge the presence of fears, distrust, 
and other reasons to oppose vaccines. Although the adverse 
reactions are minimal, to the person who suffers an adverse 
event that is one too many.  The Food and Drug Administration 
(FDA), Centers for Disease Control and Prevention (CDC) 
and American Academy of Pediatrics (AAP) all support vac-
cine administration, and have successfully reduced prevalence 
of vaccine preventable diseases. However, we must ensure that 
appropriate education is disseminated to caregivers of children 
to protect the safety and lives of others by supporting vaccine 
administration so people with inability to receive vaccines will 
be better protected against vaccine preventable diseases. By en-
suring a robust vaccination program, and supporting the expan-
sion of research on vaccine preventable diseases, we can help 
develop vaccines for illnesses and diseases that currently remain 
untreatable. Perhaps new vaccine research might dispel vaccine 
myths which will increase the rates of vaccination, protecting 
more of the population.
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Thimerosal, a mercury-based vaccine preservative, has been a 
source of controversy since the 1990’s. Many parents worried 
that the presence of mercury in vaccinations could lead to au-
tism spectrum disorder and other medical problems. The Center 
for Disease Control and the American Academy of Pediatrics 
collectively decided, in July 1999, to remove thimerosal con-
taining vaccines (Baker, 2007).  According to the Food and Drug 
Administration thimerosal has undergone various studies and it 
“has a long record of safe and effective use preventing bacterial 
and fungal contamination of vaccines, with no ill effects estab-
lished other than minor local reactions at the site of injection” 
(FDA, 2015). In the United States, the only vaccines that currently 
contain thimerosal are MPSV4-Menomune (vaccine for menin-
gitis), Td (booster for tetanus and dipthereia) manufactured by 
Decavac, Td (Mass Biologics), Dt (Sanofi) and three of the influen-
za vaccines (Hamborsky et al., 2015). Some researchers posit that 
there may be a link between thimerosal and neurodevelopmental 
problems. Other studies demonstrate that thimerosal does not 
have such effects. This study was done to determine if thimerosal 
poses a risk on childhood neurodevelopment.
Purpose of Preservatives and Adjuvants in Vaccines:
The United States Code of Federal Regulations (CFR) mandates 
the addition of preservatives to vaccines in vials containing 
multiple doses to prevent contamination of the vaccine after 
multiple needle insertions. Previously, some vaccines became 
contaminated during the manufacturing process. As a result, the 
CFR required the addition of preservatives to kill the microbes 
that contaminated the vaccine. With the advancement of aseptic 
manufacturing of vaccines, the necessity of putting preservatives 
in vaccines has decreased. As a result, many vaccines do not 
currently require the addition of preservatives into them (Geier 
et al., 2010). Adjuvants are added to vaccines to help the body 
develop immunity after injection of killed vaccines. Adjuvants 
are added to minimize the amount of antigens the body needs 
to be exposed to in order to generate an immune response 
(Petrovsky, Aguilar, 2004).
Methyl Mercury vs. Ethyl Mercury
The main question behind the debate over thimerosal is the 
comparison between ethyl and methyl mercury. Mercury expo-
sure has been found to cause severe health problems such as 
damage to the nervous, digestive and immune systems. Methyl 
mercury specifically has been found to affect the developing 
brain and nervous system. The most susceptible individuals 
to methyl mercury are fetuses exposed to methyl mercury in 
utero (WHO, 2013). Methyl mercury has been proven to cause 
neurotoxicity since the 1960’s. Mothers who ate fish in water 
contaminated by methyl mercury during their pregnancy, gave 
birth to children with mental retardation, blindness, and spas-
ticity. However, mothers exposed to methyl mercury were less 
adversely affected than the infants. A study on New Zealand 
neonates born from mothers who had hair concentrations of 
mercury greater than six micrograms per gram found that in-
fants with greater mercury exposure had a lower Intelligence 
Quotient (IQ) by three points. The United States National 
Academy of Sciences decided that fetal exposure to methyl 
mercury can be toxic even at low concentrations (Grandjean, 
Landrigan, 2006). 
The Food and Drug Administration states that the legal guide-
lines for mercury exposure were decided based on studies 
on methyl mercury. However, thimerosal’s derivative is ethyl 
mercury which as a result of being slightly chemically differ-
ent can have different effects on the body than methyl mer-
cury. Additionally, high levels of ethyl mercury were found to 
have severe neurological effects on both adults and children. 
However, the effects of low dose ethyl mercury exposure have 
not been determined (Offit, Jew, 2003). As there is no definitive 
study with a safe exposure concentration of ethyl mercury and 
the differences in the effects of methyl and ethyl mercury are 
not known, the FDA considers ethyl mercury to be as toxic 
as methyl mercury (FDA, 2015).  Ethyl mercury was found to 
increase the tissue concentration of inorganic mercury more 
than methyl mercury does in rhesus macaques (Hornig et al., 
2004). Ethyl mercury levels in the brain post exposure are lower 
than those of methyl mercury (Clements, 2004). A main source 
of the controversy on thimerosal is the question if methyl and 
ethyl mercury have the same or different effects on the body. 
Some studies show that thimerosal’s ethyl mercury does indeed 
have neurotoxic effects, while others argue that it does not.
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adverse effects on the developing nervous system.
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A variety of research papers on the subject were collected from 
Google Scholar, EBSCO and ProQuest. Access to EBSCO and 
ProQuest was given through the Touro College Library System. 
Key words used, were thimerosal, neurodevelopment, adjuvants, 
vaccines, adverse effects and immunizations.
Results
Thimerosal and Neurodevelopment:  
Thimerosal Causes Neurodevelopmental Disorders
In the 1990’s many infants had mercury exposure higher than 
that recommended by the EPA, FDA, and the United States 
Agency for Toxic Substances and Disease Registry (ATSDR) for 
methyl mercury. This was a result of both Thimerosal Containing 
Vaccine (TCV) and environmental exposure. Methyl mercury is 
a compound that is closely related to ethyl mercury, one of 
the derivatives of thimerosal. A study of 278,624 infants born 
between 1990 and 1996 and recorded in the Vaccine Safety 
Datalink was done in order to determine if thimerosal indeed 
has neurotoxic effects on infants and young children. During 
those years the main vaccines containing thimerosal were the 
Haemophilus Influenza Type b (Hib), hepatitis B, acellular DTaP 
(Diptheria, Tetanus, acellular Pertussis), and whole-cell DTP. The 
amount of mercury exposure was calculated for each individual 
based on the amount and concentration of mercury in each 
of the mercury containing vaccines. The mercury exposure was 
measured between two intervals, birth and 7 months and birth 
and 13 months. The rate of increase in six neurodevelopmental 
disorders were calculated for each additional 100 microgram of 
mercury the children were exposed to. Three control disorders 
were also observed for each 100 microgram increase in mer-
cury exposure due to thimerosal containing vaccines. (Young et 
al., 2008)
The six neurodevelopmental disorders observed were Autism, 
Autism Spectrum Disorders (ASD), Hyperkinetic syndrome of 
childhood (ADD/ADHD), Developmental/Learning Disorders, 
Disturbances of emotions specific to childhood and adoles-
cence, and tics. The control disorders observed were pneumo-
nia, congenital anomalies, and failure to thrive. The study de-
termined that the ratios of each of these disorders increased 
with the increased exposure to Thimerosal containing vaccines. 
The rate ratios were measured with a confidence interval of 
95%.  For each 100 microgram increase in mercury exposure 
the ratio of hyperkinetic syndrome of childhood increased by 
a ratio of 3.15 and Autism and Autism Spectrum disorders in-
creased by ratios of 2.87 and 2.44 respectively. Developmental 
and Learning disorders had the lowest ratio of increase, while 
hyperkinetic syndrome had the highest. The control disorders 
did not have a relatively high increase as a result of higher mer-
cury exposure (Young et al., 2008). 
The levels of autism corresponding to each year in the study 
directly correlated to the amount of mercury exposure via vac-
cine. In 1990 and 1991, hepatitis B and Hib had been added 
to the vaccine schedule. After 1992, the DTP vaccine was 
combined with Hib vaccine, thus leading to a lower mercury 
exposure than there had been when the two vaccines were 
kept separate. The levels of autism in those years fluctuate di-
rectly with the fluctuations of mercury administered via vaccine 
(Young et al., 2008). 
Another study compared the toxicities of the four most com-
mon preservatives added to vaccines in the United States. These 
four compounds were 2-phenoxyphenol, phenol, Thimerosal, 
and benzethonium chloride. These compounds were admin-
istered to human neurons in vitro and to bacterial cells. The 
toxicities to each type of cell were measured. The cytotoxic-
ity towards human neuroblastoma cells was measured after 
24 hours of incubation. Thimerosal was found to be the most 
toxic of the four preservatives added to vaccines. Each of the 
four compounds was also tested on bacterial cells. A thimerosal 
concentration of ten times the amount added to vaccines was 
not able to sufficiently kill bacterial cells within twenty minutes 
(Geier et al., 2010).
While there is room to question the certainty of the thimero-
sal’s effects on children, it his highly likely that thimerosal does 
adversely affect the neurodevelopment of susceptible infants. In 
some of the studies thimerosal was the only measured vari-
able, while in others thimerosal was taken into account with 
other possible neurotoxic environmental exposures. Using the 
Gesell Development Score, investigators found no correlation 
between thimerosal exposure from vaccines and neurodevel-
opmental disorders, if the child nursed for the first six months 
of life. The GDS was also measured from birth to five years 
and once again there was no correlation between thimerosal 
exposure and neurodevelopmental disorders. The studies that 
took environmental exposure to neurotoxic elements into con-
sideration as well as thimerosal, found that ethyl mercury, one 
of the byproducts of thimerosal, has adverse effects on neuro-
development. The controlled variables were the environmental 
factors that were known to affect neuroplasticity. For example, 
secondhand smoke, cord blood Hg, and lead (Dorea, 2015).
The Vaccine Adverse Events Reposting System (VAERS) da-
tabase was used to determine if indeed the rise in childhood 
neurodevelopmental disorders was caused by thimerosal ex-
posure due to vaccinations. A comparison was made of the 
prevalence of neurodevelopmental disorders after exposure 
to either thimerosal containing or thimerosal free DTaP vac-
cines. Three neurodevelopmental disorders were observed in 
this study; autism, personality disorders and mental retardation. 
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The participating patients were split into two groups, the first 
group had an average mercury exposure of 37.5 microgram, 
while the second group had a mercury exposure of 87.5 micro-
grams. Some of the control adverse events were fever, pain, and 
vomiting. The United States Department of Education report 
from 2001 was also evaluated to find out how many children 
in different age groups suffered from a variety of conditions; 
autism, speech disorders, orthopedic or visual impairments, and 
deaf-blindness. The amount of mercury the children were ex-
posed to was also compared to the maximum possible amount 
of mercury exposure allowed by the FDA (Geier, Geier, 2003).
Comparing the prevalence of autism, personality disorders and 
mental retardation following exposure to thimerosal from the 
DTaP vaccine and the thimerosal-free DTaP demonstrated a 
linear correlation between mercury exposure and neurode-
velopmental disorders. The odds ratio of autism increased by 
.029, personality disorders by .012, and mental retardation by 
.048 for each microgram of mercury. The odds ratio for each 
of these disorders was higher for each of them after exposure 
to the DTaP containing thimerosal than for that without it. 
The United States Department of Education report also had 
increasing ratios in autism and speech disorders. The amount 
of febrile seizure, fever, pain, edema, and vomiting was higher 
for the thimerosal containing DTaP vaccine group, however the 
amount it rose and the increasing amount of mercury exposure 
do not directly relate to one another. The study also demon-
strated that the amount of mercury the children were exposed 
to due to the childhood vaccine schedule in different years had 
3.2-32 fold higher amount than that recommended by the FDA 
for oral methylmercury. Exposure to mercury intravenously has 
more adverse effects on the body than if it has been orally in-
gested (Geier, Geier, 2003).
A study surveying British children found there to be a rela-
tionship between hyperactivity and behavioral problems, motor 
development and the necessity for speech therapy. Other stud-
ies have found that there were significant differences in the 
impact of thimerosal on different genders. Male children were 
found to have a higher IQ upon exposure, but the exposure 
also hampered their behavioral regulation and motor tics. In a 
study in Italian children thimerosal was found to detrimentally 
affect girls in the areas of language and motor function (Curtis 
et al., 2015) 
An overview was done by analyzing the results of in vivo and in 
vitro studies of the thimerosal’s effects. In the in vitro studies 
thimerosal was found to cause mitochondrial damage, reduce 
oxidation-reduction activity, cause cell degeneration and cell 
death, and increase the levels of fragmented DNA in human 
neuroblastoma cells. In some of the overviewed studies the 
concentration of thimerosal tested was lower than that found 
in TCV, while in some the concentration ranged from nano 
to micromolar concentrations. An In vivo study administered 
different concentrations of thimerosal to suckling Wistar and 
Lewis rats at 7, 9, 11 and 15 days. The thimerosal was found to 
decrease pain sensitivity and to significantly accumulate in rat 
brains. The concentration of thimerosal found in vaccines had 
neurotoxic effects on human neurons in vitro and in laboratory 
animals (Dorea, 2011). 
Thimerosal Does Not Cause 
Neurodevelopmental Disorders
A study was done in Poland to determine if there is a correla-
tion between exposure to Thimerosal containing vaccines and 
cognitive development in the children’s’ first nine years. All of 
these children had been given the DTP and hepatitis B vaccine, 
some of which contained thimerosal and some which didn’t. 
At different points during the first nine years of life, tests were 
done to assess the level of each child’s cognitive development. 
All the vaccines that the children were exposed to contained 
aluminum as an adjuvant. In the first month of life 69.2% of 
the children were exposed to thimerosal, and between the first 
month and the 6th month 86.2% of the children were exposed 
to thimerosal containing vaccines. The results of each psycho-
logical test done were similar for both children who were and 
were not exposed to thimerosal. In fact the IQ levels of those 
exposed to thimerosal was higher overall than that of the con-
trol group. The results of the study displayed no correlation be-
tween thimerosal exposure and lower cognitive developmental 
levels. (Mrozek-Budzyn et al., 2014). 
Various studies had been done testing thimerosal containing 
vaccines on rodents, with results demonstrating that thimerosal 
had no neurodevelopmental effects. However, on the rare occa-
sion that there was a problem with the vaccine, a very high dos-
age of thimerosal had been administered, 250 fold higher than 
contained in vaccines. A study was done to compare the effects 
of different vaccine schedules on a non-human primate model. 
These were chosen as their anatomy and length of development 
stages are very similar to those of humans. Neurobehavioral 
tests were done on the primates to see the effect of a variety of 
vaccine schedules on the primates’ neurodevelopment (Curtis 
et al., 2015).
In the study seventy-nine rhesus macaques were split into six 
groups. The first group, the control, received saline injections. 
The second group received only the MMR vaccine, the third 
TCV’s excluding the MMR vaccine. The fourth group was ad-
ministered the vaccine schedule from the 1990’s, while the fifth 
group received the same vaccines with accelerated timing at 
a ratio of 4:1. The sixth group was administered the vaccine 
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schedule from 2008. In the 1999 vaccine schedule, the TCV’s 
were Hepatitis B, DTaP, and Hib. In the 2008 vaccine schedule, 
the multiple-dose influenza and meningitis vaccines contained 
thimerosal. The pregnant macaques in the 2008 group were 
given the influenza vaccines a month before the expected deliv-
ery date. (Curtis et al., 2015).
Each of the infant macaques was tested on the Neonatal 
Behavioral Assessment Scale to check for nineteen neonatal 
reflexes. There was no significant difference in the results of 
each of the six groups for the NBAS test, except in one of the 
criteria. The macaques were also tested for their object con-
cept performance, their social behavior and the discrimination/
reversal learning and learning set. In each of these tests there 
were no significant differences in the results among the groups. 
The animals given TCVs reached their goal in fewer trials than 
animals in the control group in the reversal learning part of 
the test. Thereby demonstrating that thimerosal did not hamper 
this area of neurodevelopment. At the age of 12 months the fifth 
group had a significantly lower amount of exploring behaviors 
than did the control macaques. The fifth group also had a lower 
amount of positive behaviors at 2 months, while at 12 months 
they had a higher amount of positive behaviors than did the rest 
at two months of age the fourth and sixth groups had signifi-
cantly fewer negative behaviors, however at 12 months there 
were no major differences between the six groups (Curtis et 
al., 2015).
A study in Denmark, used data from the Danish Psychiatric 
Central Research Register to determine if thimerosal expo-
sure leads to autism spectrum disorder. This study was done to 
determine if removing thimerosal from vaccines decreased the 
incidence of autism. The rates of autism diagnosed from 1971 
to 2000 for children in three age groups, ages 2-4, 5-6, and 7-9, 
were reviewed. From the years 1961 to 1970 the children were 
administered 400 micrograms of thimerosal. From 1971-1992 
children were exposed to 250 micrograms of thimerosal.  After 
1992, vaccines without thimerosal were administered to Danish 
children. During this period, 956 children had been diagnosed 
with autism. From 1971 to about 1990 the rates of autism re-
mained stable. After 1991, the rates of autism began to increase, 
peaking in the year 1999 with the highest incidences occurring 
in the first two age groups, between 2 – 6 years of age. Each 
of these children had been born after thimerosal containing 
vaccines had been removed from the Danish vaccine schedule. 
Thereby indicating, that the increase of autism does not relate 
to thimerosal exposure (Madsen et. al, 2003). 
Aluminum and Neurodevelopment
Studies have demonstrated that in vitro aluminum exposure has 
the potential to cause cell death in human neurons. However, 
aluminum has been found to be less cytotoxic than thimero-
sal (Dorea, Marques, 2009). A study was done to determine if 
aluminum exposure as a result of its use as a vaccine adjuvant 
is a cause of the rise of autism. Data was taken from the US 
Department of Educational Annual Reports to Congress to de-
termine the rates of autism from 1991-2008 for individuals age 
6 – 21. The rates of autism were also compared to the aluminum 
exposure in regards to the vaccine schedule in other countries. 
The data was compared to the concentration of aluminum ex-
posure from pediatric vaccines, below 6 years of age. Results 
demonstrated that the highest level of aluminum in compari-
son was at age 2 months in the United States. Interestingly, the 
countries with higher aluminum adjuvant exposure had higher 
rate of autism (Tomljenovic, Shaw, 2011).
Discussion
Based on the reported studies there is room to question the 
effects of the Thimerosal and vaccines containing it on human 
children. Studies done in vitro demonstrate that thimerosal 
does cause apoptosis and neurotoxic effects to human neu-
rons (Dorea, 2011). However, results occurring in vitro are not 
always a directly comparable to those in vivo, as in vivo it is 
difficult to accurately evaluate the concentration of mercury 
reaching the individual’s neurons. Additionally, studies done 
on Rhesus macaques seem to point out that thimerosal does 
not hinder neurodevelopment, in some cases the exposed an-
imals had scored higher than the control (Curtis et al., 2015). 
However, the primate model is not necessarily an exact indica-
tion as to what would happen to humans when they would be 
exposed to the same concentrations of thimerosal, though the 
results would be similar as the two bodies function similarly. 
Only seventy-nine macaques were surveyed and then split into 
six groups, thereby only a small number of macaques represent-
ed each vaccine schedule. Therefore, even though the macaque 
functions similarly to humans, the validity of the results in com-
parison to human would need a higher number of macaques in 
each group to demonstrate the efficacy of the results. 
The study using the Vaccine Safety Datalink uses a large sample 
of children, and demonstrates a direct correlation between thi-
merosal exposure and neurodevelopmental disorders. However, 
the study does not take into account environmental exposure 
to mercury and other neurotoxins, thereby making it harder to 
say with certainty that thimerosal does indeed cause different 
neurodevelopmental disorders (Young et al., 2008). The study 
also does not take into account the genetics of the children and 
the possible predisposition to neurodevelopmental disorders. 
However, there does seem to be a strong indication that thi-
merosal has neurodevelopmental effects, as the prevalence of 
autism in various years was directly related to the fluctuations 
of mercury in the childhood vaccine schedule, thus indicating 
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that children born in years that a vaccine schedule with a higher 
concentration of mercury had increased rates of autism.
Additionally, the primate model is not a direct representation 
of what would happen in the human models because studies 
show that the rate of elimination in the blood and brain differ 
for methyl and ethyl mercury in primates and human infants 
(Hornig et al., 2004). As a result, ethyl mercury in humans may 
cause different mercury levels than it would for the rhesus ma-
caques used in two of the above studies. 
Based on the above studies it is hard to conclude whether or 
not thimerosal containing vaccines cause neurodevelopmental 
disorders. However, some studies do seem to indicate that thi-
merosal causes autism among other neurodevelopmental disor-
ders. Additionally, thimerosal containing vaccines were found to 
cause a significant amount of damage to human neurons in vitro, 
including cell death. As a result, further study must be done 
to determine with certainty the true effects of thimerosal on 
human neurodevelopment. 
As one study demonstrated that the concentration of thimer-
osal found in human vaccines was not sufficient to kill bac-
terial cells, the question arises as to the necessity of placing 
thimerosal into vaccines. Additionally, after administration of 
multiple does DTP and Td vaccines that contained thimerosal 
as a preservative there were outbreaks of pyogenic infections. 
Indicating that despite the addition of preservatives to vaccines, 
microbial contamination can still occur (Ball et all, 2001). One of 
the main vaccines today currently containing thimerosal is the 
multiple-dose influenza vaccine. Thimerosal is added as a preser-
vative to prevent bacterial contamination of the vaccine. If the 
concentration of thimerosal needed to effectively rid the vac-
cine of bacteria is higher than the concentration of thimerosal 
in the vaccine, then it is likely that the thimerosal is not doing its 
job. Steps should be taken to remove thimerosal from vaccines 
as there is a strong potential that thimerosal does indeed cause 
neurodevelopmental problems. If thimerosal is kept in vaccines, 
it should be determined whether the benefits thimerosal brings 
to the vaccine outweigh the risks brought onto children when 
they are vaccinated.
Fetuses, neonates, and other small children are the most sus-
ceptible to neurodevelopmental damage, as these are the peri-
ods of brain growth (WHO, 2013 and Dorea, 2015). The World 
Health Organizations states a fetus is the most susceptible to 
neurotoxic factors (WHO, 2016). Additionally, during the pre-
natal and early postnatal stages the Blood Brain Barrier (BBB) 
is not fully developed. As a result, the likelihood of neurotoxins 
crossing the BBB is higher in fetuses and newborns (Tomljenovic 
and Shaw, 2011). As the risks of thimerosal exist and there is 
not conclusive proof that there is not neurotoxicity, injecting 
pregnant woman and babies with vaccines containing thimerosal 
should be avoided, as these are the ages most critical to child-
hood neurodevelopment. For example, the Center for Disease 
Control currently recommends that the influenza vaccine be 
administered to pregnant woman as a woman suffering from in-
fluenza during her pregnancy is at great risk (Center for Disease 
Control, 2015). Pregnant woman are more likely to have longer 
stays at the hospital as a result of respiratory illnesses, than 
when not pregnant (American College of Obstetricians and 
Gynecologists). There seems to be a clear benefit of a pregnant 
woman being immunized to influenza. However, based on the 
information above, there is clearly a potential that thimerosal 
causes neurodevelopmental disorders, and this stage is where 
the fetus is the most susceptible to neurotoxins. As a result, 
measures should be taken to ensure that pregnant woman are 
given the influenza vaccine that does not contain thimerosal. 
Additionally, the postnatal stages till adolescence are still stages 
of neurodevelopment. As thimerosal potentially causes neuro-
developmental disorders, the benefits of thimerosal containing 
vaccines must be evaluated to see if they actually outweigh the 
risks presented by thimerosal exposure.
Conclusions
There is no definitive evidence to conclusively determine if 
thimerosal causes neurodevelopmental disorders in young 
children. However, the potential for thimerosal to cause neu-
rodevelopmental disorders gives rise to question the potential 
harm of the other agents used as preservatives and adjuvants 
in vaccine today. One of the main adjuvants used in vaccines 
today is Aluminum, which does seems to have the potential to 
affect neurodevelopment, specifically causing autism spectrum 
disorder. As vaccines are being administered to susceptible in-
dividuals, further studies should be done to all the chemicals 
added to vaccines to determine if they are really safe, and if the 
benefits they bring to the vaccine outweigh the risks.
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Early detection of cancer along with modern medicine has led 
to a rise in the survival rates of young cancer patients.  This 
results in many cancer survivors who are capable of childbear-
ing. However, since chemotherapy and radiation given during 
the cancer curing process can result in various fertility issues, 
patients must find a method to preserve their ability to give 
birth to children.  
One method of preservation is oocyte cryopreservation. 
Human oocyte cryopreservation is a procedure in which a 
woman’s oocytes are extracted, frozen and then stored. When 
the woman desires to become pregnant the eggs are thawed, 
fertilized and transferred in to the uterus.   
This type of preservation is preferred by many for various rea-
sons.  Many single cancer patients prefer freezing unfertilized 
eggs, as opposed to fertilized ones, as they don’t need any male 
donors at the time.  Another reason women may want to freeze 
eggs is due to the fact that oocyte quality and quantity diminish-
es with age.   This can cause a lack of healthy eggs to allow for 
pregnancy.  Considering this, many women may prefer to freeze 
their healthy young and vital oocytes, which are more likely to 
produce pregnancies.  
Furthermore, people may consider oocyte cryopreservation 
due to ethical, legal and religious hindrances that prevent them 
from doing embryo cryopreservation. Couples may not want to 
cryopreserve embryos as the embryos may have to be disposed 
if the cancer patient dies. (Noyes, et. al. 2010) 
The goal of this study is to determine if oocyte cryopreserva-
tion is a means that enables women to have healthy offspring, 
post anti-mitotic therapy.
Methods
Pub med.gov, google scholar and Touro databases such as, 
EBSCO host, were used to research relevant studies and re-
views for the background, process and results of oocyte cryo-
preservation. The review paper’s references were used to find 
additional original papers that were relevant to the question 
proposed above. Key words such as oocyte cryopreservation, 
oocyte cryopreservation in cancer patients, slow freezing and 
vitrification were used in order to find articles.
Discussion
Various studies were done on oocyte cryopreservation. In one 
experiment, twenty-two cancer patients, between ages 21 and 
38, underwent cycles of oocyte cryopreservation. After drug 
stimulation, oocytes were harvested from sixteen of the twen-
ty-two infertile women, subsequently fertilized and implanted in 
them. The other six infertile patients received donor eggs. Only 
mature oocytes were preserved. The eggs were preserved by 
two methods, slow cooling method and vitrification. A total of 
295/355 oocytes were recovered with a 92% survival rate.  
At the time of publication of the study, fourteen of the patients 
had become pregnant, one had miscarried, and three pregnan-
cies were still ongoing.  A total of thirteen babies were born to 
the other expectant ten patients. Eleven of these babies were 
completely healthy, however a set of twins were born prema-
turely due to premature dilatation of an incompetent cervix. 
These twins suffered some complications of prematurity, but 
upon reaching two years of age, the twins were thriving within 
the average norms.  Besides for two cases of gestational diabe-
tes, no other complications were reported (Grifo, Noyes, 2010). 
Gestational diabetes is common in women during pregnancy. 
According to the CDC, the ratio of women with gestational 
diabetes ranges between one in every twenty to one in every 
fifty of expectant women.
Additionally, Dr. Nicole Noyas and other researchers pooled 
together data to see how many oocyte cryopreservation’s re-
sulted in normal babies. Any incomplete data was left out. A 
total of six hundred and nine births were reported between 
the years 1986-2008. All the babies born were a result of oo-
cyte cryopreservation. However, the oocytes in those six hun-
dred and nine births were preserved using different methods 
of cryopreservation. Three hundred and eight went through 
the process of slow freezing, two hundred eighty nine were 
preserved using vitrification and twelve had a combination of 
slow freezing and vitrification. A total of eight anomalies were 
reported.  There were also three hundred twenty seven cryo-
preserved oocyte births published, totaling nine hundred thirty 
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six births. Out of the nine hundred thirty six babies, twelve ba-
bies were born with birth defects. Overall the anomaly rate is 
1.3%. According to the CDC, three percent of babies are born 
with major structural or genetic defects. The twelve defects and 
the total incidents statistically occurring in natural conception 
babies compared to oocyte cryopreservation babies are listed 
in table 1. (Noyes, et. al. 2009) 
From the table one can assess that there were no neural tube 
defects and that the defect of skin hemangioma is the same 
range as babies born from natural conception. Additionally, cleft 
lip and palate as well as cardiac defects occurred less in the 
babies born as a result of oocyte cryopreservation. 
Researchers have tried to improve the process of oocyte 
cryopreservation. One issue that arose from freezing the eggs 
was that extensive intracellular ice formed during freezing. 
Extensive intracellular ice can cause cellular disruption in the 
oocyte during the oocyte cryopreservation process. This can 
possibly be improved by using cryoprotectants such as, pro-
panediol and sucrose to increase the extent of the dehydration 
process. The aim of the study done by researchers in Infertility 
and IVF Center of Buda was to introduce their preliminary clin-
ical results with oocyte cryopreservation. They used slow cool-
ing as the procedure to freeze the eggs. They specifically used 
propanediol (1.5M) and sucrose (0.3 M) as the cryoprotectants. 
After incubating the oocytes for 4-6 hours, the oocytes were 
thawed, fertilized and embryos were transferred into twen-
ty-nine patients. Out of one hundred ten cryopreserved eggs, 
eighty-four survived. This is a 76% survival rate, which is high 
but not optimal. From fifty-two embryo transfers, seven result-
ed in clinical pregnancies, which is 7.3% implantation rate per 
egg thawed. Chorion biopsies that were performed indicated 
that there were no chromosomal abnormalities. Out of the 
seven pregnancies, five of them resulted in four singletons and 
one set of twins. One was still ongoing at the time of the study 
and the seventh spontaneously aborted in the tenth week. No 
abnormalities were indicated in the study. Additionally, there 
was only a small difference in the pregnancy rate, 33% versus 
24%, between those pregnancies that resulted from frozen oo-
cytes and those that resulted from fresh oocytes. As indicated 
from published literature at that time of the research, fifteen to 
thirty oocytes were needed in order to achieve one pregnancy. 
Previously, one hundred to one hundred fifty were needed to 
achieve one pregnancy. (Konc, et. al. 2008) The results show 
that oocyte cryopreservation is improving over time.
Vitrification is also known as ultra-rapid cooling. In recent years, 
vitrification has proven the superior method. Compared to 
slow freezing, vitrification results in higher oocyte survival and 
fertilization. (Cil, et. al. 2013) In a study done to compare the 
outcome of the two methods, the survival, fertilization, preg-
nancy and implantation rates were 57.9% versus 78.9%, 64.6% 
versus 72.8%, 7.6% versus 18.2% and 4.3% versus 9.3% corre-
spondingly. The rates were higher in all steps for the vitrification 
method. (Fadini, et al., 2009) 
The duration of cryostorage doesn’t undesirably affect the 
thawing of frozen oocytes. A study was done to see if there is 
any influence on the outcome of thawing cryopreserved oo-
cytes. There were three groups in the experiment.  Group A’s 
eggs were cryostored for one to three months, group B’s eggs 
were cryostored for four to six months and group C’s were 
cryostored for seven to forty eight months. Group C was fur-
ther divided into three subgroups. Group C1, was cryostored 
for seven to nine months, group C2 was cryostored for ten 
to twelve months and group C3 was cryostored for a total of 
thirteen to forty eight months. The researchers found no signif-
icant difference, from groups A, B and C, in the main outcome 
measurements, which were oocyte survival after thawing, fertil-
ization, implantation, embryo development and quality and birth. 
Oocytes can be cryopreserved for numerous years without 
having an effect on the oocytes quality and performance after 
thawing. (Parmegiani, et. al. 2009)
One factor that may affect the outcome of oocyte cryopreser-
vation is the age. The value of freezing an older woman’s oocytes 
is controversial. (Zhang, et. al. 2015) The rate of implantation of 
the fertilized egg that resulted from the slow freezing and vitri-
fication methods declines with age. A study was done to collect 






Incidence in total 
of 936 oocyte 
cryopreservation 
births (n)
All One in 33 12 (one in 78)
Skin hemangioma One in 50–225 1
Cardiac defects One in 125 3
Neural tube defects One in 385 0
Cleft lip and palate One in 710 1
Clubfoot One in 735 3
Arnold-Chiari syndrome One in 1200 1
Choanal atresia One in 7000 1









Birth anomalies in natural conception versus oocyte cryopreservation, 
listed most common to most rare 




researchers found that live births occur from the slow freez-
ing method until age forty-two, and until age forty-four from 
the vitrification method. They limited their results to the age 
range of twenty five to forty two years old, as there were only 
few cycles that were above or below the twenty-five through 
forty-two year old range. This study’s data was on patients that 
were infertile.  The study was not specifically performed on post 
cancer patients. (Cil, et. al. 2013) 
Furthermore, a study was implemented in order to report the 
oocyte cryopreservation experience in women aged forty and 
older. One hundred fifty eight women, aged forty to forty-nine, 
underwent minimal ovarian stimulation to retrieve their eggs. A 
total of five hundred thirty two eggs were retrieved and frozen. 
Four of the women did not have any oocytes retrieved. A total 
of four hundred eighty five embryos were formed. Out of the 
four hundred eighty five embryos, only fifty-seven were relatively 
healthy. Six clinical pregnancies were achieved. Only three resulted 
in live births. There was a 5.3 % live birth rate per embryo trans-
fer. The other three pregnancies were spontaneously aborted. As 
per the data, a woman aged forty and older can give birth to a 
baby after undergoing the process of freezing her eggs. However, 
there is a low chance that it will indeed happen, as there is a 5.3% 
chance that the woman will give birth. (Zhang, et. al. 2015)
A woman who has ovarian cancer may risk surgical menopause. 
Oocyte cryopreservation can be an option for woman facing 
ovarian cancer. It could also help patients that need to have a 
one or both ovaries removed. A twenty six year old woman 
with borderline ovarian tumors had her oocytes cryopreserved 
after a right adnexectomy. Seven mature eggs were retrieved 
and frozen. Thirty-nine months later, the woman underwent 
a left ovariectomy.  Three embryos were transferred into the 
woman’s uterus. Endometrial growth was achieved with the 
help of hormonal replacement treatment. The woman gave birth 
to healthy twin babies. (Porcu, et al., 2008) 
Oocyte cryopreservation can help women have healthy babies 
even when they don’t have their own healthy eggs. Remaining 
eggs from oocyte cryopreservation cycles can be saved and 
donated to another couple that are experiencing fertility com-
plications. A study was done in which twenty-eight infertile 
women froze their oocytes. Twelve of the twenty-eight women 
had their frozen oocytes thawed. Three of the women used their 
own eggs in IVF treatment and the other twelve donated their 
eggs to other women. Premature ovarian failure, physiological 
menopause, abnormal karyotype and poor ovarian reserve are 
the reasons that the twelve women needed to receive oocytes 
from other women. Seven women became pregnant. Six of the 
seven used donated oocytes. A total of 6 healthy babies were 
born including a set of twins. The other 2 pregnancies were 
aborted due to a blighted ovum. (Li, et al., 2005)
Oocyte cryopreservation may not be for everyone. Women 
with cancers that need to be treated immediately after diagno-
sis, may not be a candidate for oocyte cryopreservation. This is 
because oocyte cryopreservation requires ovarian stimulation 
and retrieval. This can take an average of twelve days. (Noyes, 
et al., 2011) Additionally, some women that have breast cancer 
might run into issues with preserving their eggs. This is because 
estrogen levels rise during ovarian stimulation. High levels of 
estrogen might not be safe for women with breast cancer. 
(Rodriguez-Wallberg, Oktay, 2010)
Furthermore, some women may not want to undergo oocyte 
cryopreservation as it can cause a woman to have a risk hav-
ing of intra-abdominal bleeding and ovarian hyper stimulation 
syndrome. However, there is a very low percentage rate of this 
risk. (Noyes, et al., 2011) Additionally, women with cancers may 
not be able to cryopreserve their eggs due to economic issues. 
It is a very expensive procedure. According to NYU Langone 
Medical Center’s website, oocyte cryopreservation can cost 
about $16,000- $20,000. This includes initial office consulta-
tion, egg cryopreservation cycle, prerequisite blood testing and 
screening medication.  As of 2010, cancer patients are generally 
not offered insurance coverage for oocyte cryopreservation. 
(Noyes, et al., 2011) Consequently, cryopreservation may not 
be an option for people that are struggling financially. 
Conclusion
Oocyte cryopreservation is a viable method that enables 
women post mitotic therapies to have healthy offspring.  As per 
the research discussed above, many women were able to have 
a healthy baby because they froze their oocytes. Even when 
abnormalities were reported, they were basically within nor-
mal range. Oocyte cryopreservation has even enabled a woman 
with borderline ovarian cancer to have a healthy offspring. 
Even though the value of freezing an older woman’s oocytes is 
controversial and the rate of implantation of the fertilized egg 
declines with age, data has shown that oocyte cryopreservation 
can enable older women to have healthy babies.
There are different variables that may increase the outcome of 
oocyte cryopreservation. The vitrification method has shown 
to be the efficient and more reliable method. Cryoprotectants 
such as, propanediol and sucrose can increase the extent of 
the dehydration process and thereby prevent the oocytes from 
disrupting. Furthermore, the duration of cryostorage doesn’t 
undesirably affect the outcome of oocyte cryopreservation.
Oocyte cryopreservation may not be for everyone due to eco-
nomic reasons and timing of the anti-mitotic therapies. However, 
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it is a means that enable women to have healthy children even 
after their oocyte quality and quantity diminish as result of the 
cancer treatment. 
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The human gut microbiome consists of over 100 trillion micro-
bial cells, exceeding the amount of human cells by a factor of 10. 
Bacteria are found in various parts of the body including nasal 
passages, oral cavity, skin, urogenital system and the gastrointes-
tinal tract. The gut microbiota carries out a variety of valuable 
tasks for their human hosts; it assists in the development of in-
nate and adaptive immunity, serves as an energy source, and kills 
foreign organisms. (Dave, et al. 2012). The quality and composi-
tion of the gut microbiome depends largely on diet, medication 
and weight of its host. The microbiota is capable of secreting 
or altering the production of molecules that affect both weight 
gain or loss and fat mass. (Rosenbaum, et al. 2015) 
Colonization of the microbial microflora of the internal and 
external surfaces in a human begins at birth and is termed in-
digenous bacterial microflora. (Van der Waaij, 1989) The route 
of delivery when a baby is born determines which type of bac-
teria will develop.  Infants delivered vaginally have microbiota 
comparable to their own mother’s vagina, whereas infants born 
via Cesarean section develop microbes similar to the bacteria 
found on the skin surface. (Dominguez-Bello, et al. 2010) After 
birth, microbes develop and colonize, benefitting both them-
selves and their host, each contributing something vital to the 
other. (Van der Waaij 1989) For example, the anaerobic bacte-
ria in our distal gut breaks down complex polysaccharides and 
ferments the resulting monosaccharides into short chain fatty 
acids. This is a mutually beneficial relationship; the microbes live 
in a sheltered anaerobic environment and receive a rich assort-
ment of glycans while offering the host a source of carbon and 
energy. (Backhed, et al. 2005)
Of all the microbial communities being studied by human micro-
biome researchers, the gastrointestinal tract (GI) holds a prom-
ising future for the discovery of new concepts and therapies. 
The large colon holds the most abundant and diverse commu-
nities of microbes; it has both local and systemic effects on the 
body. (Dave et al. 2012)  The gut microbiota can be thought of as 
a “microbial organ placed within a host organ,” it plays vital roles 
in metabolism and immune system function. It is known that 
the microbial communities have a method of communication; 
they also can consume, store and redistribute energy. (Bakhed, 
et al. 2005)  
Fecal Microbiota Transplantation (FMT) is an FDA experimental 
drug targeted to treat Clostridium difficile associated diseases 
(CDAD). It has been successfully used to treat patients with ul-
cerative colitis (UC) and different forms of inflammatory bowel 
diseases (IBD).  Additionally, by comparing and analyzing the 
gut microbiome of lean and obese individuals, researchers have 
been able to hypothesize a cause for obesity and other weight 
issues. Using this knowledge, microbiologists can manipulate 
the microbiome and formulate a therapy to decrease obesity 
worldwide. This research can result in a new kind of pharmaco-
peia; implanting a more refined probiotic to combat infection, 
inflammation and dysbiosis.  
Methods and Materials
To investigate the mechanism of fecal bacteriotherapy and how 
it can be utilized to treat Clostridium difficile associated diseas-
es and other gastrointestinal disorders, many original research 
articles and reviews have been read. Touro College’s online da-
tabase was employed, particularly EBSCO, PubMed, ProQuest 
and Google scholar. Further research was done by perusing 




The indigenous microbiota is vital to the human host, yet it 
can be altered by various factors of modern day life, most 
commonly repeated doses of antibiotics. (Van der Waaij, 1989). 
Dethlefsen et al. tested the fecal microbiota of adults before 
and after oral administration of ciprofloxacin for five days using 
pyrosequencing. A rapid reduction in richness of bacterial phyla 
was seen, resulting in decreased diversity, fullness and balance 
in the microbiome. Four weeks following the completion of 
the antibiotic, the microbiota returned to baseline. However, 
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in some individuals, it took 6 months for the bacterial phyla to 
completely return to normal. (Dethlefsen et al., 2008)  Infectious 
diseases of the past were thought to be linked with bacteria ca-
pable of causing disease in a susceptible host. However, present 
day infectious diseases are linked to host interaction with po-
tentially pathogenic bacteria that make up the microflora of the 
digestive tract (Van der Waaij, 1989). A particular infection that 
results from a disruption of the gut microbiota is Clostridium 
difficile infection.  Clostridium difficile is an anaerobic, spore 
forming bacillus that produces 2 exotoxins that damage the in-
testinal mucosa. It is the most commonly recognized cause of 
anti-microbial associated diarrhea.  Clostridium difficile associ-
ated disease mainly affects the large colon, causing diarrhea and 
pseudomembranous colitis. If progressed, the infection can lead 
to toxic megacolon, sepsis and death (McDonald et al., 2006). 
The microbial colonies that regularly control the Clostridium 
difficile communities are inhibited and blocked by antibiotics. 
Because C. difficile spores are generally resistant to antibiotics, 
this allows them to germinate back into their vegetative state 
after antibiotic treatment has ended. If the remaining microbes 
in the intestine cannot get rid of the infection, Clostridium dif-
ficile can multiply and release the toxins that return the disease 
symptoms. (Bakken et al., 2011)
There are different treatments that exist for recurrent 
Clostridium difficile infection, many of which involve the use 
of stronger antibiotics, such as vancomycin and metronida-
zole. However, as Dr. Johan Bakken says, “the use of antibiot-
ics represents a double-edged sword by suppressing both the 
pathogen as well as the protective microbiota.” In other words, 
repeated and extended uses of antibiotics have negative effects 
on the natural gut flora. It is a possible risk factor for further 
infection due to the continuously altered state of gut microbes. 
(Bakken et al. 2011)
Another approach to treat recurrent Clostridium difficile in-
fection is to restore the damaged microbial communities using 
probiotics. Saccharomyces bouldarii is a yeast that colonizes in 
the colon within 3 days of ingestion, survives gastric acids of 
the stomach and is cleared from the colon once treatment is 
discontinued. The effectiveness of the probiotic as an add-on 
to antibiotics was tested in two trials. The treatment did not 
decrease recurrence rates in those with their first episode of 
Clostridium difficile infection but it did decrease the frequen-
cy of relapses in those with the recurrent infection. The sec-
ond trial showed effectiveness only in patients that were on 
a high dose of vancomycin. (McFarland et al., 1994) (Bakken 
et al., 2011) Thus, probiotics may have a role in treatment of 
Clostridium difficile infection, but their effectiveness is less than 
ideal. (Kelly, LaMont 2008)
Fecal Bacteriotherapy, or fecal microbiota transplantation 
(FMT), is an innovative and effective treatment for Clostridium 
difficile infection and other infections of the colon, including ul-
cerative colitis. It involves implanting stool from a healthy donor 
into a recipient’s diseased colon, thereby allowing a newer and 
healthier microbiome to develop and flourish. From the trials 
done and the case studies reported, it seems that recurrent 
Clostridium difficile infection can be cured with a single treat-
ment of FMT. The logic behind FMT is straightforward: strong 
antibiotics can cause an imbalance in the normal intestinal flora 
and reduce colonization resistance, which allows C. difficile to 
grow and cause symptoms of infection. With the introduction of 
healthy donor feces, the imbalance can be corrected, the cycle 
interrupted and the normal colon function returns. (Bakken, et 
al. 2011)
Although the first four patients to be treated with FMT in the 
20th century was in 1958 for pseudomembranous enterocolitis, 
(Bakken, et al. 2011) the use of fecal material as a treatment 
for diseases dates back more than 2500 years ago in ancient 
China. During the Dong-jin dynasty in the 4th century China, Ge 
Hong, a well-known doctor described the use of human fecal 
suspension by mouth for people suffering from severe diarrhea 
or food poisoning. This treatment was considered a medical 
miracle that brought patients back from the brink of death. In 
the 16th century, during the Ming dynasty, Li Shizen prescribed 
a series of fecal material doses to treat abdominal diseases that 
caused severe diarrhea, fever, pain, vomiting, and constipation. 
This treatment was called “yellow soup” for aesthetic reasons. 
(Zhang, et al. 2012)
Nowadays however, the procedure is done in a more sterilized 
manner and reported to have been successful via colonoscopy 
(Persky, Brandt 2010), nasogastric tube, (Aas, et al. 2003) naso-
duodenal tube, (van Nood, et al. 2013) and self-administered 
fecal enemas. (Silverman, et al. 2010) One method of implan-
tation was not found to be superior over the other. (Rohlke, 
Stollman 2012) 
Currently, the only FDA approved drug to treat C. difficile in-
fection is the antibiotic vancomycin, which is inadequate for pa-
tients suffering from recurrent CDI. It is estimated that 80% of 
patients treated with the standard antibiotic therapy are cured, 
however, the remaining 20% are likely to recur 3-28 days after 
discontinuation of antibiotics. Disease caused by C. difficile has 
been shown to increase the length of stay of patients by a mean 
of 7 days, incurring an additional $10,500 in health care charges 
for every infected patient. (McFarland, et al. 1994) Alternative 
treatments, including probiotics, surgery and administration of 
different antibiotics, have been suggested, but none were effec-
tive, safe and inexpensive. Fecal microbiota transplant seems to 
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fit the criteria of being inexpensive, highly effective and safe. In 
fact, a study done to compare 4 different treatments for CDAD; 
metronidazole, vancomycin, fidaxomicin and FMT demonstrat-
ed that FMT was the “most cost-effective strategy.” The incre-
mental cost-effectiveness ratio (ICER) was $17, 016 relative to 
oral vancomycin. (Konijeti, et al. 2014) It is “the only therapy 
that restores the phylogenic richness of the recipient’s intestinal 
microbiota without prolonging the perturbation of the normal 
microbiotic composition.” (Bakken, et al. 2011)  
A study comparing the fecal material of a patient before and 
after FMT illustrates the effectiveness of the transplant. Before 
FMT, the patient’s fecal material was composed of atypical bacte-
rial populations including Veillonella, Clostrudium, Lactobacillus, 
and Streptococcus. Two weeks after FMT, Bacteroidetes began 
to appear and four weeks after the transplant, the stool stud-
ies were culture negative for C. difficile. The recipient’s fecal 
bacterial composition greatly resembled the donor. Throughout 
the months following FMT the patient reported issues of loose 
stool, but those issues were resolved within two weeks without 
therapy. Six months later, the patient was completely cured from 
C. difficile infection. (Khoruts, et al. 2010)
Further data is needed to assess the effectiveness of FMT, yet 
given the promising data to date and anticipated research data 
on the intestinal microbiome, it seems to be the most reason-
able treatment for recurrent C. difficile infection (CDI). Bakken 
et al. put together a guideline for the proper administration of 
FMT. Included in the guideline is a detailed description of prima-
ry indication, donor selection and directions for preparing and 
administering the stool. Many trials and studies that involving 
FMT used this guideline as instructions on how to proceed. In 
order to be eligible for FMT, a patient either has to have recur-
rent or relapsing CDI with at least three episodes of mild-mod-
erate CDI and a failure of a 6-8 week taper with vancomycin. 
Patients on major immunosuppressive agents, decompensated 
liver cirrhosis or have had a recent bone marrow transplant 
cannot receive the fecal microbiota transplant as it may cause 
adverse effects. 
Currently, little or no data is available to suggest that any rea-
sons, other than the exclusion criteria based on medical history 
and laboratory testing, would recommend a specific donor over 
another. However, using intimate contacts as donors minimizes 
the risk of transmitting an infectious disease. Donors are inter-
viewed thoroughly and must answer a detailed questionnaire 
regarding their past medical history.  Donors are disqualified 
if they test positive for HIV, Hepatitis B or C infections or had 
exposure to HIV or viral hepatitis. Individuals that have high 
risk sexual behaviors, use illicit drugs, had tattoo or body pierc-
ing within 6 months or have a history of incarceration cannot 
donate stool for FMT. Once a donor passes the medical and lab-
oratory tests, their stool is screened for enteric pathogens such 
as  C. difficile toxin A and B,  fecal Giardia and Cryptosporidium 
antigens and Helicobacter pylori fecal antigen. (Bakken, et al. 
2011)
The stool donor may or may not take an osmotic laxative the 
night before the procedure. The stool should be used as soon as 
possible, preferably within 6 hours. The choice of diluents may 
vary among practitioners, but either preservative-free normal 
saline or 4% milk is combined with the stool in a household 
blender. It should be mixed until it reaches a homogenous slur-
ry consistency and filtered to remove particulate. The slurry 
stool mixture is to be used immediately. The optimal volume 
for transplantation has not been established yet; however if by 
nasogastric tube or via other routes from above, smaller vol-
umes (25-50 mL) should be used and if by colonoscopy or other 
routes from below, larger volumes (250-500 mL) may be used. 
(Bakken et. al. 2011) 
This is a basic outline on how a practitioner would administer 
fecal microbiota transplant. However, “practical and aesthetic 
barriers” have slowed down the widespread use of FMT, despite 
its success in dramatically resolving CDI after one treatment. 
Enrollment and screening of donors is a tedious process linked 
with substantial costs, thereby inhibiting the use of FMT in se-
vere situations. Youngster et al. suggests that by establishing a 
repository of prescreened frozen donor stool, this treatment 
may be more easily obtainable from a broader population. He 
conducted a trial to evaluate the efficacy of FMT in treating 
relapsing CDI in a pilot cohort of 20 patients, comparing colo-
noscopic and nasogastric tube administration. 
The donors for the study underwent extensive physical exam-
inations and general laboratory screening tests to ensure that all 
results were within normal range for age and sex. Renal function 
and electrolytes, complete blood count with differential, complete 
liver function tests and fecal occult blood testing were some of 
the tests that fecal donors underwent. All fecal donations were 
set aside for four weeks to allow retesting of donors for HIV and 
hepatitis B and C before the feces was inoculated. To facilitate ma-
nipulation of the fecal material, donors were asked to take milk 
of magnesia the day before the donation. The feces was mixed in 
a commercial blender with normal saline and then were passed 
through 4 sieves to get rid of any particulate. The final product 
was concentrated 3-fold by centrifugation and then resuspended 
in sterile saline with 10% glycerol added as a cytoprotectant. The 
resulting mixture was frozen at -80°C. Each filtered sample was 
calculated to have come from 41g of fecal material. Inocula were 
stored frozen for up to 156 days and thawed in a 37°C water 
bath, then kept on ice until delivery. 
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Patients were ordered to stop taking antibiotics for 2 days be-
fore the procedure. Recipients designated for a colonoscopic 
administration underwent a standard bowel preparation with 
4 liters of polyethylene glycol electrolyte solution. Then, 90 cc 
of the thawed inoculum was placed in the right colon via en-
doscopy. The fecal material was further diluted to 250 cc for 
adults and 160 cc for pediatric recipients. Patients were given 
a single dose of loperamide at the time of the procedure in 
order to retain the material for as long as possible. The pa-
tients assigned to nasogastric tube administration were given 
omeprazole orally for 2 days before the procedure, to ensure 
that the fecal bacteria will not be affected by the acids in the 
stomach. After inserting the nasogastric tube, 90 cc of inoculum 
was administered. In order to minimize vomiting and aspiration, 
the inoculum was not diluted. (Youngster, et al. 2014)
The goal of the trial was the clinical resolution of diarrhea off 
antibiotics for C. difficile infection, without a recurrent episode 
within 8 weeks. Patients who showed no improvement were 
offered a second FMT by their preferred route of administra-
tion, using the same donor inoculum to minimize exposure to 
infectious agents. 
Of the 20 patients in both study arms, 14 were cured after the 
first FMT; 8 of them were in the colonoscopy group and 6 in the 
nasogastric tube group. One patient refused a second transplant 
but the remaining 5 patients were given a second infusion via 
NGT using feces from their original donors. Four patients were 
cured after the second FMT, resulting in an overall cure rate of 
90%. No patient relapsed within the 8 week period following 
the initial cure. 
There were some serious adverse effects that were deemed 
unrelated to the trial by investigators and the Institutional re-
view board, which may have been caused by the poor health 
of the patients with recurrent CDI. 2 patients died; one from 
an obstructive pulmonary disease and another from metastatic 
laryngeal cancer. A third patient was diagnosed with adenocar-
cinoma of the esophagus and a fourth (treated via NGT) was 
hospitalized for Fourier gangrene. 
This trial demonstrated that the transplantation of unrelated 
frozen donor stool is effective in treating recurrent CDI with 
an overall cure rate of 90%. Additionally, NGT appears to be a 
feasible route of administration for elderly patients with the 
infection. One 89 year old female patient had 16 documented 
cases of CDI in the previous 15 months. She was hospitalized 
4 times and placed on the intensive care unit twice due to the 
infection. After two infusions, she was cured and was free from 
any symptoms of the disease off treatment for 12 months. 
(Youngster, et. al. 2014)  
Seeing the success with frozen inocula, Youngster et al. direct-
ed another study evaluating the effectiveness of oral capsulized 
frozen fecal microbiota transplantation in treating relapsing C. 
difficile infection. The donors were thoroughly screened, as 
described in the previous study (and the guideline by Bakken, 
et al. 2011) and similar processing of the fecal material took 
place. To ensure that the acidic environment of the stomach will 
not destroy the capsule, commercially available acid-resistant 
hypromellose capsules were used. The stability of the capsules 
was tested by mimicking the acidic environment of the stomach. 
Trypan blue filled capsules were used, at a temperature of 37°C 
and a pH of 3 or less, and the capsules were stable for 115 
minutes before the dye was released. 
From July 2013 through January 2014, a total of 20 patients 
were treated using stool obtained from four donors. The recip-
ients followed up six months later in July 2014. The goal of the 
study was the clinical resolution of diarrhea, while not receiving 
antibiotic for C. difficile, without relapse within 8 weeks. 
The procedure went as follows: each patient was given 15 cap-
sules, directly from an investigator on 2 consecutive days. 2 days 
prior to FMT, patients were ordered to stop all antibiotics. They 
were asked to fast 4 hours prior to and 1 hour post taking the 
capsule for both days. If there was no improvement after 72 
hours, patients were retested and offered another treatment 
for positive test results.   
From the 20 patients treated, 14 had clinical resolution of diar-
rhea after the first FMT. The remaining 6 patients were retreat-
ed 7 days after the first procedure. 5 of the 6 had resolution of 
diarrhea after the second FMT, however one patient relapsed 
within the 8 week follow up time period. Thus the overall rate 
of diarrheal resolution was 90%. (Youngster et. al. 2014) 
Fecal microbiota transplantation used to treat C. difficile infec-
tion is a highly effective, safe and inexpensive method as de-
scribed studies and research. Very few, if not any, complications 
were caused by FMT. The fecal material can be manipulated and 
can be transplanted as a liquid via NGT or colonoscopy and can 
also be ingested as a capsule. FMT is currently an FDA experi-
mental drug and therefore the trials and studies are with small 
samples and lack of placebo or other trial to compare. Granted, 
the trials and studies done are encouraging, however this may 
be due to the small sample size. Furthermore, even with careful 
screening, there is a potential risk of transmission of infections 
via microbiota transplantation. Larger studies would be needed 
to confirm these outcomes and to evaluate long-term safety 
and effectiveness. (Youngster et. al 2014)
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Fecal Microbiota Transplant for Ulcerative Colitis
Encouraged by the success for fecal microbiota transplant in 
the treatment of C. difficile infection, researchers looked to 
other conditions related to GI microbial imbalance, such as 
inflammatory bowel disease (IBD), obesity and diabetes mel-
litus. (Borody, et al. 2103) Inflammatory bowel diseases are 
thought to be caused by an overall community dysbiosis rath-
er than a single underlying pathogen. In patients with IBD, an 
increase in Actinobacteria and Proteobacteria and a decrease 
of Lachnospiraceae, Bacteroidetes, Clostridium leptum, and 
Bifidobacteria are observed. (Clemente, et. al. 2012)
Ulcerative colitis (UC), a type of IBD, is a chronic devastating 
inflammatory bowel disease that affects the large intestine. 
Unfortunately, the current medications used to treat UC have 
significant adverse effects; they mainly target the inflammation 
without focusing on the dysbiosis. (Kunde, et al. 2013)   The 
colonic microbiome in UC patients lacks diversity and is dys-
functional. The cause of inflammation of the colon in UC is 
hypothesized to be caused by inappropriate stimulation of the 
innate mucosal immune system because of dysbiosis in a ge-
netically susceptible individual. Borody et al. asks the following 
question: C. difficile infection causes reduced microbial diversity 
which results in symptoms of colitis; if FMT can reverse this, 
perhaps a similar treatment can be used to treat ulcerative coli-
tis? (Borody, et al. 2013)  
Borody et. al. conducted a trial assessing the clinical, histological 
and colonoscopic effects of “human probiotic infusion” (HPI), or 
fecal material transplant in six selected patients with ulcerative 
colitis. All patients had suffered from severe recurrent symp-
toms of UC and each, respectively, were on series of moderate 
to high dose steroids and anti-inflammatory medications. The 
donors were chosen by the recipient patients and screened 
thoroughly to prevent any transmission of parasites or bacterial 
pathogens. The feces (200–300 g) was diluted in 200 to 300 
mL normal saline and administered to the patient via retention 
enema within 10 minutes of its preparation. This process was 
repeated daily for 5 consecutive days. One week following HPI, 
some symptoms of ulcerative colitis had resolved in several pa-
tients.  A complete reversal of symptoms was achieved in all 
patients 4 months post HPI, by which all other UC medications 
had been discontinued. From 1 to 13 years later, patients re-
mained asymptomatic with a healthy colonoscopic appearance 
and normal histology.
However, the pathogenesis of UC is unknown since it is char-
acterized by persistent inflammation. It is suggested that the 
disease is driven by a chronic infection caused by the absence 
of vital luminal anaerobes.  If the ability of the normal flora to 
resist colonization by pathogens is hindered, for example, by 
previous antibiotic use, the numbers of protective anaerobes in 
the colon, such as Bacteroides, decrease. This would allow the 
establishment of other pathogenic anaerobes or spore bearing 
bacteria and a form of recurrent, chronic colitis. The persistence 
of UC may be due to the implantation of spores in the mucosal 
surface, analogous to Clostridium difficile infection. Antibiotics 
may help briefly but are unlikely to be curative because the 
spores are not eliminated. (Borody et. al. 2003) 
Kunde et. al. conducted a pilot study to evaluate the efficiency 
and safety of fecal microbiota transplantation in children with 
ulcerative colitis. Ten children, ages 7 to 21 with mild to mod-
erate UC according to the pediatric ulcerative colitis activity 
index (PUCAI) were enrolled in the study. Clinical response and 
improvement was defined as decrease in PUCAI by more than 
15 points on the index. A decrease in PUCAI to less than 10 
points was considered clinical remission. Each donor produced 
a 90 gram stool sample every day which was blended with 250 
mL normal saline and filtered through 2 gauze pieces to remove 
sediments. It was then separated into 4 aliquots of 60 mL each 
and kept in a warm water bath (37°) until administration. Each 
patient received FMT as retention enema for 1 hour (60-mL 
enema every 15 minutes) daily for 5 days. One subject however, 
was not able to tolerate the retention enema for 3 consecutive 
days and was therefore not included in the results. Within one 
week following the procedure, 7 of the 9 subjects (78%) showed 
clinical response. Four weeks after FMT, six of the nine patients 
(67%) maintained the clinical response. However, 3 of the nine 
subjects (33%) went into clinical remission one week following 
FMT. All of the adverse events related to FMT, besides fever, 
were self-limiting, and did not require intervention from health 
care providers. The majority of them were similar to subjects’ 
baseline symptoms of UC such as bloating and diarrhea.
The dramatic response to FMT after one week was not achieved 
in all subjects, perhaps due to the severity or duration of the 
disease, or the ability to retain larger FMT volumes for longer 
periods. Using FMT via fecal enema to treat UC in children is 
feasible, as proved in the trial. However, the sample size was small 
and therefore limits future indication. In order to improve FMT a 
standardization procedure would need to be arranged for donor 
selection and ideal routes of administration. (Kunde, et al. 2013)
The Gut Microbiota and Obesity
The World Health Organization (WHO) reports that in 2014, 
more than 1.9 billion adults, 18 years and older were overweight 
and of these, over 600 million were obese. Obesity is a growing, 
worldwide epidemic that has been accompanied by increases in 
obesity related disorders, including type II diabetes, hypertension 
and nonalcoholic fatty liver disease. Much emphasis has been 
placed on the dietary excess or host genes in obese individuals. 
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Yet, in addition to increased calories or shifts in host metabolism, 
the composition of the intestinal microbiota can contribute to 
the progression of obesity. Both diet induced obesity and gene in-
duced obesity have microbe independent and microbe dependent 
pathways. (Baackhed et al. 2004, Cox, Blaser 2013)
A study was done to investigate the effect that diet has on shap-
ing the gut microbiome. The fecal material of 15 European chil-
dren and that of 14 children from a rural African village, Bukina 
Faso were compared and tested with 16S rRNA sequencing, 
and biochemical analysis. The goal of the study was to explore 
three questions: the split of bacterial diversity between the two 
populations, the connection between the gut microbiota and 
diet, and the distribution of well-known bacterial pathogens 
within the two populations given the different hygienic and geo-
graphic conditions.
The diet of Bukina Faso children is mostly vegetarian; rich in 
plant polysaccharides, starch and fiber and low in fat and ani-
mal protein. All the food was grown and harvested nearby the 
village by women.  The European children were eating a typical 
Western diet high in animal protein, sugar, starch and fat and 
low in fiber. A dataset consisting of 438, 219 of filtered, high 
quality, classifiable 16S rRNA was generated. Of all of the se-
quences in all the Bukina Faso and European samples 92.4% 
were found to belong to the most populated bacterial phyla: 
Actinobacteria, Bacteroidetes, Firmicutes, and Proteobacteria. 
However, it was the proportions that stood out: Actinobacteria 
and Bacteroidetes were more abundant in the Bukina Faso chil-
dren than the European children 10.1% versus 6.7% and 57.7% 
versus 22.4%, whereas Firmicutes and Proteobacteria were rep-
resented more in EUROPEAN than BUKINA FASO children, 
63.7% versus 27.3% and 6.7% versus 0.8%. Since Prevotella, 
Xylanibaeter (Bacteroidetes) and Treponema (Spirochaetes) 
were exclusively found in the Bukina Faso children. De Filippo 
et. al. hypothesized that these 3 genera could be a result of high 
fiber intake due to the environmental factors distinguishing the 
two populations (diet, hygiene, climate and geography). Perhaps 
these three groups contribute to the extraction of metabol-
ic energy from ingested plant polysaccharides. It is reasonable 
to deduce that the increase in the Firmicutes to Bacteroidetes 
(F/B) ratio in European children possibly triggered by their 
high-calorie diet might predispose them to future obesity. This 
Firmicutes/Bacteroidetes ratio may also be considered a useful 
obesity biomarker. (De Filippo, et al. 2010)
A study done by Turnbaugh et al.  further demonstrates the 
effect of diet on the gut microbiota. Mice raised in a germ free 
environment without any exposure to microbes, and then col-
onized at specific life stages with different microbial communi-
ties are referred to as gnotobiotic animals. Adult human fecal 
microbiota was transplanted into the recipient mice to establish 
a stable gut community similar their donors. An aliquot of the 
fecal dilution was introduced by gavage to the 15 recipient mice. 
These mice were maintained on a low fat plant polysaccharide 
(LF/PP) rich diet and fecal samples were collected 1 day, 1 week 
and 1 month after colonization. Half of the mice were then 
switched to a high-sugar, high-fat Western diet. The LF/PP and 
Western diet were maintained for 2 additional months, after 
which the mice were killed. Results showed that when the diet 
of the mice were switched from a LF/PP regimen to a high-
fat, high sugar “Western” diet the structure of the microbiota 
was shifted within a single day. The representation of metabolic 
pathways in the microbiome were changed and the microbi-
ome gene expression was altered. The mice fed a Western diet 
had an increased representation of the Erysipelotrichi class of 
bacteria within the Firmicutes phylum relative to mice fed the 
LF/PP diet. In mice that consumed a Western diet, the Bacilli, 
another class of the Firmicutes was abundant and a significant 
decrease in member of Bacteroidetes was found. These mice 
increased adiposity, demonstrating that this trait is transmissible 
via microbiota transplantation. Using germ free mice, research-
ers were able to see a clear correlation between the foods the 
mice were fed and its effect on the composition of their gut 
microbiota. Gnotobiotic technology is a promising tool for dis-
covering new classes of probiotics that affect nutrient harvest in 
a given diet.  (Turnbaugh, et al.2008) 
A study comparing the fecal material of 31 adult female monozy-
gotic and 23 dizygotic twin pairs and their mothers, concordant 
for obesity or leanness, was performed, to address how host 
genotype, environmental exposures and host adiposity influence 
the gut microbiome. All twins were 25-32 years old of European 
or African ancestry. Analysis of 16S rRNA datasets produced 
by the three PCR-based methods, plus shotgun sequencing of 
community DNA, revealed a lower proportion of Bacteroidetes 
and a higher proportion of Actinobacteria in obese versus lean 
Europeanropean and African individuals. Overall, across many 
methods, obesity was associated with a decrease in diversity 
of the gut microbiota. “This reduced diversity suggests an anal-
ogy: the obese gut microbiota is not like a rainforest or reef, 
which are adapted to high energy flux and are highly diverse, 
but rather may be more like a fertilizer runoff where a reduced 
diversity microbial community blooms with abnormal energy 
input.” (Turnbaugh, et al. 2009) 
There is an interesting case study regarding the transmission of 
“obese bacteria.” A 32 year old female patient with recurrent 
CDI elected to undergo FMT after many failed antibiotic thera-
pies. Around the same time, she tested positive for Helicobacter 
pylori. 
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The patient chose her 16 year old daughter, who was approxi-
mately 140 pounds to be her stool donor, and, subsequently, her 
weight increased to 170 pounds. The patient herself was 136 
pounds at the time of the transplant. The patient was retreat-
ed for H. pylori with metronidazole, tetracycline, bismuth and 
proton pump inhibitor, and two weeks later she had the FMT. 
Six hundred cc. of the suspension of the donor stool in sterile 
water was infused through a colonoscope. The patient dra-
matically improved after the procedure and CDI did not recur. 
However, 16 months later, the patient presented again, and re-
ported an unintentional weight gain of 34 pounds. Despite a 
medically supervised liquid protein diet and exercise program 
she had been unable to lose weight. Her weight continued to 
climb despite the diet and exercise and at 36 months post FMT 
she weighed 177 pounds. 
Alang and Kelly offer a several of hypotheses to explain the 
rapid weight gain following FMT.  There is a known link between 
H. pylori treatment and weight gain, resulting from the increase 
in appetite after the suppression of the bacteria. Yet, the patient 
was never obese before FMT and the fact that the stool donor 
also gained weight leads to the possibility that her obesity re-
sulted from the transplant (Alang, Kelly 2014). 
This hypothesis is supported in a study testing the fecal ma-
terial of twins discordant for obesity. This experiment offers 
an opportunity to examine connections between obesity and 
its associated metabolic disorders, diet, and the gut microbi-
ota. Ridaura et al. conducted a study by transplanting the fecal 
material of twins discordant for obesity into mice in order to 
replicate the donors’ microbiota community in the colon. The 
impact of these differences on the body composition and met-
abolic phenotypes were able to be detected, and the effects 
of diet-by-microbiota interactions analyzed. The mice harboring 
the transplanted microbiomes from the obese twins exhibited 
higher expression of microbial genes involved in detoxification 
and stress responses, in biosynthesis of cobalamin and metab-
olism of essential amino acids. In contrast, the transplanted 
microbiomes from lean co-twins exhibited higher expression 
of genes involved in digestion of plant-derived polysaccharides, 
fermentation to butyrate and propionate. The results suggest 
that the transplanted microbiota of the lean co-twins had great-
er capacity to breakdown and ferment polysaccharides than the 
microbiota of their obese co-twins. (Ridaura, et al. 2013)
From these studies, it is evident that the gut microbiota reflects 
the health, diet and metabolism of its host. It seems that the com-
position of the phyla that make up the gut microbiome in healthy 
individuals is properly balanced. However, a disrupted microbiome 
can contribute to obesity by altering energy extraction from food. 
Conclusion
By transplanting stool from a healthy donor into a recipient’s 
diseased colon via fecal bacteriotherapy, a newer and healthier 
microbiome can flourish and the function of the large intestine 
can be restored. Fecal microbiota transplant has been proven 
by many clinical trials to be a safe, effective and inexpensive 
procedure. FMT has been successful in treating many cases C. 
difficile infection, as well as ulcerative colitis and has a promising 
future in the field of diet and obesity. The stool material can be 
readily administered in different ways, as a slurry consistency 
administered via colonoscopy or nasogastric tube, or packaged 
in a pill and taken orally; this therapy is easily accessible to al-
most all populations. 
However, one potential drawback of FMT is the small sample 
size in many of the clinical trials done. Additionally, fecal bacte-
riotherapy may not be the ideal treatment for every individual 
suffering with GI tract disorders, for example, it may not be 
ideal in immunocompromised patients. However, FMT is an FDA 
approved drug and will undergo further standardization regard-
ing donors and the preparations and administration of the stool. 
The future of the gut microbiota related treatment is an active 
topic of research; much is anticipated from this exploration into 
the microbiome. 
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Introduction
In a society plagued by obesity, diabetes and overeating, we 
search for ways to counteract these negative effects. Early 
research into these problems led to the assumption that the 
major cause of these maladies was over consumption of sugar. 
The food industry was taken by storm with the introduction 
of non-caloric artificial sweeteners (AS) such as saccharin, su-
cralose, and aspartame, which are widely used to replace sugar 
in the average western diet. However, are these sweeteners 
fighting or feeding the problems they were intended to combat? 
Studies conducted in this area of science see a direct dose-re-
sponse relationship between artificial sweetener use and weight 
gain. This relationship begs an explanation. Researchers propose 
that the weight gain caused by artificial sweetener can be due 
to natural circumstances, flawed gut microbial activity, or altered 
neurometabolic functions.  Artificial sweeteners have been con-
nected to both an increased appetite, and inefficient energy ab-
sorption. This combination can lead to weight gain and obesity. 
Methods
The studies and information in this paper were acquired through 
the PubMed government database and the Touro College Library 
databases such as J Store, Ebsco Host, and Proquest. To answer 
the present questions the articles and reviews have been read 
through; only the relevant information has been included.
History of Artificial Sweetners
The first sweetener to be discovered was saccharin. A scientist 
named Constantine Fahlberg stumbled upon it in 1879 at Johns 
Hopkins University. For nearly half a century saccharin was the 
only artificial sweetener on the market. Originally, it was for 
diabetics only, later it was used for anyone wanting to limit their 
sugar intake. Fifty years later, in the University of Illinois, Michal 
Sveda discovered Cyclamate. Combining cyclamate with saccha-
rin improved the taste and soon became common practice. By 
1969 the FDA banned cyclamate because of its link to cancer, 
while they deemed saccharin safe to use. Artificial Sweeteners 
use went down in the general population until the new prod-
ucts surfaced. Aspartame was found in 1965 by James Schlatter 
at Searle while researching ulcer drugs. This was the first AS 
that could be metabolized, and the FDA approved it in 1981. 
Next came acesulfame potassium in 1967 and sucralose in 1979. 
Neotame was later approved for use is 2002 by the FDA. 
In the years between 1999 and 2004 more than 6,000 new 
products have been created using artificial sweeteners. These 
sweeteners are most commonly used in carbonated drinks. 
Sucralose is the most widely used due to its close mimicry of 
real sucrose taste. The wide use of these sweeteners in count-
less products ensures that sweeteners affect most aspects of 
our dietary life (Yang, 2010).
Discussion
Artificial Sweetener use and Weight Change: 
The perpetual debate surrounding the effects of artificial 
sweeteners on the human body gave rise to a lengthy list of 
studies that attempt to determine the risks as well as the 
benefits. A controversial matter that has taken priority in these 
studies is the question regarding weight change in relation to 
artificial sweetener use. Due to their lack of calories, sweet-
eners have been used to control diseases such as diabetes as 
well as prevent diseases such as obesity. Yet, studies have found 
a substantial dose-response relationship between artificial 
sweetener use and weight gain. These studies range from 4 day 
studies to 10 year epidemiological events.
One of the largest scale studies performed was the San Antonio 
Heart Study (Fowler et al, 2008). The study included 5,158 
Mexican and non-Hispanic white Americans between the ages 
of 25 and 64. All the members of the study lived in randomly 
selected homes in the San Antonio area. Consisting of 2 cohort 
studies, the first of which was from 1979 to 1982, the second 
was from 1984 to 1988. Of the 4,998 surviving individuals,  took 
part in a follow-up study 7- 8 years later. This study focused 
on artificial sweetener consumption in beverages. Participants 
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were asked to answer a series of questions regarding amount 
of cans, bottles or cups of beverages, such as soft drinks, diet or 
regular, and coffee, sweetened with sugar or AS, they consumed 
per week. Based on their answers participants were placed in 
either a user or nonuser category. Dieting status and exercise 
frequency were recorded at baseline as well. Each participant 
was categorized by weight at baseline. A BMI of <25 was catego-
rized as normal weight (NW), _>25 but _<30 was overweight 
(OW) and _>30 was obese (OB). Incidence of OW/OB was 
defined as the percentage of originally NW participants who 
entered the OW/OB category by follow-up. 
Results of the study show a strong dose-response relationship 
between AS beverage consumption and change in BMI. In Cohort 
1 AS users had a 78% greater change in BMI than non-users and 
Cohort 2 experienced 74% and 83% greater change in BMIs 
in quartiles 3 and 4 respectively. The change in BMI followed a 
consistent pattern within the user subset. The more artificial-
ly sweetened beverages consumed per week the greater the 
change in BMI. Less than 3 ASBs consumed per week resulted 
in an average change of 1.2 kg/m2 while 22+ ASB per week 
resulted in 2.0 kg/m2 change and up. Participants who started 
out as users then chose to discontinue use experienced 58% 
lower BMIs than those who continued use. Once gender, ethnic-
ity, weight category at baseline, diabetes, dieting status, exercise 
and cohort were factored in, change in BMIs were 47% higher 
in artificial sweetener users than non-users, suggesting greater 
gains, or smaller loses, for users versus non-users. Limitations of 
the study include a lack of sweetener specific study ability, fruit 
juices were not included, neither were artificial sweeteners con-
sumed in products including food, other beverages, cosmetics 
and pharmaceuticals (which can contain aspartame) (Theodore, 
2006). 
The San Antonio Heart Study is far from the only one per-
formed on this topic. Many studies have lead to the same 
conclusion showing a relationship between artificial sweeten-
er consumption and weight gain. The list is never ending. The 
American Cancer Society Study (Stellman, Garfunkel, 1986), 
which focused on 78,694 women, was conducted in the early 
1980’s. At a one-year follow-up 2.7 compared to 7.1% more 
AS users gained weight than non-users. The average difference 
in the amount gained was just shy of two pounds, nevertheless 
it was statistically significant. A third well known study was the 
Nurse’s Health Study (Colditz et al, 1990) conducted between 
the years of 1976 and 1984. In this study 8 year weight gain was 
associated with saccharin use in 31,940 women. 
Researchers such as Blundell (Blundell, Hill, 1986), Rogers 
(Rogers et al, 1988)(Rogers, Blundell, 1989), Tordoff (Tordoff, 
Alleva, 1990)(Tordoff, Friedman, 1989), and Lavin (Lavin et al, 
1997), who have conducted studies attempting to find a reason 
for this phenomenon, have seen increased hunger, appetite, and 
food consumption as a result of AS users. However, reviews 
written by Rolls 
91991) and Malik et al, (2006), which consist of multiple short 
term studies, have seen either no weight gain, or even increased 
weight loss in users. A meta analysis of nine interventional stud-
ies summarized by De La Hunty (De La Hunty et al, 2006) saw 
significantly greater weight loss in aspartame users versus non 
users.
When researchers saw the incongruent results of these studies 
they chose to conduct a study of their own. In a 10-week study 
they tried to prove their claim that  “short term studies are not 
very informative because appetite regulation and macronutri-
ent balance probably do not correct for the missing energy and 
sucrose until the individual has consumed the diet for several 
days” (Raben et al, 2002).  Their results, however, proved their 
hypothesis wrong. For 10 weeks overweight individuals were 
placed into either a sucrose group or an artificial sweetener 
group. The study found no increased hunger or appetite in the 
AS group compared to the sucrose group, and weight gain was 
observed in the sucrose group while weight loss occurred in the 
artificial sweetener group.
The lack of consistent results in these studies can obviously 
be due to the human components. The controlled short term 
studies consisted much more of restricting diets and exercise 
regiments. The long-term studies, spanning multiple years, thus 
allowing natural eating habits and appetites to develop, were 
more likely to see increased BMI amongst artificial sweetener 
users. There is a possibility that those using AS are those who 
are more susceptible to weight gain, and therefore, we see these 
results. But research doesn’t stop with speculation. Scientists 
are now trying to understand how non-caloric sweeteners 
could lead to weight gain.
Biological Response to Sweet Taste  
Natural Sugars:
Many different explanations have been suggested as to why arti-
ficial sweeteners would cause an increase in weight. The first is 
the suggestion of increased appetite or lack of appetite suppres-
sion. As stated previously, AS use has been continuously linked 
to hunger and overeating. The debate lies in how sweeteners 
can cause these biological reactions. In order to understand the 
specific way in which the body reacts with artificial sweeteners 
we must first understand how the body acts with natural sugars. 
There are 2 pathways of glucose absorption (Mace et al, 2007). 
One is active transport through the Na+ glucose co-transporter 
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SGLT1. This pathway reacts only with glucose and is thus unaf-
fected by artificial sweeteners. The second route is known as 
the apical GLUT2 pathway. This pathway reacts at high concen-
trations of glucose and can have 3 to 5 times more rapid and 
precise absorption than the classic SGLT1. The GLUT2 route 
is mediated by Ca2+. Depolarization of the apical membrane 
through glucose transport via SGLT1 allows Ca2+ to enter the 
L-type channel Cav1.3, this causes the terminal web to contract. 
This is essential for insertion. Little insertion occurs at low con-
centrations of glucose, in which case the SGLT1 transporter 
dominates. However, at 30 mM (millimoles) of glucose or more 
the GLUT2 pathway takes over as the main absorption pathway 
for unknown reasons.
The calcium concentration goes up as a result of the G- pro-
tein coupling receptor, α-gustducin, activated phospholipase c 
β2- dependent pathway. The GCPR is coupled with the T1R2 
and T1R3 sweet taste receptor heterodimer. When these re-
ceptors, found in both lingual cells on the tongue and intestinal 
brush cells in the duodenum, sense sweet taste they release the 
α-gustducin and set this reaction in motion. 
The α-gustducin also induces the secretion of glucagon-like 
peptide (GLP)-1 and peptide YY from enteroendocrine L-cells 
(Ford et al, 2011). Both GLP-1 and PYY have been observed 
to be satiety factors in humans (Flint et al, 1998, Gutzwiller et 
al, 1999). GLP-1 is known to raise insulin sensitivity as well as 
increase leptin levels in the hypothalamus, thus increasing sati-
ety in the brain. The sweet taste path continues eventually ter-
minating in the insula/frontal operculum and the orbitofrontal 
cortex (Small, 2006). The mesolimbic system sends the feeling 
of satisfaction received for the good taste (Stice et al, 2008). 
The metabolic products of the ingested foods determine this 
post-ingestive effect. Therefore, when sugar, enters the body it 
stimulates the sweet taste receptors, which activate both the 
absorption pathway and the satiety pathway, providing both an 
energy source for the body and a reward for the brain. The 
combination of these factors means the person is no longer in 
search for food; he is satisfied.
Biological Response to Sweet Taste 
Artificial Sweeteners:
In 2010, Ford and Peters conducted an experiment to deter-
mine if artificial sweeteners invoke this same response as sugar 
does in the body (Ford et al, 2011). They conducted a signal 
blind, randomized, crossover study in eight healthy volunteers 
over a 4 day period. The volunteers consisted of seven females 
and one male ages 22-27, all in the normal body weight range. 
The subjects were randomly selected to receive one of four 
solutions: 50ml of either water, sucralose, maltodextrin (a 
non-sweet caloric substance, matched for the sweetness of su-
cralose in this experiment) or a modified sham-feeding protocol 
of sucralose (used to study oral stimulation of sweet taste re-
ceptors in the mouth versus those in the gastro-intestinal tract). 
The dose of sucralose used was based on the observed average 
intake of sucralose per day. Observations were made on four 
separate days with a minimum of three days left in between 
each solution study. Participants initial blood work was taken 
on arrival, they then ingested one of the first three solutions 
followed by the MSF of the solution that they had swallowed. 
Blood samples were taken -15 minutes and 0 minutes prior to 
ingestion and then 15, 30, 45, 60, 90, and 120 min after inges-
tion. To analyze cephalic phase insulin response as well as GLP-1 
release, samples were taken at 2, 4, 6, 8, and 10 minutes after 
ingestion. Participants were asked to rate their appetites using 
visual analogue scores for 120 minutes following ingestion, after 
which time they sat down to a meal and their food intake was 
noted.
Researchers found that there was no increase in appetite or 
energy intake after the 2-hour waiting period, however, what 
they found in the blood samples, is quite fascinating. The plasma 
insulin and GLP-1 showed no significant change in the first 10 
minutes and GLP-1 and PYY concentration were similar in all 
groups. The stimulation of T1R receptors did not occur in the 
case of sucralose ingestion. As a result GLP-1 and PYY were not 
secreted and appetite suppression did not occur. Perhaps the 
most interesting part is that in vitro sucralose did stimulate the 
receptors and, as a result, the L-cell secretions of GLP-1 and 
PYY occurred. The reason for this disparity is still unknown at 
this point in time.
Though artificial sweeteners don’t stimulate these receptors on 
their own,  a study done on rat intestinal tracts was very infor-
mative as to the mechanism that is used. In this study on rat 
intestinal tracts, it was demonstrated that, when combined with 
a small amount of glucose, AS stimulate the GLUT2 response 
in a similar way to that of large amounts of glucose (Mace et al, 
2007).  The rapid absorption of glucose through this pathway is 
only first observed at a threshold value of 30 mM of glucose, 
even then it is a minimal response. However, when 20 mM of 
glucose were ingested in conjunction with just 1 mM of su-
cralose the rate of glucose absorption doubled (as compared to 
just 20 mM of glucose). This effect was equivalent to the effect 
of 75 mM of glucose ingestion. The rapid absorption may lead to 
a feeling of satiety, but blood glucose levels sky rocket as a result 
as well. High glucose levels will lead to fat production as a means 
of conserving all the extra energy in the body. Therefore, trying 
to save calories “part of the time” can actually have worse re-
percussions for weight gain and obesity than natural sugars can. 
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In another study examining a connected response, Graaf et al, 
studied the functional magnetic resonance images (fMRIs) of 
subjects who had recently ingested glucose, water, maltodextrin, 
or aspartame (Graaf et al, 2005). The objective of the study was 
to examine the separate effects of energy content and sweet 
taste on the hypothalamic responses, such as cephalic phase 
insulin response, and ghrelin (the hunger hormone) response 
suppression, which contribute to a sensation of satiety. 
Five participants were scanned for 37 minutes at a time on 
4 separate days. The participants were healthy normal weight 
males. A questionnaire was used to assess the general level 
of health in their daily lifestyle. Solutions were randomly as-
signed to participants by picking lots the day before each visit. 
The aspartame and maltodextrin solutions were matched for 
sweetness to that of the glucose solution. The subjects didn’t 
know which solution they were receiving. One blood sample 
was taken before entering the fMRI machine, others were taken 
once the subjects were inside. The first was taken -5 minutes 
and -3 minutes before ingestion and then 1, 3, 5, 7, 10, 20, and 
29 minutes after ingestion of the substance. Each subject’s hy-
pothalamus was segmented into four regions. The regions of 
interest (ROI) were the upper anterior hypothalamus (UAH) 
and upper posterior hypothalamus (UPH) because these are the 
regions known to respond to glucose (Smeets et al, 2005). At 
each time slot the mean gray matter value of the hypothalamus 
was calculated and compared to the 7-minute reference period 
of each participant. 
Results of the study show that glucose was the only one of the 
four substances that resulted in a prolonged decrease in the hy-
pothalamic hunger signal (ghrelin response). Neither the sweet 
taste of aspartame alone, or the caloric intake of maltodextrin 
alone elicited this same response. The results blood samples 
showed that both glucose and maltodextin ingestion resulted 
in a cephalic phase insulin response and 6increased blood glu-
cose levels. However, the glucose response was much stronger. 
Increased glucose levels result in leptin release, which is itself 
associated with a decrease in ghrelin signals, ultimately giving 
the person a feeling of satiety. Aspartame and water had no 
such effects. In a similar study, saccharin was tested in place of 
aspartame, the saccharin did not result in a CPIR either (Teff et 
al, 1995). 
What these studies suggest is that artificial sweeteners do not 
send the same signals to our brain as real sugars. As a result one 
doesn’t feel satisfied or rewarded after eating. In the absence 
of these biological reactions there is typically an increase in fat 
and protein calorie intake (Benton, 2005, Beaton et al, 1992). It 
has also been noted that the reward system for food shares the 
behavioral paradigm with all different forms of addiction (Avena 
et al, 2008). And like other addictions a period of abstinence 
can lead to a period of over indulgence. Avena et al. noted that 
after a period in which rats were denied sucrose, an increase 
in sucrose self-administration occurred (Avena et al, 2005), 
quite similar to binge eating in humans. Applying this concept 
to artificial sweetener use, one can assume that replacing sugar 
with non-caloric sweeteners can actually result in an increase 
in caloric intake.
Gut Microbial Adaptation to Artificial 
Sweeteners:
In the early 1980’s it was suggested that there might be a link 
between the commensal flora of the gut and obesity. This sug-
gestion came about when a noted change occurred in the gut 
microbiota composition after weight loss (Bjorneklett et al, 
1981). In 2005 a well known study stated that obesity can result 
from a higher Firmicutes : Bacteroidetes ratio (Ley et al, 2005), 
further studies found that there is definitely an altered biome 
in the GI tract of obese people (Payne, er al., 2012). The de-
bate on this topic is a cause or consequence question. Is it that 
individuals who have altered gut microbes become obese, or 
does the micro-biome only change once the person is already 
obese? Payne suggests that the cycle begins by not eating prop-
erly, thereby destroying the natural gut environment. The new 
ecosystem reacts differently to the substances that enter the 
system; this behavior can contribute to obesity.
Payne says that our non-diverse “fructose-and sugar substi-
tute-laden, plant polysaccharide- poor Western diets” force the 
microbiota to adapt to the new and unknown substrates such 
as artificial sweeteners while being bombarded by familiar sub-
stances like fructose. These conditions force the environment 
to adapt, changing structure, enzyme production and patterns 
of energy absorption. This survival mechanism, called adaptive 
metabolism, was demonstrated in rat and pig models for D- 
tagatose fermentation (Laerke et al, 2000). At the same time 
that this diet creates new adaptive forms of bacteria, the normal 
diversity that exists begins to diminish. The link between obe-
sity and a lack of diversity of gut microbiota is widely accepted 
(Turnbaugh et al, 2008; Ley et al, 2005; Turnbaugh et al, 2006). 
Turnbaugh et al’s. study suggests that the typical western diet 
promotes growth of Firmicutes while it depletes Bacteroidetes 
contributing to the unhealthy ratio. Bacteriodetes are the ones 
most well equipped for the digestion of starch and sucrose. 
This newly formed ecosystem evolved in order to promote 
efficient energy extraction. While the body can only absorb as 
much energy as was ingested, increased exposure to unknown 
substrates can put the body into panic mode. As a result of 
over exposure to unfamiliar substances the bacteria react by ac-
quiring supplementary metabolic energy sources. For example 
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short chain fatty acids (SCFAs) taken up by the intestine can be 
converted to energy via the Krebs cycle (Leng et al, 1963). The 
idea of efficient energy extractions has been observed in obese 
individuals (Turnbaugh et al, 2006). The extra absorption creates 
more energy; energy that is unnecessary. The extra energy then 
has to be stored as adipose tissue, over time this can lead to a 
build-up and cause someone to become overweight and possi-
bly obese. 
Resting Metabolic Rate Adaptation to Artificial 
Sweeteners:
The resting metabolic rate (RMR) of a person’s body has a large 
effect on total energy expenditure (Ravussin et al, 1982) and 
low RMR (calculated by using fat-free mass as a reference point) 
puts them at a greater risk of obesity (Ravussin et al, 1988). In a 
study done by Kiortsis et al, obese children were put on a calo-
rie restricting diet for six weeks (Kiortsis et al, 1998). After the 
six week period, weight loss occurred and lower BMI and FFM 
were calculated. RMR at this time averaged around 10.1% lower 
than the starting metabolic rate. As RMR went down so did the 
Serum tri-iodothyronine (Serum T3) levels. A correlation is not 
well understood but this may be an adaptive response attempt-
ing to conserve energy during a period of caloric deprivation.
The data gathered in this study can be applied to this discussion. 
Artificial sweetener use is a form of calorie reduction. When 
depriving the body of proper energy sources the RMR decreas-
es. When a person goes back to eating the way they did before 
the calorie withdrawal period, their new, lower RMR will not 
be able monitor proper energy expenditure. The low metabolic 
rate also greatly increases an individual’s risk of obesity, so the 
short term weight loss may not be all that successful.
“The Sweetening of the World’s Diet” (Popkin, 
Neilsen 2003)
The Sweeteners that have been approved by the FDA are in-
tensely sweet. So much so that very little has to be used to 
achieve the sweetness of sucrose. Sweetners, from aspartame, 
which is 180 times sweeter than sucrose, to neotame, which can 
be 7,000 to 13,000 times sweeter, have desensitized the present 
day palate. We are so used to products with this uber sweetness 
that companies that use real sugars are forced to manipulate 
their products so our trained palates recognize them as sweet. 
This extreme use of sugar in such large quantities is not healthy 
for anyone and, of course, contributes to the obesity epidemic.
“Low- Fat” Syndrome:
As the prevalence of obesity rises and people become more and 
more aware of the dangers of being over weight a new culture 
has been born. Nearly every product known from chocolate 
to pasta to alcohol can now be found in a low fat, sugar free, 
or low carb form. Studies show that these labels can distort 
a person’s perception of serving size, and calories per serving 
(Wansink, Chandon, 2006). These assumptions then mold his or 
her anticipated pleasure, from the taste of the food, and/or guilt, 
from the calorie intake, that they will feel for consuming this 
product. The guilt experienced by consumers is a product of the 
conflict of interest that goes on in their heads. On the one hand 
they want the pleasure for the taste of the food, on the other 
they know the long-term health risks of eating unhealthy foods. 
These factors combined then determine how much the per-
son will actually eat. When the guilt is decreased or completely 
erased from the equation, consumers make decisions that are 
extremely detrimental to their health.
A study was performed to see if this theoretical phenomenon 
proved to be real. It took place at a university open house to 
allow for diversity, 361 participants were included in the study. 
Upon arrival participants were brought to one of two bowls 
of regular M&M’s. The first bowl was labels “Regular M&M’s” 
while the second was labeled “Low-Fat M&M’s”. The participants 
were told to serve themselves what they thought was an av-
erage serving size, and their bowls were weighed. They were 
then asked to estimate how many calories they believed were in 
their serving size. After eating their M&M’s the participants were 
asked how guilty they felt for eating them. 
The results of the study show that low-fat labels can be ex-
tremely hazardous. Participants ate 28.4% more M&M’s when 
they were labeled “low-fat”, their perceived serving size was 
25.1% greater and their calorie estimates were nearly 300 cal-
ories lower as compared to regular M&M’s. All participants felt 
guiltier for eating the regular M&M’s than for eating the low-
fat ones, however, overweight individuals felt less guilty about it 
than the normal weight individuals. The overweight individuals 
actually said they felt no guilt at all for eating the low-fat M&M’s.
The larger problem that this presents is that low-fat does not 
necessarily mean low calorie. In a survey done on 17 brands that 
sold a regular and low fat version of the same product, it was 
determined that though low-fat products had, on average, 59% 
less fat than the regular products, they only had 15% less cal-
ories. Applying these statistics to the previous study outcomes 
would mean that though consumers had 48% less fat (based 
on the average lower fat percentage of low fat products) they 
would have had 9% more calories. 
Conclusion
This review was written as an attempt to understand the 
correlation between artificial sweetener use and weight gain. 
Multiple scientific and sociological/ psychological hypotheses 
were studied. Each one can explain this surprising phenomenon. 
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However, they don’t have to stand alone. Combined the multiple 
hypothesis can tell the life story of an obese individual. It is a 
vicious cycle that has no real beginning and it can start at any 
point. But each leads to the next. If you begin at “The sweet-
ening of the worlds diet” you can see an individual enjoying 
himself with all his overly sugary snacks, because that is what 
his palate has become accustomed to. Soon he notices his jeans 
have gotten a little snug so he begins eating “low-fat” products 
to reduce the guilt he feels for what he’s doing to himself. The 
low-fat products, which contain artificial sweeteners, increase 
his appetite because they do not stimulate his taste receptors 
to provide a reward response in his brain. But, maybe this works 
for him for a while and he drops a few pounds. By then resting 
metabolic rate will have lowered putting him at a higher risk for 
obesity. When he can’t deprive himself of sugar any longer he’ll 
binge eat those calories that he’s been missing. The lower RMR 
that was created can no longer handle these massive amounts 
of sugar and cause fat storage to occur. All the while he’s been 
destroying his gut microbe environment. Now, whatever he in-
gests his body searches for additional energy sources because 
it fears the lack of sucrose will deplete its energy storage. 
Combining this glucose intake with AS use also leads to stimu-
lation of the GLUT2 pathway for rapid unnecessary absorption. 
And so, more and more adipose tissue accumulates. Slowly, day 
after day, year after year this cycle occurs. Soon he finds himself 
obese, with metabolic syndrome, diabetes, and chronic heart 
disease. Though further research is necessary to understand 
how this affects different age groups, ethnicities, and genders, 
this can occur. And it’s all a result of an attempt to create a 
non-caloric, healthier sweetener.
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There has been a worldwide increase in autism cases in the past 
few decades, but the cause of it is unclear.  It has been suggested 
that vaccines may be contributing to the rise in autism rates. 
One claim is that the MMR vaccine can cause intestinal inflam-
mation that may lead non-permeable peptides to be transferred 
to the brain where it will affect neurodevelopment.  This may 
lead to autism with symptoms of developmental regression 
and gastrointestinal problems. Another major hypothesis that 
has received much attention is that a mercury-containing com-
pound, thimerosal, found in many vaccines, can have toxic effects 
on the central nervous system.  By retrieving studies from data-
bases such as Ebsco, Proquest, and Pubmed found in the Touro 
College Library, this review investigates if there is any truth to 
these claims.  No evidence of a direct link between vaccines and 
an increase in autism cases have been found. 
Introduction
Autism Spectrum Disorder (ASD) is a neurodevelopmental dis-
order that impairs a child’s ability to interact and communicate 
with others.  It is commonly associated with certain behaviors 
such as difficulty making conversation, delayed language acqui-
sition, and poor motor skills.   Autism seems to originate from 
very early brain development.  The most obvious symptoms of 
the disorder, however, usually begin to show between the ages 
of 2 and 3. (Autism Speaks, 2016)  Autism diagnoses have great-
ly increased in the past few decades.  According to statistics 
from the U.S. Centers for Disease Control and Prevention, the 
prevalence of autism in 1000 children was approximately 6.7 in 
the year 2000 and 14.7 in 2010, a significant increase.  (Data & 
Statistics, 2015). The cause for this dramatic increase is unknown 
and has been the subject of much investigation.  It is believed 
that genes play a role in an increasing risk for autism (Mascarelli, 
2010). However, environmental factors play a part in most cases 
of autism too.  There has been a growing concern of a possible 
link between vaccines and autism.  Two separate theories have 
been proposed over the years.  One is that the Measles-Mumps-
Rubella (MMR) vaccine causes autism.  The other is that thimer-
osal, a mercury containing preservative found in many vaccines 
can lead to damage in the brain.  Researchers have sought to 
discover if there is any truth to these claims. 
Methods
Information and research was obtained through databases such 
as Ebsco, Proquest, and Pubmed.  Access was provided by the 
Touro College Library.  Google Scholar was also used to find 
research articles. Keywords like vaccines, autism, and thimerosal 
were used to search for relevant material.  In addition, refer-
ences in these articles were retrieved and used as additional 
sources for further research.
Discussion
MMR Vaccine
In 1968 a link was suggested between the Mumps, Measles, and 
Rubella (MMR) vaccine and the onset of ASD.   Unusual bowel 
symptoms were described among 12 children who showed de-
velopmental regression like losing acquired skills despite previ-
ous normal progress.  Eight out of the twelve children who had 
gastrointestinal signs had reported their first symptoms of au-
tism within a month of receiving the MMR immunization.  It was 
concluded that the MMR vaccine caused intestinal inflammation 
allowing usually non-permeable peptides to be translocated to 
the bloodstream and ultimately to the brain, where they affect-
ed development. (Wakefield, et al. 1998) Although the sample 
was small with only a dozen children and the results were never 
replicated, the study received lots of attention from the pub-
lic, and served as the foundation for much controversy in the 
years to come.  Parent’s anecdotes of their own personal ex-
periences were enough for many to keep this alive.  As a result, 
many refused to vaccinate their children worrying about their 
safety, and outbreaks of vaccine preventable diseases began re-
appearing in certain areas.  The MMR-autism controversy was 
responsible for a significant decrease in immunizations following 
that year.  The MMR immunization rates in the United Kingdom 
dropped from 90% in 1988, when they were first introduced, 
to 80% in 2004, after the article had been read by the public. 
(Kolodziejski, 2014)
Possible Developmental Regression and 
Gastrointestinal Symptoms Associated with MMR
Whether MMR is really associated with autism has been under 
constant debate.  There have been many studies done to see if 
the link exists.  Fombonne and Chakrabarti (2001) tested out 
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the hypothesis that a form of autism existed involving devel-
opmental regression and gastrointestinal symptoms caused by 
the MMR vaccine.  It was proposed that if one or more of the 
following predictions were proved by the data collected, the hy-
pothesis could be validated.  The first prediction was that child-
hood disintegrative disorder (CDD) had become more com-
mon.  Another is that the average age of first parental concern 
in autistic children in those who received the MMR vaccine is 
closer to the mean age of immunization than in those who were 
not vaccinated with MMR. The third prediction was that devel-
opmental regression in those who are vaccinated with MMR 
had become more frequent.  If the age of onset of autism with 
regression is closer to MMR-vaccination as opposed to those 
who did have autism without regression, it could also prove 
that MMR could have caused autism.  Another prediction is that 
those with regressive autism have different symptoms.  Finally, 
those with regressive autism would have gastrointestinal signs 
and/or inflammatory bowel disorder. 
Three samples, 1 epidemiological (n=96) and 2 clinical sam-
ples, a pre-MMR (n=68) and a post-MMR (n=98) were used 
to gather information.  In order to assess age of first onset of 
autistic signs, the parents were asked how old their child was 
when they first became concerned with his/her development. 
Regression was noted when a loss of skill, such as language 
was confirmed based on certain criteria.  Assessment of bowel 
symptoms was done by retrieving data from both the parents 
and pediatrician.  
The first prediction of childhood disintegrative disorder (CDD) 
increasing was not supported by the data as only one boy met 
the criterion for CDD, which seems likely to have originated 
from brain pathology before the MMR immunization was even 
given.  In this epidemiological sample where nearly all the chil-
dren were vaccinated, it can be assumed that CDD is not in-
creased with vaccine exposure.  Second, there was no difference 
in age of first parental concern in two of the samples exposed to 
MMR (19.3 and 19.2) compared to the pre-MMR clinical sample 
(19.5).  Third, the rate of regression for the post-MMR sample 
(15.6%) was lower than the rate in the pre-MMR sample (18.4%). 
This rules out MMR-induced regressive autism as a cause for 
the dramatic increase in autism cases.  In the epidemiologic 
sample, 18.8% had gastrointestinal symptoms.  Constipation was 
the most common symptom (9.4%), and no inflammatory bowel 
disorder was reported. Only 2.1% of the sample experienced 
both developmental regression and gastrointestinal symptoms, 
a rate which shows no association between the two.  None of 
the 6 predictions were supported in this study, and no evidence 
was found to show a distinct syndrome of MMR-induced autism. 
(Fombonne E, Chakrabarti S, 2001). 
Measles Virus RNA in Patients with Autism
There are studies that have reported Measles Virus (MV) RNA 
in bowel biopsies in autistic children, showing a possible link 
between intestinal inflammation and the measles virus.  A study 
done by Kawashima et al (2000), examined children with gastro-
intestinal problems to see if they have the measles virus and if 
they did, if it derived from wild strains or vaccine strains. Eight 
of the patients had Crohn’s disease, 3 had ulcerative colitis, and 
9 had autistic enterocolitis.  One of the patients with Crohn’s 
disease, 1 with ulcerative colitis, and 3 of 9 with autism were 
positive for the virus, while the controls were all negative.  The 
measles virus found in the patient with Crohn’s disease proved 
to have characteristics of wild-strain virus, while the one with 
ulcerative colitis and in the autistic patients had vaccine strains.
A study including 125 autistic children and 92 control children. 
MMR antibodies were first measured by ELISA in sera of 24 
randomly selected autistic children, 16 normal children, and 14 
children with other developmental problems.   Autistic children 
had a higher number of MMR antibodies compared to the other 
children.  Soon after all of the 217 children were checked for 
MMR antibodies by immunoblotting assay for serum screening. 
They found that 75 (n=125) autistic children’s sera were positive 
for an unusual MMR antibody, whereas none of the control sera 
had the antibody. A protein band was detected in the antibody 
which was immunopositive for measles HA protein but not for 
measles nucleoprotein and rubella or mumps viral proteins.  The 
results showed that autistic sera detected measles HA protein 
in the MMR antibody.  It is suggested that an inappropriate anti-
body response to MMR might be related to the development of 
autism.  (Singh, et al, 2002)
However, despite those few studies, many studies have been 
done that disprove the link between autism and MMR including 
a few that failed to detect MV-RNA in cases of autism.  A case 
control study tested for the presence of measles virus (MV) 
RNA in bowel tissue in children with ASD. The purpose was to 
see if those with GI disturbances and autism are more likely to 
have MV RNA in their bowel tissue than those with GI symp-
toms but no autism.  This can determine if MMR is linked to this 
type of autism.  The ileal and cecal tissues of 25 children with GI 
disturbances and autism and 13 children with GI disturbances 
but no autism were analyzed for MV RNA in 3 different labora-
tories.  The timing of the autistic and gastrointestinal symptoms 
in respect to MMR immunization was also documented.  The 
results showed no difference in MV RNA findings in the case 
group and the control group.  The timing of the vaccine in re-
gards to the GI symptoms and autism onset were inconsistent 
with the theory that MMR triggers either the GI symptoms or 
autism.  (Hornig, et al, 2008) 
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A 14 year prospective study reviewed the number of vaccines 
that were given from the time The National Board of Health 
and National Public Health Institute launched their MMR vac-
cination program in 1982 till the year 1996.  3 million vaccines 
were given during that period of time and 31 cases of gastro-
intestinal symptoms were reported after vaccination, ranging 
from 20 hours to 15 days.   Fifty five percent (n=17) had symp-
toms of diarrhea and vomiting, 23% (n=7) had gingivostomatitis, 
16% (n=5) had vomiting only, and (n=2) had abdominal pains. 
The symptoms usually lasted about a week.  None of the chil-
dren developed autism.  In this study, no association was found 
between MMR and pervasive developmental disorder or inflam-
matory bowel disease.  (Peltola et al, 1998)
Epidemiological Studies
Numerous epidemiologic studies have been done to see if there 
is an association between MMR and autism.  Taylor, et al (1999) 
did a chart review of cases of autism diagnosed in a region in 
England, in children born between 1979-1992.  They identified 
498 cases of ASDs in the population, of which only 293 could 
be confirmed according to ICD-10 criteria. They analyzed the 
data in different ways to test if autism was related to the MMR 
vaccination. Data they collected included the age at which the 
children were diagnosed, the age of first parental concern, and 
age when regression became obvious.  The trend of autism 
was examined to see whether or not there had been a sudden 
step-up in autism diagnoses in children who received the MMR 
vaccine after it was introduced in England in 1988.  They found 
that the prevalence rates of autism began an exponential rise 
starting with children born a couple of years before the intro-
duction of the MMR vaccine, and that there had been no sudden 
step-up after 1988.  They concluded that this refuted a temporal 
relationship. 
A study done in California collected data regarding MMR cov-
erage rates and age at the time of immunization for children 
born between the years 1980-1994 from school immunization 
records in California Kindergartens.  The number of cases of 
autism diagnosed during those years were retrieved from the 
California Department of Developmental Services where they 
were enrolled.   The results did not show a correlation between 
rates of autism and number of immunizations given.  As can 
be seen by Figure 1, autism cases increased from 44 cases per 
100,000 live births in the 1980 cohort to 208 cases per 100,000 
live birth in the 1994 cohort, a 393% increase.  In contrast, MMR 
immunization rates by the age of 24 months increased from 
72% to 82%, only a 10% increase.  Since the rate of increasing 
autism cases does not compare with the only small rise in MMR 
coverage, a correlation was not observed between the two. 
(Dales, et al, 2001)
A population study was done in Japan by Honda, et al (2005).  It 
examined incidence of ASD in children born from 1988-1996. 
Japan’s MMR immunization program was launched in 1989 but 
ended in 1993, due to suspected side effects of the mumps vac-
cine.  This allowed for an opportunity to research the effect 
of removing the MMR vaccine which was believed to cause a 
rise in autism.  If it was really the cause of the increased autism 
caseloads when it was introduced, autism would drop after the 
risk factor (MMR vaccine) was withdrawn.  All children who had 
been diagnosed with ASD were selected from a patient list of 
the YRC Developmental Psychiatry Unit, which offers diagnostic 
and intervention services to all those with ASD.  The annual 
trends for both typical autism and all other categories of ASD 
were examined.  According to the statistics, MMR vaccination 
rates were 69.8%, 42.9%, 33.6%, 24.0%, and 1.8% respectively 
in the years 1989-1993.  As can be seen by this data, the rate 
decreased significantly during these years, with only a bare mini-
mum of 1.8% of children vaccinated with MMR in the year 1993. 
The annual trends of ASD were compiled for the years 1988-
1996.  The ASD incidence rates ranged from 47.6 per 10000 in 
1988 to 117.2 per 10000 in those that were born in 1996.  The 
rate of autism incidences continued to rise even after the MMR 
vaccination program was terminated.  This provides evidence 
that it is highly unlikely that MMR is linked to greater autism 
incidences. (Table 1) (Honda, et al, 2005)
Percentage of Children Receiving Measles-Mumps-Rubella (MMR) 
Immunization in Second Year of Life and Caseload of Children With 





Since the 1930s, thimerosal, a mercury-containing preservative 
has been used in many biological and drug products, including 
multi-dose vaccines, to prevent bacterial and fungal contamination 
Thimerosal is not found in live vaccines, such as MMR because of 
the damaging interaction they can have with the active substance. 
Before 1991, diphtheria-tetanus-pertussis (DTaP) vaccination was 
the only common vaccine that contained thimerosal.  Recently 
though, more vaccines have been introduced that consist of thi-
merosal like Hepatitis B and HIB.  (Nelson, Bauman, 2003) Too 
much mercury can have toxic effects especially in little children, 
where the brain is still developing.  As can be seen by Table 2, 
the FDA estimated that 6-month old babies could have received 
doses of mercury as high as 187.5 µg in their vaccines and 2 year 
olds as much as 237.5 µg.  (Freed, et al, 2002)
Because of the increasing amount of this chemical that babies 
were being exposed to, there was a growing concern that the 
ethylmercury which is found in thimerosal can cause brain dam-
age and contribute to autism.  Fearing this, the FDA removed 
thimerosal from all vaccines in 1999 even though direct evi-
dence of harm was not found.  Since not much was not known 
about ethylmercury at that point in time, assumptions were 
made based on knowledge of methylmercury.  Methylmercury 
was known to have toxic effects and many assumed that 
ethylmercury has similar consequences. 
Since ethylmercury had not been exten-
sively studied, researchers began to ex-
periment with ethylmercury to see if it 
can really have those damaging effects in 
vaccines.  (Straton, 2001)
Research was done by analyzing the 
VAERS database, a database maintained by 
the CDC which holds a record of all ad-
verse reactions.  The VAERS database was 
used to compare the neurodevelopmental 
disorders that were found following the administration of thi-
merosal-containing DTaP vaccines in contrast to thimerosal-free 
DTaP vaccines. A close linear correlation was found between in-
creasing mercury due to thimerosal vaccines and an increase in 
the odds ratio of neurodevelopmental disorders.   According to 
the results in the baseline year of 1984, the odds ratio of autism 
increased by 0.029 per mg of mercury, personality disorders by 
0.012 per mg of mercury, and mental retardation by 0.048 per 
mg of mercury.  The total odds of developing autism increased in 
those immunized with thimerosal-containing vaccines vs those 
who received thimerosal-free vaccines.  This study showed that 
more research had to be done to see if there is indeed a cor-
relation between mercury levels and higher risks of autism and 
other developmental disorders.  (Geier et al, 2003)
A study done used hair and urine analysis to detect heavy metal 
exposure in those with autism compared to those who did not 
have autism.  It consisted of 25 autistic children and 25 con-
trols.  Metal testing was performed via ICP-MS spectroscopy 
utilizing cell technique to detect levels of different metals in the 
hair. The mean mercury level in the hair of autistic children was 
0.47±0.42 while the levels in the control children was a lower 
mean of 0.30±0.3.  A similar observation was found of the mer-
cury levels in the urine of autistic children compared to control 
children, with means of 2.48±2, and 1.10±0, respectively. These 
results seem to show an association between higher levels of 
mercury in those with autism.  Limitations in the amount of 
mercury they ingest seems to be important for the safety of 
these children.  However, a larger sample size should be studied 
on in order to validate these findings.   (Blaurock-Busch, 2011)
A study was done by Pichichero et al, (2002) to measure the 
concentration of mercury found in infants’ stool, blood, and 
urine after they received vaccines.  If high levels were found, it 
would show that thimerosal can be potentially harmful in vac-
cines.   In this experiment, 40 infants who were 6 months or 
younger received thimerosal containing vaccines while 21 con-
trols received thimerosal free vaccines.  Samples of the infants’ 





tested for mercury levels.  Blood samples contained low levels 
of mercury with a range of 4.50-20.55 nmol/L.  Fourteen out of 
15 controls did not have quantifiable levels of mercury.  Those 
with the highest levels of mercury were infants who were mea-
sured soon after they were vaccinated.  There was no mercury 
found in urine samples, besides for one of the 2-month olds 
and three of the 6-month olds who had received thimerosal 
in their vaccines.  The highest amount of mercury in the urine 
was 6.45 nmol/L.  No mercury was found in any of the control 
infants.   Detectable amounts of mercury were found in stool 
samples in those who were exposed to thimerosal containing 
vaccines.  Those who did received thimerosal free vaccines were 
not measured for mercury levels in their stool. (Table 3)
To determine if dietary intake could contribute to mercury 
levels in the stool, samples were obtained from 9 infants who 
were age-matched to those who received thimerosal containing 
vaccines but were not exposed to thimerosal themselves.  The 
mean levels of mercury in these samples was 22 ng/g which 
was considerably lower than those exposed to thimerosal.  Out 
of all these samples, however, no concentration exceeded 29 
nmol/L which is known to be an accepted safe value.  The results 
did show an increased amount of mercury in those who were 
vaccinated compared to those who did not receive thimerosal, 
but the quantity was still below the harmful level.  Before the 
samples were measured, a prediction model was made of the 
expected measurements of mercury corresponding to the pos-
sible half-life days ranging from 1-45.  The best estimate of the 
half-life of ethylmercury would be the difference between the 
predicted value and the observed value.
The concentration of mercury in the blood not long after vac-
cination suggests that the half-life of ethylmercury is not nearly 
as long as the half-life of methylmercury.   As we can see from 
Figure 2, the estimated half-life for ethylmercury was 7 days. 
This contrasts with the half-life of around 40-50 days in meth-
ylmercury.  The long half-life of methylmercury can allow the 
organic-mercury to cross over the blood brain barrier where it 
can accumulate and get converted to inorganic mercury which 
can cause neurodevelopmental damage.  Ethylmercury, however, 
which is found in thimerosal is rapidly eliminated through the 
stool which prevents toxicity from accumulating that could be 
detrimental to parts of the body including the brain.  (Pichichero, 
et al, 2002)
Since creating controlled experiments is not possible in an ex-
isting vaccination program, determining if there is an association 
between thimerosal and autism is not so simple.  Several epi-
demiological studies have been done to see if there is a causal 
relationship between receiving thimerosal containing vaccines 
and an increase in autism cases.   A population cohort study of 
children in Denmark who were born in the years 1990-1996 
was done to compare children who received thimerosal in their 
vaccines and those who did not.  Doses that were adminis-
tered before 1992 were considered to be vaccines containing 
thimerosal and those doses given after 1992 were thimerosal 
free vaccines.  Information regarding vaccine administrations 
was obtained from the Danish Board of Health and data regard-
ing autism diagnoses was retrieved from the Danish Psychiatric 
Central Register.  Follow ups were done from one year of age 
till the year 2000 to see if there would be possible cases of au-
tism disorders in those children.  During these years, 440 cases 
of autism and 787 cases of other autistic-spectrum disorders 






We can see from the results shown in table 4, that when com-
paring those who received at least one dose of thimerosal-con-
taining vaccine and those who only received thimerosal-free 
vaccinations there was a rate ratio of 0.85% for autism and 
1.12% for other autistic spectrum disorders. Also, there was 
no association between a higher dose of thimerosal-contain-
ing vaccine and a higher rate of autism disorders.  The increase 
in rate ratio per 25 ug of mercury was 0.98% in autism and 
1.03% in other autistic spectrum disorders.  In order to rule out 
the possibility that some thimerosal-containing vaccines were 
administered soon after 1992, the vaccinations between June 
and December of 1992 were omitted from the data and similar 
results were found.  This study showed no association between 
thimerosal intake and increased autism rates.  (Hviid, et al, 2003)
In the United Kingdom, the only thimerosal containing vaccines 
that have been administered in the past few decades is DTaP 
and DT.  The total amount of thimerosal per dose in these vac-
cines is 50 ug (25 ug of ethylmercury).  In the United Kingdom, 
the schedule for vaccination called for 3 doses by the age of 4 
months, totaling 150 ug of thimerosal at that age.  Data regarding 
date of birth and vaccination dates were obtained for 109,863 
children who were born from 1988 to 1997.  Some children 
were excluded from the study including those who had certain 
medical conditions before the age of 6 months and those who 
had received the Hep B or flu vaccination before 6 months of 
age.  Hg exposure was calculated based on the number of vac-
cine doses the children received.  A number of developmental 
disorders were investigated and the number of cases diagnosed, 
the mean age of diagnoses, and the percentage that was male 
was assessed.  When these children were linked to the dates of 
their vaccination and any of the neurodevelopmental disorders 
they had, no evidence of increasing neurodevelopmental disor-
der rate was found with an increasing dose of ethylmercury. 
The only disorder that showed a possible link to thimerosal was 
tics, which had a hazard rate of 1.50 in 4 months of age.  The rest 
of the disorders had a Hazard rate close to 1, showing no link to 
thimerosal.  (Andrews, et al, 2004) 
Another study was done in Sweden and Denmark to compare 
the prevalence of autism cases with the exposure of thimero-
sal-containing vaccines during the 1980s and 1990s.  Data re-
garding vaccine coverage and autism cases were collected in 
these countries.  The total amount of ethylmercury exposure 
was calculated by multiplying the amount of thimerosal in vac-
cines by the number of vaccines with thimerosal administered 
during that time period.  The rate of autism was calculated by di-
viding the total number of autism cases diagnosed in those years 
by the number of person-years accumulated during those years. 
As shown in figure 3a, the incidences of autism in Sweden began 
to rise in the year 1985 to a rate of around 6 per 100,000 
person-years and peaked in the year 1993 to a rate of 9.2 per 
100,000 person-years.  The coverage of thimerosal-containing 
vaccines, however, have remained steady over most of those 
years, decreasing over time and eventually being completely 
removed in 1993.  A similar explanation goes for Denmark, 
shown in figure 3b.  Thimerosal-containing vaccination coverage 
remained constant throughout the years 1981-1991 and ended 
in 1992, but autism rates continued to increase sharply in the 
years after that.  We can see from these studies that the rise of 
autism needs a better explanation than the exposure of thimer-
osal to children. 
Conclusion
From the studies that have been done so far, no evidence 
has been found to show a link between vaccines and autism. 
Increasing autism rates need to have another explanation.  It 
has been suggested that the broadening of the diagnosis, and the 
greater awareness of autism and other ASDs have contributed 





with a regressive form of autism has been proven to be highly 
unlikely. The fact that MMR vaccination withdrawal did not lead 
to a decrease in autism cases indicated that there is not any cor-
relation between the two. The concern that thimerosal-contain-
ing vaccines cause autism has also not been validated.  However, 
despite the shorter half-life and less damage that ethylmercury 
can have in comparison to other mercury compounds like 
methylmercury, the current literature does not rule out a role 
for thimerosal in neurodevelopmental damage other than au-
tism to children. Therefore, it is best that thimerosal continue 
to remain excluded from vaccines.
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Cow’s Milk in the Human Diet:
Humans are the only animals known to consume the milk 
of another species, a unique behavior that arose during the 
Neolithic Revolution. The end of the Younger Dryas coincided 
with a transformation of human subsistence patterns around 
the world. Populations of hunter-gatherers became more sed-
entary and experimented with the domestication of plants and 
animals. The first cattle were domesticated from wild aurochs 
(Bos primigenius) over 10,000 years ago, in regions that are part 
of present-day Turkey and Pakistan (McTavish et al. 2013). There 
is disagreement about when cattle were first exploited for milk 
production. The “secondary products revolution” theory, pop-
ular during the 1980s and 1990s, held that Neolithic people 
did not consume dairy products until the fourth millennium 
BCE, despite much earlier advances in domestication (Sherratt, 
1983: Greenfield et al., 1988). Recent evidence has pushed that 
date back as far as the 9th millennium BCE, when human beings 
were still “stock-keeping hunter-cultivators” (Vigne and Helmer, 
2007). Residue from pottery shards suggests that milk products 
were widely consumed in Southwestern Asia and Southeastern 
Europe by the seventh millennium BCE (Evershed et al. 2008).  
Since it was first consumed during the Neolithic period, cow’s 
milk has been an essential dietary staple for numerous popula-
tions around the globe and has developed an evolving cultural 
significance. On the Indian subcontinent, cows have been re-
vered for thousands of years and their milk is used for ritual 
purification as well as nutrition (Simmons, 1974). Ancient Norse 
mythology tells of how the first creature, Ymir, was sustained 
by milk from the sacred cow Auðumbla (Haug, Høstmark, and 
Harstad 2007). In Medieval Europe, cow’s milk was venerated as 
a spiritual substance, embodying the divine rhythms of nature; 
during the Renaissance it was celebrated for its taste and health 
giving properties, with folk remedies citing it as a cure for ev-
erything from ulcers to epilepsy (Valenze, 2011). Milk consump-
tion was transformed by two factors in the 19th century: an 
improved - transportation system, which aided in the delivery 
of fresh milk from local farms to cities, and the development 
of pasteurization, which helped curb the very serious problem 
of milk-borne disease (Wilson, 1943: Atkins, 1978). These two 
advances made cow’s milk more safe and convenient than ever 
before and guaranteed its central place in the Western diet. 
Today cow’s milk and dairy products are an almost ubiquitous 
component of human nutrition, accounting for 14% of the ca-
loric intake in developed countries (Bordoni et al., 2015). Global 
milk production amounted to an estimated 784 million tons 
in 2013, or 100 L of milk per year per person (Bordoni et al., 
2015). This massive consumption occurs despite the fact that a 
substantial majority of the world’s adult population is deficient 
in the lactase enzyme and may experience digestion issues with 
dairy (Lomer et al. 2008).  
The Economics of cow’s milk in the United 
States:
Cow’s milk is a major economic commodity in the United 
States. A 2002 survey estimated that the dairy industry accounts 
for $140 billion in economic output, $29 billion in household 
earnings, and more than 900,000 jobs (Cryan, 2004). The U.S. 
Department of Agriculture estimates that domestic cow’s milk 
production will reach a record 208.7 billion pounds in 2015 
(“Dairy Farmers at the Barricades,” 2015).
Chemistry and Nutrition of Cow’s Milk:
Cow’s milk is complex mixture of lipids, proteins, bioactive pep-
tides (e.g. immunoglobulin, cytokines, and enzymes), amino acids, 
vitamins and minerals. The sugars (primarily lactose) and most 
minerals are dissolved in solution, the lipids are emulsified in 
globules, and the proteins are suspended in colloidal dispersions 
(Huag et al. 2007).  About 80% of the proteins in cow’s milk 
are caseins, which form complexes with calcium and phosphate 
(Huag et al. 2007).  Although the composition of cow’s milk can 
vary with the age, breed, nutrition, and stage of lactation of the 
cow, on average, a cup of milk (244 grams) provides 146 calories, 
7.9 grams of fat (4.6 saturated), 7.9 grams of protein, 276 mil-
ligrams of calcium, 349 milligrams of potassium, 222 milligrams 
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of phosphorous, 249 IU of Vitamin A, and 97.6 IU of Vitamin D 
(USDA, 2015). cow’s milk is an important dietary source of the 
cis9, trans 11 isomer of conjugated linoleic acid and glutathione 
(Huag et al., 2012).
Allergy, Autoimmunity, and the Hypothetical 
Role of “Leaky Gut”
The human immune system is an enormously complex collec-
tion of structures and processes that protects the body against 
harm by pathogens. Immunity operates at a number of levels. 
The skin and mucosal membranes are the first line of protec-
tion, acting as a physical and chemical barrier to invaders. The 
second level of defense is the innate immune system, in which 
macrophages and neutrophils of the innate immune system 
provide a robust, but non-specific defense against pathogens, 
including the cytokine-mediated inflammatory response. Finally, 
the adaptive immune system provides a targeted response to 
specific pathogens. It is divided into humoral immunity, mediated 
by B lymphocytes and their antibodies, and cell-mediated immu-
nity, mediated by T lymphocytes. (Hall, 2016)
Allergy refers to an inappropriate immune response to a harm-
less substance. Most allergies are mediated by the IgE antibody, 
which is secreted by B-cells in response to antigens binding 
mast cells and basophils until a second exposure. Autoimmunity 
refers to an immune response against the body’s own cells and 
tissues. There are two classical models for the pathogenesis of 
autoimmune disorders (Fasano, 2012). According to the “mo-
lecular mimicry” model, certain microbial antigens resemble 
self-antigens to a degree that the immune system cross-reacts 
with the latter and targets them for destruction. In the “bystand-
er effect” model, microbes directly damage tissues, leading to 
the exposure of internal self-antigens that the immune system 
interprets as foreign. These two models are continuously being 
expanded and revised with ongoing research and may represent 
complementary descriptions of the multifaceted phenomenon 
of autoimmunity. A third, more tentative hypothesis involving 
the gut is presented below.   
The role of the gut in immune disorders is a fascinating new 
area of research. While we often think of the skin as great pri-
mary barrier of our immune system, the intestines are actually 
the largest surface in the body, amounting to an area more than 
200 times greater than the skin (Hollander 1999). Maintaining a 
proper balance between immune tolerance and sensitivity over 
this vast surface area is an exceedingly complicated task, and the 
failure of such regulation is associated with allergy and various 
forms of autoimmunity (Dejaco et al. 2006: Vitaliti et al. 2012). 
cow’s milk is often the first foreign substance that an infant’s 
gut will encounter and the first serious challenge to immune 
homeostasis in the intestines. Some researchers have suggested 
that there is a group of individuals who are especially prone 
to immune complications from food antigens, due to excessive 
permeability of the intestines and abnormal microbiota (Perrier, 
C and Corthésy, 2010: Fasano 2012). These individuals, the the-
ory goes, are not only at a greater risk for conventional food 
allergies but may also find that various foods which are well 
tolerated by the general populations contribute to immune dys-
function. While some promising research has been conducted 
into the contributions of intestinal barrier dysfunction to im-
mune-mediated disorders (De Kort, et al. 2011), and excessive 
intestinal permeability is particularly well attested in the patho-
genesis of celiac disease (Hollander, 1999), the general role of 
“leaky gut” in autoimmunity remains ill-defined and controver-
sial. While this paper does not intend to assess the validity of 
this hypothesis, a growing body of research on diet, allergy, and 
immune disorders suggests the need for an evolving paradigm 
of the role of the gut in autoimmunity. 
Purpose:
This paper will review current research on cow’s milk and the 
human immune system. It will begin by exploring the prev-
alence, natural history, and immunopathogenesis of cow milk 
allergies (CMA). It will then examine research on the possible 
contributions of cow’s milk to systemic inflammation in people 
without clinically defined CMA. Finally, it will assess the possible 
link between the consumption of cow’s milk and a number of 
immune-mediated disorders. All research into the role of cow’s 
milk in non-immune-mediated disorders, including lactose intol-
erance, has been excluded. The discussion will examine the fac-
tors affecting research into the health of cow’s milk and assess 
nutritional guidelines in light of current findings.
Methods
All research articles for this paper were obtained by searching 
Google Scholar and Touro’s Library Database.
Literature Review
Definition, Prevalence, and Natural History of 
Cow’s Milk Allergy (CMA):
Cow’s milk allergy (CMA) is an adverse immune reaction to one 
or more components of cow’s milk. CMA is the most common 
food allergy in infancy and childhood, occurring in in 2%-3% 
of children in the developed world, (Ahrens et al., 2012). It is 
typically classified into IgE-mediated allergies and non-IgE-medi-
ated allergies; the former are more common and almost always 
resolve during childhood and the latter persist in a small per-
centage of adults (Crittenden and Bennett, 2005). One study of 
over 4,000 children with IgE-mediated CMA found total res-
olution to be 19% by age 4 years, 42% by age 8 years, 64% by 
age 12 years, and 79% by 16 years (Skripak, et al., 2007). CMA 
can cause a range of reactions, including diarrhea and vomiting, 
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loss of blood into the intestines, respiratory tract infection, and 
anaphylaxis (Freier and Kletter, 1970). A study of food allergies 
in Britain during the 1990s found that CMA accounted for 
greatest number of fatalities (Macdougall et al., 2002). Some of 
the symptoms of CMA may initially be confused with lactose 
intolerance or Hirschsprung’s disease (Kubota et al. 2006). In 
order to make the diagnose a physician must observe “a definite 
disappearance of symptoms after elimination of cow’s milk from 
the diet, recurrence of identical symptoms after one cow’s milk 
challenge, disappearance of symptoms after re-elimination of 
cow’s milk, and exclusion of lactose intolerance and coinciden-
tal infections” (Sprikkelman et al. 2000).
Immunopathogenesis of CMA:
Research into the immunopathogenesis of CMA is ongoing and 
its mechanisms are not fully understood.  The major allergic 
components of milk have been identified as four proteins in 
the casein fraction (as1-, as2-, b-and k-casein) and two pro-
teins in the whey family, although there is great heterogeneity 
among the allergenic epitopes of these proteins (Ahrens et al., 
2012). The mechanisms of CMA are typically classified into IgE-
mediated and non-IgE-mediated. 
IgE-mediated CMA occurs in two stages (Vitaliti et al. 2012: 
Brandtzaeg 2001: Beyer et al. 2002). When an allergic child first 
consumes cow’s milk, the immune system undergoes a process 
of “sensibilization.” First, antigen-presenting cells (APCs) con-
sume milk particles and display allergenic fragments on their 
surfaces. Then 2 T helper (Th2) cells, which are insufficiently 
regulated by the immune system in CMA, come into contact 
with the allergen fragments and become activated. The Th2 cells 
in turn activate B cells, which produce large amounts of anti-
gen-specific IgE. IgE antibodies against cow’s milk proteins are 
then secreted and bind to the surface of mast cells and baso-
philes. After this immune arsenal has been built up and the child 
again consumes cow’s milk, the allergy moves to its “activation” 
phase. IgE associated with mast cells bind allergenic epitopes on 
milk proteins, triggering an intracellular cascade that culminates 
in the release of histamine, platelet activating factor, and other 
inflammatory mediators. Chatchatee et al. (2001) found that the 
presence or absence of two binding regions IgE (AA 69-78 and 
AA 173-194) can be used to predict whether an allergy will 
resolve in early childhood or persist. 
Although many cases of CMA involve an IgE-mediated mecha-
nism there are also many cases that do not present circulating 
IgE specific for cow’s milk proteins. The immunopathogenesis 
of non-IgE- mediated CMA is more obscure and a number of 
mechanisms have been proposed.  One theory suggests the re-
action is mediated by Th1 cells, host immunity effectors that 
typically act against intracellular bacteria and protozoa and have 
already been implicated in Type-1 Diabetes (Lee et al., 2010: Zhu 
and Paul, 2008). Another theory points to interactions between 
T lymphocytes, mast cells, and neurons (Lee et al. 2010). Some 
individuals with CMA demonstrate both IgE-mediated and 
non-IgE-mediated reactions. 
Research has implicated the dysfunction of Tregs, a subpopula-
tion of T cells that modulate the immune system and maintain 
tolerance to self-antigens in both IgE-mediated and non-IgE-me-
diated reactions. The body must maintain a delicate balance 
between mucosal tolerance and hypersensitivity: too great a 
tolerance will allow dangerous antigens to accumulate in the 
body and too great a sensitivity will lead to indiscriminate 
immunization against harmless foreign particles. Tregs help to 
regulate this balance by secreting “tolerogenic cytokines” such 
as TGF-beta 1 and IL-10. The resolution of CMA in children has 
been associated with the development of Treg cells. For exam-
ple, Karlsson et al. (2004) gave milk to 21 children who had been 
following an elimination diet for at least two months and found 
that those who had outgrown the allergy had higher levels of 
circulating CD4(+)CD25(+) T cells.
Looking Beyond CMA:
The prevalence of CMA is well established and research has 
increasingly shed light on its mechanisms, but what about the 
impact of cow’s milk on the immune systems of people without 
clinically defined CMA? In some quarters dairy has been ac-
cused of having “pro-inflammatory” properties and implicated 
as a cause or aggravating factor in a number of immune-mediat-
ed conditions. Some health resources have advised that people 
cut out dairy entirely. The rest of this paper will examine some 
of the research on these claims about cow’s milk and the im-
mune system. 
Cow’s milk and Systemic Inflammation:
Systemic inflammation is caused by the release of pro-inflam-
matory cytokines from immune-related cells and the chronic 
activation of the innate immune system. It is a risk factor for 
atherosclerosis, metabolic syndrome, type 2 diabetes, cardio-
vascular diseases, and other conditions (Labonte et al. 2013). 
The causes of systemic inflammation are notoriously difficult to 
isolate, and there has been disagreement over whether cow’s 
milk-based dairy can contribute to systemic inflammation in 
healthy adults.
Although some epidemiological studies have found a correlation 
between dairy consumption and biomarkers of inflammation, 
the overwhelming majority of controlled studies have found a 
neutral or anti-inflammatory effect (Bordoni et al. 2015). Nestel 
et al. (2012) looked at four different full-fat dairy foods and 
found that they did not increase eight circulating biomarkers 
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related to inflammation. Schmid et al. (2015) found no signif-
icant difference in inflammatory markers after subjects ate a 
high-fat dairy and high-fat non-dairy meal. Several studies have 
even reported an inverse correlation between dairy consump-
tion and inflammation. Panagiotakos et al. (2010) looked at 
the concentrations of the inflammatory factors CRP, IL-6, and 
TNF-α in individuals consuming more than 14 servings of dairy 
products a week and found them to be 29%, 9%, and 20% lower 
than those in individuals consuming less than 8 servings a week. 
Esmaillzadeh and Azadbakht (2010) studied 486 healthy women 
aged 40-60 years found that subjects on a low-fat dairy diet had 
lower circulating levels of IL-6 and sVCAM-1 than the control. 
Labonte, et al. (2013) conducted a meta-analysis of 9 studies and 
found no significant relationship between dairy consumption 
and systemic inflammation. Finally, Bordoni et al. (2015) con-
ducted the largest meta-study to date (52 human studies) and 
found that the consumption of dairy products is generally as-
sociated with anti-inflammatory effects in humans. Of particular 
note was that none of the studies using low-fat dairy products 
indicated a pro-inflammatory response. Taken together, these 
findings suggest that the association between cow’s milk and 
systemic inflammation in healthy adults is largely unfounded. 
Cow’s milk and Immune-Mediated Diabetes:
Diabetes mellitus type 1 (T1D) is a form of diabetes mellitus 
that results when T-cell-mediated autoimmunity destroys the 
insulin-producing beta cells of the pancreas. Although this form 
of diabetes has a strong genetic basis, it is also influenced by 
environment.  The precise environmental triggers of T1D are a 
matter of ongoing research and debate, with some suggesting 
the role of particular antigens (Knip and Simell, 2012). The liter-
ature appears to be split on the question of whether cow’s milk 
has a role in the pathogenesis of T1D. 
The controversy began in 1984, when Borch-Johnsen et al. sug-
gested there was an inverse-correlation between T1D and the 
duration of breast-feeding. Although some subsequent studies 
cast doubt on this link, researchers began to explore early ex-
posure to cow’s milk (as opposed to discontinued feeding by 
human milk) as a possible cause. Following this hypothesis, Scott 
(1990) looked at consumption of milk per-capita and found a 
significant positive correlation between consumption of unfer-
mented milk protein and incidence of T1D in data from various 
countries. More precise epidemiological studies soon followed, 
such as a study of 690 T1D children in Finland, which found 
that children were 1.5 times more likely to develop T1D if they 
were exposed cow’s milk early in life (Virtanen et al. 1993). The 
first meta-analyses showed a modest, but significant increase of 
diabetes in children who were exposed to cow’s milk before the 
age of 3 months (Gerstein, 1994; Norris & Scott, 1996).  Some 
recent studies have expanded on these findings. Kinip et al. 
(2010) reported on the Trial to Reduce IDDM in the Genetically 
at Risk (TRIGR), in which Finnish researchers assigned 230 in-
fants to drink either conventional cow’s milk-based formula or a 
dairy-free alternative. Ten years later, children who were fed the 
non-dairy alternative exhibited 50-60% fewer markers of β-cell 
autoimmunity. Villagrán-García et al. (2015) studied 150 children 
and found that those who began drinking cow’s milk in early 
childhood were four times more likely to have T1D, one of the 
most dramatic results yet reported. 
Several mechanisms have been proposed for a possible link be-
tween a child’s early exposure to cow’s milk and T1D. One the-
ory suggests that cow’s milk proteins may mimic autoantigens of 
the pancreas beta cells, leading to the autoimmune destruction 
of these cells (Kolb & Pozzilli, 1999). Another suggests that early 
exposure to cow’s milk leads to elevated antibodies against 
bovine insulin and subsequent immunization against human 
insulin (Vaarala et al., 1999). A more recent proposal involves 
beta-lactoglobulin, a whey protein found in cow’s milk but not 
in human milk, and glycodelin, a near-homologue that regulates 
T-cells. According to this theory, some infants produce antibod-
ies against beta-lactoglobulin, which cross-react with glycodelin 
and allow autoreactive T-cells to proliferate (Goldfarb, 2008). 
Although some epidemiological studies have supported a link 
between cow’s milk and T1D, and a number of plausible mech-
anisms have been proposed, there is also conflicting evidence. 
For example, Savilahti and Saarinen (2009) found that infants 
who were exposed to cow’s milk very early in life were actually 
slightly less likely to develop T1D before age 8 (although the dis-
crepancy disappeared by age 11.5). Karlsson et al. (2001) studied 
30 children with T1D and 18 healthy, age-matched children and 
found no difference in their Th1- and Th2-like immune response 
to cow’s milk proteins, suggesting that cow’s milk antigens do 
not have a significant role pathogenesis. Some researchers have 
argued that the existence of populations in which there is a high 
level of dairy consumption and a low rate of T1D disproves any 
connection (e.g. Iceland and Zealand), although these discrepan-
cies have also been explained by the fact that protein content 
can vary by region (Thorsdottir, 2000). Some have suggested 
that only cow’s milk with A1-type casein is contributing factor 
to T1D (Laugensen and Elliot, 2003), while others argue that 
the apparent differences between A1-type and A2-type milk are 
really due to differences in sun-exposure and vitamin D produc-
tion (Merriman, 2009). Ultimately, the relationship of cow’s milk 
and T1D remains a matter of debate, despite some epidemio-
logical evidence supporting a causal link and the elaboration of 
a number of plausible mechanisms.  
Cow’s milk and Multiple Sclerosis:
Multiple sclerosis (MS) is a chronic inflammatory disease in 
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which the myelin sheaths that insulate the central nervous 
system are damaged. A connection between cow’s milk and 
multiple sclerosis (MS) has long been debated. One of the first 
large scale studies on the question was Malosse et al. (1992), 
which examined the relationship between MS prevalence and 
dairy product consumption in 27 countries and 29 populations 
all over the world. The study found there was strong correlation 
between MS prevalence and the consumption of liquid cow’s 
milk, but not between MS and more processed forms of dairy, 
like cheese. Some researchers have proposed that molecular 
mimicry between CNS myelin antigens and cow’s milk proteins 
could explain the relationship. According to this theory, the IgE 
targeted to the cow’s milk proteins cross-react with the myelin 
and lead to damage of the nerve cells (Ahrens et al., 2012). It has 
been suggested that the failure of T cells to regulate auto-reac-
tive CD4+ and CD8+ cells has a role in the disease (Viglietta 
et al., 2004). Given the possible role of autoreactive T cells in 
MS, the mechanism proposed by Goldfarb (2008) for T1D may 
also be plausible here. Particularly interesting in this respect are 
studies linking the autoimmunity of T1D and MS (Winer et al., 
2001).
 Some studies have questioned the link between cow’s milk and 
MS. Ramagopalan et al. (2010) examined 6638 cases of MS in 
Canada and found no significant difference in the percentage 
who reported childhood CMA, an odd finding if there is a sig-
nificant cross-reaction between cow’s milk proteins and myelin. 
Ashtari et al. (2012) examined 48 healthy subjects and 48 sub-
jects with MS and found no difference in the detection of cow’s 
milk-specific IgE. Given these contradictory results, the role of 
cow’s milk in MS remains uncertain.
Cow’s milk and Betcet’s Disease:
Betcet’s disease (BD) is characterized by chronic, immune-me-
diated inflammation of the blood vessels, leading to skin rashes 
and lesions, optic atrophy, and ulcers of the mouth and genitals. 
Although the etiology of the disease is not fully known, there is 
strong evidence for the role of Th17 cells, adaptive immune cells 
that are also associated with MS and RA (Hatemi et al. 2012). 
Research on cow’s milk as a factor in Betcet’s disease is cur-
rently very limited. Triolo et al. (2002) cited promising research 
on the relationship between cow’s milk and immune-mediated 
conditions like T1D and MS as a basis for examining the role of 
cow’s milk in BD. First, the study cultured lymphocytes from 16 
patients with BD and eight normal controls in the presence of 
ß-casein, ß-lactoglobulin, and a number of controls. ELISA re-
vealed that when cultured with milk proteins lymphocytes from 
BD subjects produced significantly more IFNγ, a cytokine asso-
ciated with auto-inflammation, than lymphocytes from the con-
trols. Then the study used ELISA to analyze the serum antibody 
levels of 46 patients with BD and 37 healthy controls and found 
significantly higher levels of anti-ß-casein and anti-ß-lactoglobu-
lin antibodies in the subjects with BD.  
These results suggest some correlation between BD and sensi-
tivity to milk proteins, but do not define a causal order. The au-
thors suggest that milk proteins may damage the gut and lead to 
immune dysfunction and offer two possible mechanisms. First, 
the caseins in cow’s milk may give rise to peptides that mimic 
opiates and bind T cells and macrophages, disrupting their func-
tion. Second, molecular mimicry between cow’s milk proteins 
and self-proteins may lead to damaging cross-reactivity.  These 
mechanisms are only speculative however, and there has been 
little research on the relationship between cow’s milk and BD. 
The rarity of BD (approximately 0.1-7.5 /100,000 in Europe and 
the USA ) makes epidemiological studies difficult to conduct 
(Zouboulis, 1999). 
Cow’s milk and Rheumatoid Arthritis:
Rheumatoid arthritis (RA) is a chronic inflammatory disorder 
that primarily affects the small joints in the hands and feet, lead-
ing to swelling, pain, and loss of mobility. cow’s milk has some-
times been cited as a contributing factor to RA. Although dairy 
has been identified as an aggravating factor in individual cases of 
RA (Panush et al. 1986: Panush, 1990), larger studies have failed 
to find a connection between the disease and the consump-
tion of cow’s milk.  Panush et al. (1983), for example, studied 11 
subjects on a dairy-free diet and 15 subjects on a placebo diet 
and found no significant differences in rheumatologic or immu-
nologic findings.  The literature on diet-therapy for RA is not 
extensive and tends to dispute any connection between cow’s 
milk and RA; however, there are indications that dairy may be an 
aggravating factor in a small percentage of cases.
Discussion
The Challenges of Studying cow’s milk:
Determining the impact of cow’s milk on the immune system is 
complicated by a number of factors. Allergic and autoimmune 
reactions are multifaceted and reflect a confluence of individ-
ual biochemistry, genetics, and environmental influences that 
is not fully understood. Milk itself is a complex mixture with 
numerous bioactive components, and its composition can vary 
by region. Moreover, the consumption of cow’s milk is always 
part of a large, multivariable diet, making it hard to rule out 
confounding factors. Any interpretation of the evidence must 
be cautious given the enormous complexity of the variables.
Current Nutritional Guidelines for cow’s milk:
The 2010 dietary guidelines authored jointly by the Department 
of Agriculture and the U.S. Department of Health and Human 
Services stress the importance of cow’s milk and cow’s milk-prod-
ucts as part of a healthy diet. The guidelines recommend 3 cups 
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per day of fat-free or low-fat milk and milk products for adults 
and children over 9, 2.5 cups per day for children ages 4-8, and 
2 cups for children ages 2 -3.
Assessment of Results:
Cow’s milk is a vital staple of American nutrition, economy, and 
culture. This does not diminish the importance of continued 
research into the effects of cow’s milk on human health. CMA 
is the most common form of allergy in childhood and can lead 
to serious complications. Beyond clinical CMA, cow’s milk may 
impact the immune system in subtle, unexpected ways. Upon 
reviewing the evidence, there is no strong indication that cow’s 
milk is a contributing factor to systemic inflammation in healthy 
adults or to RA. However, there is some significant, but con-
tested evidence that it plays a role in the pathogenesis of T1D, 
MS, and Behcet disease. Currently, there is much we do not 
know. One theme emerging from the literature is the difficul-
ty of drawing conclusions from epidemiological studies. Some 
epidemiological studies reveal a striking correlation between 
cow’s milk and various immune disorders while others yield 
conflicting results. While prospective cohort studies offer ob-
vious advantages over retrospective studies, they can still yield 
opposing findings, as evidenced by the large disagreement be-
tween Savilahti and Saarinen (2009) and Knip et al. (2010) over 
whether cow’s milk is a risk factor for T1D. Such discrepancies 
suggest the need for further research and meta-analysis.
Additional Considerations and Conclusions:
The results are too messy and speculative to write off cow’s 
milk as a “dangerous” food or to clear it of all suspicion. They do 
underscore the fact that we do not yet know enough about the 
bioactivity of cow’s milk to rule out the possibility of detrimen-
tal effects on immune function. This uncertainty is compounded 
by recent findings that link cow’s milk to prostate cancer and 
Parkinson’s (Chen et al., 2007: Mandair et al., 2014). Numerous 
studies have questioned the traditional belief that consuming 
cow’s milk improves bone health and some have even found 
that it increases risk of fracture (Michaëlsson K. et. al. 2014: 
Feskanich et al. 2014). Although many of these findings are still 
questionable, taken together they may warrant a reconsider-
ation of current guidelines, especially when people in developed 
nations generally can obtain calcium and other vital nutrients 
from alternative sources. Given the important place that cow’s 
milk has held in human nutrition and culture for thousands of 
years, and the vital role it plays in the contemporary American 
economy, any shift in thinking about dairy might be difficult to 
achieve. Nevertheless, it is important to evaluate the evolving 
body of evidence without cultural or economic bias and arrive 
at nutritional guidelines on the basis of sound science alone.
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Acronyms:
CBP  Chronic Back Pain
CCK   Cholecystokinin 
CR    Conditioned Response
CS    Conditioned Stimulus/Stimuli 
NSAID   Nonsteroidal Anti-Inflammatory Drug
PAG  Periaqueductal Gray 
UCR  Unconditioned Response
UCS   Unconditioned Stimulus/Stimuli
Introduction
Since the 18th century, people have believed that placebo pills 
were inert drugs or medically unqualified measures that have 
psychological effects on the patient, therefore easing the pa-
tient’s pain (Beecher 1955). Hence, the term placebo is a Latin 
derivative for “I shall please” (Moerman 2002). Furthermore, in 
recent years, many studies are associating neurological aspects 
to the psychological effects of the placebo effect. 
Today there is a range of treatment that people categorize as 
placebo - as basic as administering a Band-Aid on a wound to 
inserting needles into a patient receiving acupuncture. Because 
such procedures do not contain much medical efficiency, their 
pain-reducing results are termed ‘placebo effect.’ If these prac-
tices do not involve elements or substances that are responsi-
ble for altering a health condition then what is it about these 
techniques that can make one pain free? Because placebo an-
algesia has proven to be one of the most successful models in 
the research of the placebo effect, this review will explain the 
long-known psychological influences of the placebo analgesia, as 
well as the newer and unconcluded neurological influences of 
the placebo analgesia. 
Several psychological mechanisms contribute to the appear-
ance, enhancement or duration of the placebo effects. Firstly, 
Pavlov’s classical conditioning is a major contributor towards 
the placebo effect, whereby a patient is trained to respond pos-
itively towards a placebo stimulus.  Expectations also play a big 
role - the patient’s anticipation of clinical improvement is par-
tially responsible for the onset of the placebo effect. The overall 
experience that the patient experiences influences the patient’s 
expectations; doctor-patient relationship, the trial site, the ap-
pearance of the pill, and the way the treatment is given are all 
experience related factors that impact one’s expectations. 
How can it be that just by one merely having belief one can 
experience less or no pain? The neural mechanisms whereby 
placebo conditioning leads to placebo analgesia remain unclear. 
Scientists are attempting to find better explanations for the 
placebo effect by attributing it to neurological mechanisms of 
the body. Ascending pain signals travel through one’s spinal cord, 
then to the thalamus, and then to the sensory- processing re-
gions of one’s cerebral cortex. In order for one not to experi-
ence pain due do to a pain provoking stimulus, there would have 
to be changes in the sensory network of the brain or in the spi-
nal cord. Recently, researchers are associating opiate analgesics 
to the placebo effect. They are attempting to prove that placebo 
treatment engages opioid systems which block pain in the spinal 
cord. However, studies also show that there in fact is non-opioid 
related analgesia. Nonetheless, the explanations remain unclear. 
From the research done, it is evident that the placebo effect has 
psychological aspects and that there is a difference in brain ac-
tivity due to placebo treatment which is seemingly responsible 
for placebo analgesia. Nonetheless, future research is required 
in order to pinpoint the definite neural activity responsible for 
the pain reduction.
Methods
In an effort to answer the question asked above, many published 
articles, clinical trials, and research papers have been examined. 
Primarily, Touro College’s library database as well as Google 
Scholar were used to search for pertinent material. Original 
research papers that were referenced were also studied. An 
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attempt was made to determine if the placebo effect, as a result 
of the placebo treatment, is psychologically and or neurological-
ly fact or fiction.
Discussion
Psychological Aspects: Learning and Classical 
Conditioning
People who suffer from pain, like a headache, and who usually 
ingest aspirin, learn to associate the color, taste, and shape of 
the pill with pain-decrease. After recurring associations, if such 
people are given a placebo pill, such as a sugar pill resembling as-
pirin, they will feel less pain. Other stimuli, such as medical per-
sonnel features, hospitals, and therapeutic equipment can also 
be associated with clinical improvements and therefore act as 
conditioned stimuli that impact healing effects (Benedetti, et. al. 
2010). A 1960s’ experiment found that a scopolamine injection, 
a medication used to treat motion sickness and other types of 
nausea, affected motor changes in a rat. Furthermore, identical 
motor changes also transpired after a placebo injection made 
of saline solution was administered after the scopolamine in-
jection (Herrnstein 1962). Corresponding occurrences exist in 
humans too. Notably, if a placebo pill or procedure is given after 
two preceding administrations of an effective painkiller or prac-
tice, the placebo analgesic response is much larger (Amanzio, 
Benedetti, 1999). That effect emphasizes that the placebo effect 
is definitely a learning phenomenon.
Like other profound scientific developments, classical condition-
ing was discovered accidentally. In the 1890s, Russian physiolo-
gist Ivan Pavlov was observing dogs salivate in response to being 
fed. He then noticed that the dogs began salivating whenever 
he arrived in the room they were in, while he did not always 
have food with him (McLeod 2007). From this incident, Pavlov 
believed that some responses are innate, they don’t need to 
be learned. In example, dogs do not learn to salivate whenever 
they see food as this reflex is inherent. In psychological terms, 
an unconditioned stimulus leads to an unconditioned response. 
Furthermore, over time the dogs began salivating as soon as they 
saw anything that they associated with their food. Therefore, 
they would salivate in the presence of a lab assistant even when 
he did not come with food (Windholz 1995). In psychological 
terms, the phenomenon is due because when an unconditioned 
stimulus is paired with a neutral stimulus, the latter becomes a 
conditioned stimulus that propels a conditioned response com-
parable to the unconditioned response. Pavlov furthered his 
research by experimenting with a bell; the dog was conditioned 
to salivate when a bell rang as he associated it with the food.
Numerous clinical trials attribute the positive placebo treat-
ment effects to Pavlov’s classical conditioning. Just as a dog sali-
vated in response to a food-associated person or object, people 
can experience a reduction in pain due to a painkiller-associated 
placebo procedure or drug. Indeed, a 1970s’ experiment proves 
that placebo effects are in large due to classical conditioning; 
saccharin, a flavored drinking solution, was paired with cyclo-
phosphamide, an immunosuppressive drug, and given to rats. 
After, the rats were immunized with sheep red blood cells. 
On the seventh day, the rats that had been again exposed to 
saccharin at the time of antigenic stimulation had a lower con-
centration of hemagglutinating antibodies in comparison with 
non-conditioned animals given saccharin, conditioned animals 
that were not re-exposed to saccharin, and a placebo group. 
Hence, the experiment proves that after associative learning, 
simply a liquid has the ability to mimic the effects of an active 
drug and thus legitimizes the placebo effect (Ader, Cohen 1975). 
In response to people who argue that such conditioning is 
not possible to exist amongst human beings, an analogous trial 
provides substantial evidence that behavioral conditioning of 
immunosuppression is in fact promising in humans. Recurrent 
associations between cyclosporine A - an immunosuppressant 
drug - and a flavored drink incited conditioned immunosup-
pression in healthy male volunteers. However, more than one 
associative learning trial was necessary in order to bring about 
the fascinating results (Goebel, et al 2002).
Psychological Aspects: Expectancy
While Pavlovian conditioning serves as an unconscious influ-
ence towards placebo effects, expectancy serves as a conscious 
one. The expectancy theory hypothesizes that one’s expecta-
tions impact ones future experience (Kirsch 1999). Therefore, if 
one expects clinical improvement, his chances of improving are 
that much greater. This theory is evident in the following 2010 
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double-blind clinical trial: A painful laser stimulus was delivered 
individually to twenty healthy participants before and after each 
was given a 0 or 4 mg/kg cup of caffeine. Some participants were 
told that their drink contained a painkiller, while the others 
were told their drink was a placebo solution. After measuring 
the reported pain and expectancy levels, it was clear that the 
information that a painkiller was given enhanced the analgesic 
effect of caffeine compared to caffeine given with no drug infor-
mation (Bjørkedal, Flaten 2011). Moreover, those that were in 
the active placebo condition group - were told they were given 
a painkiller and they received caffeine – overall reported less 
pain than the subjects in the caffeine condition group – were 
not told they were given painkiller and they received caffeine. 
This reiterates the expectancy theory, as the first group was 
given two qualities (caffeine and drug information) that made 
them expect an improvement, while the latter group was only 
given one (caffeine).The expectancy of pain relief modulated the 
decreased pain experienced by the subjects (fig. 2).  
From the above trial, it is evident that verbal gestures enhance 
expectancy in patients. Additionally, the overall experience 
that the patient experiences influences his/her expectancy of 
clinical improvement and consequently his/her clinical results. 
The doctor-patient relationship, the trial site, the appearance 
of the pill, and the way the treatment is given are all includ-
ed in one’s experience and can enhance the placebo effect.  In 
another study, the effectiveness of 5% Lidocaine patches was 
compared with the effectiveness of placebo patches in treating 
chronic back pain. In the randomized double-blind study, 15 pa-
tients received 5% Lidocaine patches and 15 received placebo 
patches. Functional MRI was used to ascertain brain activity for 
variations of spontaneous pain, at the starting time and at two 
more points thereafter (6 hours and 2 weeks). As reported, 
there was no noteworthy difference between the two groups 
in their pain intensity and in pain related brain activity. And both 
groups reported more than a 50% pain decrease. Moreover, 
when compared with an untreated chronic-back-pain-group at 
similar intervals, the patch treated CBP group experienced a 
considerably bigger decrease in back pain (Hashmi et al, 2012). 
These findings support the expectancy theory, as the patients 
who experienced a more encouraging experience by being 
given a patch consequently felt less pain later on (fig. 3). 
Another method to reinforce one’s expectation of clinical 
improvement, is to educate the individual about the so-called 
painkiller one is going to ingest. A random group of fifty uni-
versity students agreed to either undergo placebo treatment 
under the appearance of a new analgesic painkiller capsule or 
to be put in the control group which did not receive placebo 
treatment. While some participants were handed educational 
handouts explaining the analgesic effect, others were not. The 
subjects then received electrically-induced pain at varied inten-
sities, and those that ingested the realistic looking drug capsules 
reported analgesia. Furthermore, participants who also read the 
handouts regarding analgesia reported an even higher decrease 
in pain (Tang, Colagiuri 2013). This experiment highlights that 
the appearance of the pill and the knowledge of analgesia both 
contribute towards the patients expectancy and thus towards 
his or her placebo analgesia. 
Psychological Aspects: Conditioning vs. 
Expectancy Theory
After much research, it is evident that both the conditioning 
and expectancy theories are driving forces of placebo effects. 
Subjects reported larger reductions in pain after 4mg/kg caffeine 
(caffeine, active placebo) compared to after 0mg caffeine (control, 
placebo)  (Bjørkedal, Flaten 2011)
Figure 2
Variation of CBP pain with treatment type and treatment duration. 
Treatment duration, but not type, significantly decreased CBP pain. 




However, can they coexist, and is one more potent than the 
other? In response to the former, both psychological mecha-
nisms can surely coincide. For example, a patient who receives 
a sugar pill on its own after repetitively receiving the pill togeth-
er with other analgesic drugs will imply both mechanisms; the 
sugar pill has become the conditioned stimulus to invoke anal-
gesia, and the fact that the patient received medicine prompts 
him to expect a recovery. 
Regarding which mechanism is more vital, Stewart-Williams 
and Podd (2004) reviewed many clinical trials and concluded 
similarly to what many others have suggested: each mechanism 
plays a different part in the production of placebo effects. When 
a doctor verbally encourages a patient, when an inert pill or 
procedure resembles a legitimate pill or procedure, and when 
other such characteristics mentioned previously exist when 
a patient receives a placebo, he/she learns to expect an im-
provement, which is a conscious belief. When one’s conscious 
is involved, he can experience subjective and or physiological 
placebo effects. On the other hand, when placebos represent 
CS, the patient can either unconsciously believe in a placebo 
effect or the patient can consciously expect improvements in 
his situation. The conscious expectations and the non-conscious 
learning yields subjective and physiological (objective) placebo 
effects. Whilst expectancy learning is always a conscious action, 
conditioning can be conscious or not - depending on whether 
expectancy coincides with the conditioning. Nonetheless, each 
form of learning can produce subjective as well as physiological 
outcomes.  
Others describe the correlation between expectations and 
conditioning differently. A study concluded that placebo re-
sponses are facilitated by expectation when conscious physi-
ological processes - for example, pain - exist, notwithstanding, 
a conditioning procedure may simultaneously be implemented 
(Benedetti et. al, 2003). Sixty participants were divided into five 
groups and induced with pain in their forearms once per day 
for five days. Such ischemic pain increases over time rapidly, and 
the pain becomes excruciating after approximately 13 minutes. 
After the painful stimulus was implied, each participant stopped 
a timer when the pain became unbearable, and thus the average 
pain tolerance level for each group was recorded. As each group 
was treated differently throughout the five days, the results of 
each group greatly varied. Some were told analgesia suggestions 
or hyperalgesia suggestion, some experienced conditioining 
via ketorolac anti inflamatory analgesic, and some received a 
combination. Evidently, verbally induced analgesia expectations 
raised the pain tolerance; whereas, suggestions of hyperalgesia 
eradicated pain tolerance. This testifies that not only are pos-
itive words empowering, negativity is impactful too. Moreover, 
this highlights the detrimental effects of unencouraging words 
in the medical scene. When analgesia suggestions and condition-
ing were both implemented, the tolerance level rose higher. Yet, 
when conditioning and hyperalgesia suggestions coincided, the 
expectations outweighed the preconditioning effects of ketoro-
lac, as the subjects’s overall pain tolerance decreased. The study 
proves that analgesic placebo responses seem to be primarily 
mediated by expectations, such as verbally induced expectations. 
The study of the placebo phenomenon has important implica-
tions on non-placebo procedures. The equivalent psychological 
factors that mediate the placebo effect are likely to be effective 
when an individual is given an active substance or undergoes 
an active procedure. Accordingly, a better understanding of 
the psychological mechanisms essential to the placebo effect 
is relevant in order to contribute these psychological factors 
to non-placebo treatments as well. For example, by increasing 
patients’ positive expectancies for the effects of an active drug 
or procedure, it is conceivable that the drug or procedure will 
yield stronger drug effects without the use of stronger doses. 
There are numerous ways that physicians can achieve this: They 
can inform patients about others for whom the treatment 
proved successful, and doctors should update patients on the 
clinical research that portrays the treatment as worthwhile. 
Additionally, physicians should make people aware of the minor 
side effects related with the treatment. Then, when people 
come across any such symptoms in themselves (irrespective 
of whether these symptoms are a result of the active drug), 
they are likely to assume that the drug is working well. This will 
possibly boost their expectations for a positive effect, which will 
thereafter enhance the placebo element of the active treatment. 
Using these strategies, physicians can probably achieve stronger 
drug results without administering alternative stronger drugs or 
greater doses. This would be a safer solution for the patient, as 
he or she will not be exposed to unnecessary strong medica-
tion, and this will also decrease the costs of medical care. (Podd, 
Stewart-Williams 2004)
Neurological Aspects
Placebos have no innate power to elicit given results. Yet, they 
can produce the effects which are anticipated or sought. Placebo 
pills and procedures do not act on the brain to bring about pla-
cebo effects; however, placebos can stimulate expectations and 
CR which impact pain-reducing neural systems. What is respon-
sible for the relation between the psychological mechanisms 
and placebo analgesia?
Neurological Aspects: Opioids
The neurology of placebo was discovered when researchers 
found that placebo analgesia is facilitated by endogenous opi-
oids. They were prompted to make this hypothesis after they 
observed that naloxone, the opioid antagonist, can oppose the 
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effects of placebo analgesia (Levine et. al, 1978). Since then, fur-
ther studies have emphasized that finding. Researchers exam-
ined the mechanisms fundamental to the activation of endog-
enous opioids in placebo analgesia (Benedetti, Amanzio 1999). 
Once a day, for five days, ischemic arm pain was induced into 
229 participants. The subjects were divided into twelve groups, 
each treated differently. Each group received a combination of 
two or more of these 
treatments throughout the five-day-experiment duration: the 
opioid agonist morphine hydrochloride, the non-opioid ketoro-
lac (nonsteroidal anti-inflammatory drug; NSAID) trometh-
amine, no treatment, an open injection of saline, or open or 
hidden opioid antagonist naloxone. The order of each group’s 
treatment was made so that the treatment can serve as drug 
conditioning, expectation cues, or both. When morphine was 
administered, and when saline was openly injected and was 
believed to be a morphine-like (expectation and or drug con-
ditioning), participants experienced less pain. Any participant 
who received naloxone after morphine (ketorolac was not 
administered), whether open or hidden and whether used as 
an expectation cue or not, experienced no difference in pain. 
When ketorolac was issued, there was pain relief. Moreover, 
when saline was issued, it mimicked the ketorolac effects. What 
was even more fascinating about the results was that when nal-
oxone was issued after ketorolac, pain was partially diminished. 
This proves that naloxone only somewhat blocks analgesic ef-
fects; therefore, there must be non-opioid factors in addition to 
opioid factors influencing placebo analgesia. The results of the 
experiment prove that the opioid system is surely involved in 
placebo analgesia, yet there are also other aspects sometimes 
involved. 
There is a lack of evidence proving how non-opioid pathways 
serve in placebo analgesia. However, just as ketorolac is a 
NSAID, placebos that mimic ketorolac or other NSAIDs’ ac-
tivity, probably behave like such drugs. They act at peripheral 
and also central places in the spinal cord, hindering the cyc-
lo-oxygenase enzyme that is essential for the transformation 
of arachidonic acid into prostaglandins and thus preventing a 
painful experience. 
Because studies prove the anti-opioid accomplishments of the 
neuropeptide cholecystokinin (CCK), further studies were done 
and demonstrated that the blockade of CCK receptors makes 
the placebo analgesic response possible, thus suggesting that the 
CCK role in placebo analgesia is quite impeding and that the 
opioid system is important in order for placebo analgesia to 
occur. This finding imparts that by irritating the anti-opioid ac-
tion of CCK at the time of a placebo practice, the endogenous 
opioid systems can be activated. (Benedetti, Amanzio 1997) In 
a more recent study, forty participants were divided into four 
groups in order for the effects of CCK type-2 receptors to 
be examined (Benedetti et. al, 2010). Each participant was in-
duced with ischemic arm pain like in previously mentioned ex-
periments, and each group was treated differently. The results 
portrayed that activation of CCK type-2 receptors, which was 
achieved by means of administering the agonist pentagastrin, 
abolished placebo analgesia even after morphine-conditioning 
(placebo treatment) occurred. Evidently, CCK resembles nal-
oxone. Furthermore, this study suggests that the equilibrium 
between CCK elements and opioids is critical in placebo treat-
ment. So, when patients do not respond as predicted to placebo 
treatments, possibly CCK type-2 receptor hyperactivity exists 
in the patient’s body-makeup.
What exactly is the endogenous opioid system? In general, the 
endogenous opioid system is an inborn pain-relieving method. 
It consists of dispersed neurons that produce three opioids: be-
ta-endorphin, the met- and leu-enkephalins, and the dynorphins. 
These opioids behave like neurotransmitters and neuromodu-
lators at three main categories of receptors - mu (µ), Delta (δ), 
and kappa (κ). Once attached to the receptors, they send signals 
which in turn block pain, slow down breathing, and have an over-
all calming effect; therefore, the patient experiences analgesia. 
In order to more fully comprehend how opioids modulate the 
conduction of pain, one needs to understand the pathway by 
which pain is transmitted - beginning from its origin until its place 
of interpretation and perception in the brain.  There are two 
types of first order neurons in which pain is transmitted along: 
In terms of nociceptive pain transmission, acute pain is trans-
mitted mainly by A-delta afferent sensory nerve fibers, while 
chronic pain is transmitted mainly by unmyelinated C sensory 
afferent nerve fibers until it reaches the spinal cord. Because 
these nerve fibers are unmyelinated, chronic pain is transmitted 
slower than acute pain. Nociceptors, free nerve endings which 
are found in numerous visceral and somatic tissues all over the 
body, are stimulated by different sorts of noxious (harmful) 
stimuli - such as chemical, thermal, and mechanical - and once 
stimulated there is a release of leukotrienes, bradykinin, hista-
mine, prostaglandins, potassium ions, and substance P.  These 
substances activate the nociceptors which results in the gener-
ation of an action potential down the first order neurons and 
heading towards the spinal cord.  When the fibers arrive at the 
dorsal gray horn of the spinal cord, they release neurotransmit-
ters - glutamate, substance P, and calcitonin gene related peptide 
- and thus synapse with second order nerve fibers. The released 
neurotransmitters incite the depolarization of the second order 
neuron which crosses over to the opposite side of the spinal 
cord, entering the contralateral spinothalamic tract and from 
there ascends up the spinal cord and ultimately into the brain. 
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Here, pain is modified via descending pathways and this results 
in an individual experiencing pain. 
Now, how do opioids hinder the descending pathways so that 
an individual does not perceive pain? Opioid agonists bind to 
µ -opioid receptors within the midbrain of the brainstem, on 
inhibitory interneurons. The opioid agonist action at these neu-
rons results in a lessening in the inhibitory effects on the nerve 
fibers exiting the periaqueductal gray (PAG). Hence, they lead 
to disinhibition of the descending nerves from the PAG. In turn, 
there is an increase in their motion and in their communication 
to the raphe nuclei. Moreover, there will be a disinhibition of 
neurons in the raphe nuclei. There will be a general stimulation 
of the descending nerve fibers which are descending through 
the lateral funiculus in the spinal cord, and they eventually reach 
the dorsal horn of the spinal cord. As this is the site in which the 
original pain stimulus enters the spinal cord in its ascent to the 
brain, here the nerve fibers influence the activity of the initial 
pain stimulus.
Opioids impede afferent sensory nerve fibers, as well, that are 
ascending the spinal cord traveling towards the brain. Opioids di-
rectly attach to presynaptic mu-opioid receptors and thus cause 
an inhibition of pain transmission through the first order affer-
ent sensory nerve fibers which enter the spinal cord. This leads 
to a lessening in the discharge of substance P that is required 
for the stimulation of second order neurons. Furthermore, opi-
oids can directly attach to postsynaptic mu-opioid receptors on 
different ascending nerve fibers, and this adds to the diminished 
communication to the ventral posterolateral nucleus and con-
sequently to the cerebral cortex. Additionally, opioids can indi-
rectly inhibit second order ascending neurons in the spinal cord; 
they modify the ejection of substance P and serotonin from the 
stimulated descending nerve fibers from the raphe nuclei which 
control endorphin containing neurons inside the dorsal horn. 
The outcome of the impacts of opioids on the nerves found in 
the dorsal horn is the pain transmission inhibition.
As one’s body does not produce enough natural opioids to 
alleviate excruciating or prolonged pain, opioid drugs are man-
ufactured. Comparable to their endogenous complements, opi-
oid drugs - opiates - act at the same receptor sites, producing 
analgesia as well. This wonder is possible, as the drugs mimic the 
endogenous opioids’ chemical makeup. For this reason, patients 
who experience much pain are prescribed with painkillers –as 
they are opiates which mediate analgesia. When a placebo is 
administered, the goal is that the endogenous opioid system 
is activated as a result of the psychological influence on the 
patient’s mind – the individual is convinced he or she received 
an opiate, so his body responds respectively.
Ethics of Placebo Treatment
As the physiology caused by placebo treatment is not conclu-
sive, the placebo effect is not universally recommended. In fact, 
many view placebo treatment as immoral. According to Nikola 
Biller-Andorno (2004) of University of Goettingen, Germany, 
placebo treatment is only permissible when used for thera-
peutic reasons and when no better proven alternative exists. 
Additionally, the patient cannot be deceived, rather the doctor 
must acknowledge the patient’s empowerment and autonomy. 
If the physician fails to abide by these standards, rather than 
practicing ethically he is practicing blunderingly. Because of such 
guidelines, it is difficult to practice placebo treatment on sick 
patients. Therefore, researchers are forced to set up trials in 
order to examine placebo effects.
Ethnic
After much research, it is noticeable that the placebo effect has 
become more effective. DiSalvo elaborated about the placebo 
effect in a 2015 edition of the Forbes magazine. He wrote that 
after reviewing a study of 84 clinical trials which were carried 
out between the years 1990 and 2013, he concluded that the 
placebo effect is getting stronger. However, he adds that this is 
only true of trials in the United States. Possibly because America 
is more advanced than many countries, the ability to conduct 
placebo treatments is more feasible. More importantly, he adds 
that America is the only country aside from New Zealand 
that allows drug companies to sell their products directly to 
consumers. This is blatant when one watches TV and sees the 
numerous drug commercials. The advertising in itself can con-
tribute towards the placebo effect by creating expectation cues.
Conclusion
After examining the articles and experiments regarding pla-
cebo treatments and effects, it is apparent that while placebo 
treatment definitely has psychological influence on patients, the 
neurological influence is unclear. Many are skeptical of placebo 
effect all together. They argue that possibly the percentage of 
patients that report improvement would regardless have im-
provement – that is to say, often pain reduces over time so even 
without a placebo treatment one can be somewhat relieved 
from pain. However, in many trials, there are ‘natural history’ 
groups which are used to compare their pain tolerance to the 
placebo treated group’s pain tolerance. And these studies have 
proven that the placebo treated group’s pain tolerance was bet-
ter than the non-placebo treated group’s tolerance. This topic 
is fascinating as it proves the power of the mind over matter. 
Placebo management can trigger mechanisms that are equiv-
alent to those triggered by drugs, which points out a parallel 
between psychological and pharmaceutical effects. With further 
research, placebo effect may become completely acceptable and 
instead of administering drugs which often have harmful side 
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effects or which are sometimes rejected by patients, placebo 
treatments will serve as alternatives.
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